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Abstract 
Retinoids are a class of signalling molecules that includes vitamin A along with its 
natural and synthetic analogues. Retinoids regulate important biological pathways 
from embryogenesis through to adult homeostasis, and influence the proliferation and 
differentiation of a variety of cell types. The effects of retinoids are primarily mediated 
through binding to and activation of the retinoic acid receptors (RARs) and retinoid X 
receptors (RXRs). Three subtypes of RARs exist: RARα, RARβ and RARγ. Isoforms for 
each of these receptor subtypes are known, with the RARβ2 isoform in particular 
known to stimulate neurite outgrowth. 
The design of isoform-selective ligands is thus an important area to allow investigation 
into the mechanism of activity of the individual RAR isoforms. Syntheses of the 
proposed RARβ2 agonists containing phenyl- and tetramethyltetrahydronaphthyl-
substituted side chains are described herein. These thiazole-containing small 
molecules were assessed for activity in inducing the differentiation of human 
pluripotent TERA2.cl.SP12 embryonal carcinoma (EC) cells, with the more bulky 
tetramethyltetrahydronaphthyl analogue able to induce differentiation of this cell line 
to a level comparable to that of the natural retinoid, ATRA. Furthermore, at 0.1 µM, 
this analogue promoted enhanced neural commitment and neurite outgrowth over 
ATRA, with levels similar to that observed with the synthetic retinoid EC23. 
The second part of this thesis concerns the synthesis of a fluorescent retinoid, GZ108, 
and preliminary assessments of its fluorescence and biological activities. In an effort to 
optimise the synthetic route and to improve compound stability, the preparation of N-
acetyl, amide, and oxazoline analogues are also discussed. 
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1.1. Retinoids 
 
Vitamin A (retinol) and its derivatives belong to a class of compounds known as 
retinoids. This term encompasses a group of signalling molecules that regulates many 
important biological pathways from embryogenesis through to adult homeostasis, and 
controls many aspects of cell development, proliferation, differentiation, and 
apoptosis.1 There are over 4000 natural and synthetic molecules that are structurally 
and/or functionally related to vitamin A; naturally occurring retinoids possessing 
biological activity include all-trans-retinoic acid (ATRA, or simply RA), 9-cis-retinoic acid 
(9-cis-RA), 11-cis retinaldehyde, and 3,4-didehydro retinoic acid.2 ATRA is the most 
abundant endogenous retinoid and has been widely studied for many years; ATRA 
isomerises under physiological and experimental conditions, with different isomers 
activating different receptors, thus accounting for the variety of biological effects 
observed with these small molecules. 
  
 
 
 
Cellular uptake of retinoids 
Since animal species are unable to synthesise vitamin A, it is therefore obtained solely 
through the diet in the form of retinol, retinyl esters, or β-carotene. Ingested vitamin A 
is stored as retinyl esters in the liver, as well as in various extrahepatic sites including 
the heart, kidney, lung, adipose tissue, skeletal muscle, bone marrow, spleen, eye, and 
testis.3,4 Retinol is secreted from these areas and is transported in the blood bound to 
Fig. 1   Examples of some naturally occurring retinoids: (a) retinol (vitamin A);  
(b) all-trans-retinoic acid (ATRA); (c) 9-cis-retinoic acid (9-cis-RA). 
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the serum retinol-binding protein 4 (RBP4), where it is taken up by target cells through 
interacting with STRA6, a widely expressed multi-transmembrane receptor protein.5 
An enzyme responsible for esterifying vitamin A within the cell, lecithin:retinol acyl 
transferase (LRAT), is also required for effective uptake of vitamin A via this pathway.6 
High levels of STRA6 are expressed at blood/organ barriers, as well as in various 
embryonic and adult cell types during development,7 which is indicative of a necessity 
for retinoid action at these sites; vitamin A can thus be delivered to defined cell types 
according to requirement. 
Metabolism of retinoids 
Upon entering the cytoplasm, retinol is either stored or converted into a form that is 
able to regulate gene transcription. In the latter case, retinol binds to the cellular 
retinol-binding protein 1 (CRBP1) and is subsequently metabolised in two steps to 
ATRA: in many cell types the enzyme retinol dehydrogenase 10 (RDH10) reversibly 
oxidises retinol to retinal, which may then be irreversibly oxidised to ATRA by retinal 
dehydrogenases (RALDHs).8 The cytoplasmic proteins cellular RA-binding proteins 1 
and 2 (CRABP1 and CRABP2) bind to the newly synthesised RA; CRABP1 is known to 
inhibit retinoid activity by sequestering free RA, while CRABP2 appears to regulate RA 
transport and metabolism both in the developing embryo and throughout adult life.9 
Thus, the in vivo regulation of vitamin A metabolism by these binding proteins to 
generate biologically active retinoids is an important area for investigation.  
Retinoid signalling 
Inside the cell, CRABP2-bound RA is transported to the nucleus and exerts its 
physiological effects through interacting with the retinoic acid receptors (RARs) and 
retinoid X receptors (RXRs).10 These heterodimerise and bind specific DNA sequences 
termed retinoic acid response elements (RAREs) in the promoter region of target 
genes; the ternary complex of ligand-bound RAR with RXR and a RARE regulates gene 
transcription through altering the binding of corepressors and coactivators. ATRA 
binds predominately to RARs, while other retinoids such as 9-cis-RA exhibit a greater 
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affinity for RXRs.11 Following RAR activation, ATRA is released, exits the nucleus, and is 
oxidised for degradation and removal in the cytoplasm of cells expressing cytochrome 
P450, CYP26 (Fig. 2). 
 
 
 
 
Effects of retinoids 
By regulating gene expression through binding their nuclear receptors, retinoids 
control the development and maintain the functions of numerous biological systems. 
Important processes regulated by these signalling molecules include reproduction 
(spermatogenesis, conception, placental formation), embryogenesis (patterning of the 
Fig. 2  Pathways involved in the generation, action and catabolism of RA.
12
 
Reprinted by permission from Macmillan Publishers Ltd: NATURE REVIEWS 
NEUROSCIENCE (M. Maden, 2007, 8, 755-765), copyright 2007. 
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body axis, development of the nervous system, formation of digits), bone remodelling, 
epithelial differentiation, and the immune system. 
 
 
 
Retinoids are vital for cell proliferation, differentiation, and apoptosis in both normal 
and cancerous cells. A particular area of interest concerns the role of RA in the survival 
and differentiation of vertebrate central nervous system (CNS) neurons in the 
developing embryo.13 While many factors are involved in the regulation of 
neurogenesis, recent studies indicate that RA is able to induce differentiation of 
progenitor cells into neuronal cells.14 Similarly, RA is known to induce differentiation of 
various types of neurons and glia through transcriptional activation of genes encoding 
transcription factors, cell signalling molecules, structural proteins, enzymes, and cell-
surface receptors.15,16 RA also plays a role in maintaining the differentiated state of 
adult neurons and neural stem cells, with altered RA signalling levels contributing to 
the symptoms of some neurodegenerative diseases.17  
The generation of specific classes of neurons from neural progenitor cells in response 
to RA has been studied extensively,18 including the differentiation of neuroepithelial 
cells into ventral spinal progenitors and postmitotic motorneurons after treatment 
with RA followed by an additional small molecule, purmorphamine.19 It is interesting 
Fig. 3  Functions of naturally-occurring retinoids.
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to note that, while the role of RA in directing a high specification of distinct cell types 
has been established in various progenitor stem cell lines, there is a lack of compelling 
evidence thus far to support comparable retinoid activity at the level of the 
pluripotent stem cell. 
Retinoids are widely used in the treatment of visual and dermatological conditions, 
and they have also gained considerable attention in the field of cancer research, 
specifically as chemopreventive and chemotherapeutic agents, due to their 
differentiation, anti-proliferative, pro-apoptotic, and anti-oxidant effects. Retinoids 
were found to suppress carcinogenesis in studies using animal models for bladder, 
breast, lung, oral, ovarian, prostate, and skin cancer.20-26 In humans, retinoid 
treatment reversed premalignant human epithelial lesions and prevented lung, liver, 
and breast cancers.27-30  
 
1.2. Retinoic acid receptors 
Receptor structure 
Retinoids exert their physiological effects primarily through binding to and activating 
the ligand-dependent transcription factors RAR and RXR, leading to transcriptional 
activation of their downstream target genes. These two distinct classes of receptors 
belong to the superfamily of nuclear receptors, the common structure of which is 
shown in Fig. 4: the N-terminal A/B region is the ligand-independent transactivation 
domain, AF-1, that associates with co-activators and other transcription factors; the 
DNA-binding domain (DBD) contains two zinc finger motifs that bind specific DNA 
target sequences (RARE); the ligand-binding domain (LBD) consists of twelve α-helices 
forming a ligand-binding pocket (LBP) and is highly conserved among the nuclear 
receptor family. This latter region also contains the ligand-induced activation function, 
AF-2, that is critical in receptor interaction with transcriptional coregulators.31 
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Receptor subtypes 
RARs and RXRs each consist of three subtypes: α, β, γ, which are encoded by separate 
genes on six different chromosomes.32,33 As a result of the differential usage of two 
promoters and alternative splicing, isoforms of each subtype exist in a tissue-related 
pattern. These isoforms differ in their N-terminal regions; there are two major 
isoforms for RARα (α1 and α2) and RARγ (γ1 and γ2), and five major isoforms for RARβ 
(β1-β4 and β1’).  Two major isoforms for RXRα (α1 and α2), RXRβ (β1 and β2), and 
RXRγ (γ1 and γ2) are also known. 
RARs and RXRs are expressed in a tissue-specific manner during development: RARα is 
expressed ubiquitously in adult tissue and in the developing embryo, while RARβ and 
RARγ display highly regionalised and/or cell type-specific expression: RARβ is prevalent 
in neural tissues and RARγ is expressed predominately in the skin. RXRα is found in 
limited adult and embryo tissues including the liver, skin, kidney, spleen, and lung. 
RXRβ is more widely expressed in both the adult and embryo, while RXRγ expression 
appears to be restricted to mainly muscle and brain tissues.34 
Fig. 4  Structural organisation of nuclear receptors. 
(Reproduced from: http://en.wikipedia.org/wiki/Nuclear_receptor) 
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Receptor functions 
Numerous knockout studies using mice have been carried out in order to determine 
the in vivo functions of RAR and RXR: spermatogenesis was inhibited in RARα-null 
males, rendering the subjects sterile; abnormalities in the vitreous body of the eye, 
and impaired movement and motor coordination were observed in RARβ-null mice; 
RARγ knockout animals displayed both skeletal and epithelial defects.35-37 Targeted 
disruption of the RXRα gene resulted in embryonic lethality due to incomplete 
development of the ventricular chambers of the heart; foetuses lacking RXRα 
displayed ocular malformations, and it appears that this gene is also involved in 
mediating the teratogenic effects of retinoids.38-40 Ablation of RXRβ in mice gave rise 
to approximately 50% lethality in utero;  similar to RARα-knockout mice, RXRβ-null 
mice are also sterile: however, this is due to testicular defects and abnormal spermatid 
maturation.41 RXRβ also appears to be involved with other nuclear receptors in the 
control of lipid metabolism.42 Disruption of RXRγ produced no adverse effects on 
growth, fertility, viability, and behaviour in mice, suggesting that this gene does not 
exert any essential functional that is not also performed by the other RXR subtypes.43 
In addition to the knockout approach, selective activation with retinoids is able to 
provide further insight into the individual functions of these receptors. For example, 
abnormalities observed in RARα and RARβ double null mice in the area of early lung 
morphogenesis include unilateral lung agenesis and unilateral or bilateral lung 
hypoplasia,44 however, these effects are not observed in RAR single knockout mice.45.46 
Thus, in order to define specific roles for the individual receptors, synthetic retinoids 
were used to selectively activate RARα and RARβ signalling in RALDH2-null mice: 
activation of RARβ, but not RARα, induced expression of the fibroblast growth factor 
FGF10 and bud morphogenesis in the lung field. RARα activity was required to 
maintain overall RA signalling, and to assist in the effects mediated by RARβ.47  
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1.3. Retinoic acid receptor β (RARβ) 
Role in cancer 
Due to their involvement in regulating gene networks that control cell growth, 
differentiation, survival, and death, RARs are linked to the cancer chemotherapeutic 
and chemopreventive properties of retinoids. RARβ has received considerable 
attention in this field, and many studies have documented the critical role of this 
receptor subtype in mediating the retinoid growth-inhibitory effect in various types of 
cancer cells, including breast cancer, lung cancer, ovarian cancer, prostate cancer, 
neuroblastoma, renal cell carcinoma, pancreatic cancer, and liver cancer.48-55 
Expression of RARβ is often lost in many abnormal tissues, and in certain cases this 
may be attributed to gene silencing through epigenetic modifications such as DNA 
methylation, histone hypermethylation, and deacetylation.56-58 Treatments that 
reverse these alterations have thus been highly successful in restoring the retinoid-
induced anti-proliferative effect in various types of tumours.58,59 Similarly, transfection 
of RARβ into RARβ-null cervical, breast, and lung cancer cells also increased 
responsiveness to the growth inhibitory and apoptosis action of retinoids.60-62 Since 
expression of RARβ inversely correlates with tumour grade, this receptor is an 
important target for anticancer research, and ligands that exhibit RARβ-selective 
agonist activities constitute highly desirable targets for synthesis and application in 
this field.  
Isoform-specific effects 
In humans, the tumour-suppressive properties of retinoids are thought to be mediated 
primarily through the RARβ2 isoform, which is the most abundant of the RARβ 
isoforms.63 The promoter region of the gene encoding this receptor contains a very 
high affinity RA-responsive element,64 which directly accounts for the rapid RA-
induced transcriptional activation of RARβ2 in various cell types.65 
RARβ2 is thought to be the crucial transducer of the RA signal in neurons, and holds 
particular interest in the area of neurodegenerative disease research. Following 
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treatment with RA, upregulation of RARβ2 was observed in both embryonic and adult 
mouse dorsal root ganglia (DRG) neurons, along with stimulation of neurite outgrowth 
in both cell cultures.66 Strikingly, it was an RARβ-specific ligand that induced these 
effects, rather than an RARα or RARγ agonist. A failure to regenerate axonal 
projections in these tissues could, therefore, be attributed to the absence, or reduced 
level, of RARβ; this theory is supported by the lack of peripheral axonal regeneration 
observed in adult RARβ-null mice.67  
Compelling evidence to support isoform-specific receptor activity was observed when 
a viral vector expressing RARβ2 was transduced with non-regenerative adult mouse 
and rat spinal cord.68 This produced a large number of neurites in both mouse and rat 
cords, which was not observed in spinal cords transfected with empty or mutated 
vectors, when different RAR isoforms were used, or when the cells were treated with 
nerve growth factor. Overexpression of RARβ2 by lentiviral vectors in adult DRG or 
corticospinal tract (CST) neurons has also resulted in axonal outgrowth and functional 
recovery in models of CNS injury.69,70 
Since the gene for RARβ contains an RARE that can bind RARβ2, introduction of an 
RARβ agonist may be expected to give rise to in vivo autoregulation of RARβ2 
expression in neurons. This concept has been applied in a rodent model of spinal cord 
injury in order to demonstrate that both axonal outgrowth and functional recovery are 
induced in response to an RARβ agonist, CD2019.71 These results indicate that loss of 
RA-driven signalling pathways arising from a lack of an appropriate ligand to activate 
RARβ2/RXR heterodimers may be a contributing factor in the failure of axonal 
outgrowth in the injured CNS. The ligand may be administered at the time of spinal 
cord injury, with enhanced neurite outgrowth evident in DRG explants from CD2019-
treated lesioned animals (Fig. 5). Moreover, studies have shown that RARβ agonists 
are able to stimulate proliferation and differentiation of neural progenitor cells,72 
which may also be a contributing factor in the functional recovery observed with the 
CD2019-treated lesioned animals. Ligand therapy thus presents a simpler and more 
practical alternative to using lentiviral vectors overexpressing RARβ2: the dosage of, 
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and length of exposure to, the agonist may be controlled, and the small size and 
lipophilicity of the ligand means that potentially all affected neurons may be reached.  
 
 
 
 
 
Fig. 5  Stimulation of neurite outgrowth observed in the cortex and DRG 
explants obtained from lesioned animals treated with the RARβ agonist 
CD2019. A control vehicle was included consisting of 10% DMSO in PBS.
71 
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1.4. Synthetic retinoids 
Toxicity of natural retinoids 
Due to the diverse functions of the retinoic acid receptors (discussed in sections 1.2 
and 1.3), the non-selective receptor activation exhibited by natural retinoids is 
accompanied by a high toxicity profile, with severe side-effects observed when 
administering RA and its derivatives in various clinical trials.73 Toxicities associated 
with long-term retinoid treatment affect the skin, mucous membranes, hair, eyes, 
gastrointestinal system, liver, neuromuscular system, endocrine system, kidneys, and 
bone.74 The adverse effects of vitamin A are well documented in the medical 
community, with reports of patients presenting with unusual symptoms, notably 
hepatic congestion and fibrosis, after ingesting large doses of vitamin A.75 Patients 
with increased risk of hypervitaminosis A include those with severe type I 
hyperlipidaemia, causing an impaired ability to metabolise retinoids,76 and a familial 
clustering of individuals exhibiting characteristic symptoms of toxicity despite only a 
modest retinol intake implies a genetic predisposition towards intoxication.77 Natural 
retinoids are thus unsuitable for long-term clinical studies, and the synthesis of 
analogues possessing enhanced receptor-selective agonist activity and, as a result, a 
reduced level of toxicity, is highly desirable for facilitating such studies. 
General structure of retinoids 
Retinoids can be considered to have three units: a bulky hydrophobic region, a linker 
unit, and a polar terminus, which is usually a carboxylic acid (Fig. 6). The small size and 
amphiphilic nature of retinoids means they may be effectively transported across lipid 
cell membranes and into the nucleus, where receptor binding initiates a signalling 
cascade that produces the physiological effects observed with these biomolecules.  
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The presence of a long-chain conjugated polyene unit in natural retinoids renders 
these molecules sensitive to oxidation and isomerisation in response to acid, light, or 
heat. Furthermore, the susceptibility of retinoids to metabolic removal, and a poor 
solubility in aqueous media, limits their pharmacological utility.78 Thus, the design and 
synthesis of ligands that are stable under both laboratory and metabolic conditions 
will assist in a more thorough analysis of the effects and therapeutic potential of 
retinoids. 
Arotinoids and heteroarotinoids 
It was recognised that structures without the classic polyene chain could also be 
effective as retinoid substitutes, which led to the dramatic expansion of the range of 
molecules synthesised for biological evaluation. 4-[(1E0-2-(5,5,8,8-Tetramethyl-
5,6,7,8-tetrahydro-2-naphthalenyl)-1-propen-1-yl]benzoic acid, TTNPB (Fig. 7), is 
generally viewed as the first stable and highly potent RAR-selective agonist.79 This 
molecule contains the 1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene moiety, 
which is structurally similar to the trimethylcyclohexenylvinyl unit present in natural 
retinoids. Since the number of atoms exposed to enzymatic digestion is reduced, this 
building block is more resistant to radical oxidation and epoxidation, and there is also 
less potential for conformational isomerisation. The successful substitution of 
aromatic rings into retinoid structures, giving rise to a class of compounds known as 
arotinoids, have afforded RAR-selective agonists exhibiting remarkable chemical 
Fig. 6  The general structure of retinoids (exemplified by ATRA). 
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stability along with improved bioavailability. Hence, in biological assays, TTNPB was 
found to be 10-fold more potent than ATRA, but also considerably more toxic, when 
used as a pharmacological agent.80 
 
 
 
Retinoids selective to each RAR subtype have also been reported: the TTNPB 
derivative Am80 demonstrates selective activity towards RARα as well as RARβ, and 
led to the development of further RARα-selective retinoids, such as Am555S and AGN-
193836; BMS961 was developed as a RARγ-selective retinoid (Fig. 8).81-83 It is 
interesting to note in these structures the presence of an amide linking group between 
two aromatic rings.  
 
 
Fig. 7  TTNPB, a RAR-selective synthetic retinoid.
80 
Fig. 8  RAR-subtype selective arotinoids: Am80 (RARα- and RARβ-selective); Am555S 
and AGN-193836 (RARα-selective); BMS961 (RARγ-selective).
81-83 
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The substitution of one of the gem-dimethyl groups on the tetrahydronaphthalene 
ring of TTNPB with oxygen or sulphur produces a group of compounds known as 
heteroarotinoids (Fig. 9). Similar biological activities of these molecules compared to 
ATRA were observed,84 along with reduced toxicities,85 which may be attributed to the 
presence of an electronegative heteroatom.86 However, the reported lower activities 
of some heteroarotinoids can be due to the increased susceptibility of the molecules 
towards metabolic removal: for example, TTNPB may be expected to be more active 
than its thia-analogue, since the sulphur atom present in the latter can potentially be 
oxidised to a sulfone or sulfoxide. Although beyond the scope of this introduction, it is 
worth noting that RXR-selective ligands are also known.87,88 
 
 
 
 
Fig. 9  Examples of heteroarotinoids.
84-88 
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Most potent synthetic retinoids consist of a benzoic acid or other aromatic carboxylic 
group in place of the unstable polyenecarboxylic acid present in natural retinoids. 
Additionally, the structure of the hydrophobic region and linking group may be varied 
while retaining high activity. However, replacing the terminal carboxylic acid with 
other functional groups such as an aminosulfonyl, amidino, or tetrazolyl, is generally 
accompanied by a significant decrease, or loss, of activity.81 However, a 
thiazolidinedione moiety (such as TZ335, Fig. 10a) has been suggested as an effective 
replacement,89 as well as a tropolone ring (for example, Tp80, Fig. 10b).90 The latter 
moiety, 2-hydroxy-2,4,6-cycloheptatrien-1-one, is an isomer of benzoic acid, consisting 
of a seven-membered, non-benzenoid aromatic molecule containing three double 
bonds conjugated with a carbonyl group. Furthermore, a novel retinoid structure has 
recently been reported containing a 1,2,4-oxadiazol-5-one group as the polar 
terminus, with one compound in particular displaying significant activity towards RARβ 
(Fig. 10c).91 
 
 
 
 
Fig. 10  Synthetic retinoids containing (a) thiazolidinedione
89
, (b) tropolone
90
, and 
(c) 1,2,4-oxadiazol-5-one
91
 functional groups in place of a carboxylic acid terminus.
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Subtype-selective ligands 
A ligand exhibiting an affinity difference greater than 100-fold between its primary 
target and other receptors may be considered as selective for this particular 
receptor.92 Below this threshold, the ligand is defined as showing preference for the 
given receptor. The advantages of producing RAR-selective agonists for the purposes 
of investigating the physiological function of these receptors, as well as to provide 
novel tools for research and therapeutic exploitation, are clear: synthetic ligands with 
reduced toxicity profiles and increased stabilities compared to natural retinoids will 
greatly assist in the application and study of these compounds in the context of 
biological systems. 
The individual RAR subtypes are associated with different phenotypes: RARγ is linked 
to skin,93 bone and teratogenic toxicity,94 whereas RARα is associated with elevated 
triglyceride levels.95 Examples of synthetic retinoids that selectively target these 
subtypes are known.82,96 RARβ exhibits a more restricted expression profile97 and 
appears to be a promising anticancer target due to its ability to supress proliferation of 
specific cell types.98 The major toxicity issues associated with the other RARs mean 
that the use of an RARβ-selective ligand can potentially circumvent these problems. 
However, the design of these subtype-selective ligands is complicated by the similarity 
of the RAR LBDs: the LBD of RARβ differs from that of RARα and RARγ by only one and 
two residues, respectively.  
In order to gain more insight into the distinguishing structural features of the RAR 
isotypes, the 3D-structure of the RARβ LBD was determined (Fig. 11), and 
superposition with the RARγ LBD revealed the former to be significantly larger.99 
Rather than being due to a conformational adaptation in response to ligand-binding, 
this reflects a different architecture of the LBDs: In RARβ, the I263 side chain is in a 
position that allows for the creation of an additional cavity between H5 and H10. This 
is not possible in the case of the RARγ LBD, since the residue M272 is directed towards 
the interior of the binding-pocket.100 From these findings, it can be inferred that 
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ligands able to occupy the additional space in RARβ may acquire selectivity for this 
subtype. 
    
 
 
 
Through screening a panel of synthetic retinoids using an in vivo reporter cell system, 
BMS641 (Fig. 12) was found to exclusively activate RARβ with an affinity 100 times 
greater than that for RARα or RARγ.99 Since the non-chlorinated analogue was able to 
bind to all three RARs with similar affinity profiles, the presence of a halogen at the C3 
position was thought to be a crucial determinant for generating RARβ selectivity. 
  
 
 
Fig. 12  RARβ-selective agonist, BMS641.
99 
Fig. 11  Left: Electron density map of TTNPB in RARβ LBD; Right: Superposition of TTNPB-RARβ 
(blue) and 9-cis-RA-RARγ (grey) LBDs. Isotype-specific residues are shown in cyan (RARβ) and 
orange (RARγ), and TTNPB in yellow (reproduced with permission).
99 
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RARβ isoform selectivity 
It is evident that ligands selectively targeting RARβ2 would be of great advantage in 
exploring conditions associated with an absence, or lack of function, of this receptor; 
however, the design of these isoform-selective agonists represents an even more 
challenging prospect: The LBDs of the isoforms are identical and differ only in their N-
terminus, in a region encompassing the ligand-independent activation domain AF-1. 
Therefore, rational drug design based on the current crystal structures of RARβ is 
unlikely to be extended to include isoform selectivity. 
Despite these difficulties, isoform-selective agonists have been identified using a high 
throughput screening assay, namely, receptor selection and amplification technology 
(R-SAT). Thus, a chemical library of over 160,000 compounds was assessed for activity 
against the RARβ2 receptor, and led to the identification of 4’-octyl-4-
biphenylcarboxylic acid, AC-55649 (Fig. 13) as an RARβ2-selective ligand, which 
displayed 100-fold activity for RARβ2 over other RARs, along with a potency of 100 
nM.101 Studies of structure-activity relationships of these biphenyl compounds 
revealed the importance of chain length for activity, with the octyl to nonyl chain 
analogues displaying optimal RARβ2-agonist activity. A hit-to-lead optimisation led to 
the synthesis of a more potent RARβ2 agonist possessing drug-like properties, the 
thiazole-containing compound AC-261066 (Fig. 13).  
 
 
 
 
Fig. 13  RARβ2-selective agonists.
101 
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Docking studies with AC-55649 and thiazole AC-261066, along with ATRA, were carried 
out in a model of the ligand-binding domain of the RARβ receptor (Fig. 14):101 The 
polar carboxy-aromatic section of the molecules can be seen to overlap, where a 
network of hydrogen bonds is formed between the negatively-charged carboxylate 
and the polar amino acid residues Arg278 and Ser289. The aliphatic side chains and 
cyclohexenyl ring were positioned in the lipophilic pocket, and it was suggested that 
favourable interactions with Leu407, Met406, and Ile403 contributed to the agonist 
activity observed with AC-55649 and AC-261066. Thus, it was concluded that the lower 
activity observed with ligands containing shorter side chains was due to insufficient 
contact with the residues in the LBP. However, since molecular docking studies with 
these small molecules were carried out using the RARγ subtype, the basis for their 
receptor-selective activity should be further investigated. 
 
 
 
 
 
Fig 14  Docking of AC-55649 (blue), AC-261066 (green) and ATRA (red) in a 
model of the ligand-binding domain of the RARβ receptor.
101 
(Reprinted with permission from: B. W. Lund, F. Piu, N. K. Gauthier, A. Eeg, 
E. Currier, V. Sherbukhin, M. R. Brann, U Hacksell and R. Olsson, J. Med. 
Chem., 2005, 48, 7517-7519. Copyright 2005 American Chemical Society.)  
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1.5. Summary 
 
The present challenge lies in the integration of structural and molecular biological 
information for the study of the physiological significance of retinoid receptor 
signalling, which will facilitate the development of investigative tools for research and 
therapeutic applications. Well-documented evidence has identified retinoic acid and 
its derivatives as potential agents for treating neurodegenerative diseases; a 
prominent target is RARβ2, with the discovery of a number of molecules exhibiting 
potent agonistic properties towards this receptor. Thus, if a particular receptor 
isoform could be selectively targeted for activation, specific biological outcomes could, 
potentially, be promoted, along with reduced unwanted and/or toxic side effects. It 
remains to be seen if such selectively could be achieved in the design and synthesis of 
synthetic retinoids, and, if successful, to what extent these molecules may be 
manipulated in biological systems in order to produce the desired result.  
 
1.6. Project Aims 
 
The synthesis of thiazole-containing small molecules is described in the following 
chapter, along with an evaluation of their activity in the TERA2.cl.SP12 EC stem cell 
line, in order to ascertain if enhancement of neural differentiation may be induced by 
these compounds, and if these effects may be attributed to activation of the RARβ2 
receptor. 
In the second part of this thesis, the synthesis and characterisation of a fluorescent 
analogue of EC23, which is a highly stable and potent synthetic retinoid developed in 
our laboratory,115 is described. The ultimate goal was to produce a fluorescent probe 
which would also be an active small molecule modulator of stem cell differentiation: 
this would allow the pathway of retinoid transport to be followed in live-cell tracking 
studies, and could potentially constitute a powerful tool in the field of retinoid 
research. 
  
 
 
 
 
 
2. SYNTHESIS AND BIOLOGICAL 
EVALUATION OF THIAZOLE-
CONTAINING RETINOIDS 
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2.1. Background and Aims 
 
A cell-based functional assay using R-SAT identified 4-[4-(2-ethoxy-ethoxy)-5-methyl-
thiazol-2-yl]-benzoic acid (A, Fig. 15) as displaying 78% of the activity for RARβ2 
compared to the reference compound, AM580.102 The thiazole moiety is present in 
naturally-occurring molecules possessing important antibiotic,103 antitumour,104 and 
immunosuppressive properties.105 The presence of a sulphur atom means that 
thiazole-containing compounds may be susceptible to metabolic oxidation and 
removal, in which case they will be inherently less toxic than synthetic retinoids that 
are unable to be metabolised.  
 
   
 
 
Compound A was duly synthesised in our laboratory and assessed for its ability to 
induce cellular differentiation of the human pluripotent embryonal carcinoma (EC) 
stem cell line, TERA2.cl.SP12.106 However, a comparison of cell morphology between 
cell cultures treated with thiazole A and those treated with the natural retinoid ATRA 
showed that the synthetic molecule was unable to arrest cell proliferation and direct 
differentiation at the concentration used. Quantification of the effects of this 
compound on inducing differentiation of this cell line by analysing for expression of 
known markers for stem cell and differentiated cell phenotypes further confirmed that 
compound A was unable to induce the differentiation of EC stem cells. 
The ability of compound A to modulate the differentiation of the neuroprogenitor cell 
line, ReNcell 197VM, was also assessed: after 7 days, cultures exposed to thiazole A 
Fig. 15  RARβ2-selective 4-[4-(2-ethoxy-ethoxy)-5-methyl-thiazol-2-yl]-benzoic acid (A) 
and reference compound AM580.
102 
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appeared similar to the control differentiation cultures, while cells treated with ATRA 
displayed predominately neuronal morphology compared to the control cultures. 
Immunocytochemical staining to record the expression of the pan-neuronal marker β-
III-tubulin, and the marker of mature neurons, NF-200, was then performed (Fig. 16). 
 
        
 
 
 
Quantification of positively stained cells for these markers showed that, compared to 
the differentiated control cultures, compound A did not induce significant neuronal 
differentiation in this cell line: Control differentiation cultures stained for the general 
neuronal marker β-III-tubulin, and showed minimal levels of NF-200 expression, which 
CONTROL DIFF COMPOUND A ATRA 
P
H
A
SE
 
β
-I
II
-T
U
B
U
LI
N
 
N
F-
2
0
0
 
Fig. 16  Effect of supplementation of ReNcell 197VM culture media with 1 µM compound A or ATRA 
on the induction of neural differentiation as observed by immunocytochemical staining for markers 
for β-III-tubulin (a general neuronal marker protein) and neurofilament protein NF-200 (a 200 kDa 
protein expressed in mature neurons), compared to differentiated (control diff) control cultures. 
Scale bar represents 100 µm.
106 
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was indicative of an immature neuronal phenotype. In contrast, cultures exposed to 
ATRA displayed an approximately 1.5-fold increase in cells staining positive for β-III-
tubulin, along with a 3-fold increase in those staining positive for NF-200. 
It was hypothesised that modification of the side chain to a more bulky hydrophobic 
group may mean that the molecule is better able to bind in the larger cavity of the 
RARβ2 receptor, thereby eliciting a more effective retinoid response. Hence, in order 
to determine if such analogues are capable of inducing cellular differentiation, the  
synthesis of two thiazole derivatives containing phenyl and 1,1,4,4-tetramethyl-
1,2,3,4-tetrahydronaphthalene groups (Fig. 17), and their biological evaluation in the 
TERA2.cl.SP12 EC stem cell line, are described in the following sections.  
 
              
 
2.2. Synthesis of 2,4-disubstituted thiazole derivatives 
 
Ethyl 4-cyanobenzoate (3) was heated with equimolar equivalents of 2-
mercaptopropionic acid (4) and pyridine under microwave (MW) conditions to provide 
the desired hydroxythiazole 5a after recrystallisation (Equation 1). The reaction 
appeared to be reversible, with the product reverting back to the starting material if 
not isolated immediately. 
Fig. 17  Proposed novel 2,4-disubstituted thiazole derivatives with bulky phenyl 
(1) and 1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene (2) side chains.
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Despite TLC and MS analyses indicating the presence of only one product, two species 
were observed by 1H NMR spectroscopy, and were found to be inseparable by either 
recrystallisation or column chromatography. The overlapping ethyl signals, along with 
an additional doublet and quartet peak in the alkyl region of the spectrum, were 
deduced to be consistent with the keto-tautomer 5b (Scheme 1). This occurrence was 
not reported previously, and compound 5b constituted a significant proportion of the 
mixture (approximately 15%). 
 
 
 
4-Hydroxy-1,3-thiazoles are known as active inhibitors of 5-lipoxygenase107 and 
CDK5,108 and exist in different tautomeric forms: the enol-form is favoured in polar 
solvents and the keto-form in non-polar solvents.109 In this case, the lower energy of 
the aromatic 4-hydroxythiazole structure, as well as the presence of an aromatic 
substituent at the 2-position, is likely to account for the predominance of the enol 
tautomer.110 Furthermore, functionalising the hydroxyl group of compound 5a would 
Equation 1 
Scheme 1  Keto-enol tautomerism of 5a. 
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be expected to ‘lock’ the product in the aromatic form; indeed, this was observed 
when the keto-enol mixture was treated with triflic anhydride to provide triflate 6, and 
loss of signals associated with the keto-tautomer was accordingly observed by 1H NMR 
analysis of the product.  
Procedures for the conversion of hydroxythiazoles to triflates are known,111 and have 
been employed in the derivatisation of these compounds to give biologically-useful 
agents.112 Initially, the Comin’s reagent was stirred with the hydroxythiazole in 
tetrahydrofuran, however, a TLC analysis after 6 h showed predominately a mixture of 
starting materials was present. The use of triflic anhydride with pyridine as base was 
similarly ineffective in promoting product formation; however, when pyridine was 
replaced by triethylamine, triflate 6 was obtained in 20% yield after purification by 
silica-gel chromatography. The yield was improved by the use of a more hindered 
base, diisopropylethylamine (DIPEA), which provided compound 6 in 81% yield 
following purification (Equation 2). 
 
 
 
With triflate 6 in hand, Suzuki-Miyaura cross couplings were performed in order to 
provide small molecules with retinoid-like structures (Scheme 2). Commercially-
available 4,4,5,5-tetramethyl-2-phenyl-[1,3,2]-dioxaborolane (7) was reacted with 
triflate 6 in DMF/H2O, using K3PO4 and 3 mol% Pd(dppf)Cl2 as catalyst. After heating to 
80 °C for 18 h, an aqueous workup was performed, and the residue was purified by 
silica-gel chromatography to give 4-(5-methyl-4-phenyl-thiazol-2-yl)-benzoic acid ethyl 
ester 9 in 69% yield. Compound 10 was prepared in an analogous manner using 
Equation 2 
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4,4,5,5-tetramethyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-[1,3,2]-
dioxaborolane (8), and the product was obtained in 87% yield following purification by 
column chromatography. 
 
      
 
 
Base hydrolyses of esters 9 and 10 were attempted using the conventional method of 
stirring in THF with LiOH·H2O at ambient temperature. However, the reactions were 
slow and poor-yielding, despite the addition of more base and heating for a period of a 
few days. Instead, a microwave-assisted method of heating to 160 °C for 15 min 
provided the desired acids 1 and 2 in good yields (88% and 85%, respectively) 
following aqueous workup and recrystallisation. 
 
Scheme 2  Suzuki-Miyaura coupling reactions to give retinoid-like structures containing 
bulky phenyl  (9) and 1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene (10) side chains. 
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2.3. Effect of thiazole retinoid-like small molecules on the differentiation 
of human pluripotent stem cells 
Cell culture 
Having prepared the 2,4-disubstituted thiazole molecules 1 and 2, they were assessed 
for their ability to induce differentiation of the pluripotent human embryonal 
carcinoma stem cell line, TERA2.cl.SP12. Cells of this lineage are proven models of 
human embryonic development,113 and have been used to study neural 
differentiation.114 Cultures of TERA2.cl.SP12 EC cells were duly incubated with 
compounds 1 or 2 supplemented in the culture media to a final concentration of 10 
μM for up to 14 days. 
Scheme 3  Hydrolysis reactions of esters 9 and 10. 
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The effects of the test compounds on inducing stem cell differentiation were 
compared with the effect of the natural retinoid ATRA, which acted as a positive 
control. Hence, cultures consisting of cells treated with 10 μM ATRA in the growth 
media were also established and incubated alongside the test cultures. Cell cultures 
supplemented with the loading vehicle DMSO were also set up to act as a negative 
differentiation control, and these were processed for analysis after 3 days. In order to 
minimise ATRA degradation and isomerisation, all culture flasks were handled under 
reduced light conditions. Furthermore, for reproducibility of results, cell cultures for 
each compound were set up in triplicate for each time point, and these were 
processed for analysis after 3, 7, and 14 days. 
                                    
        
 
After 7 days, it became apparent that cell proliferation in cultures exposed to ATRA 
and compound 2 had slowed considerably, which was consistent with cells committing 
to differentiate. In contrast, cells treated with compound 1 continued to proliferate, 
and very high cell numbers were observed (Fig. 18), which was a clear indication that 
these molecules were unable to arrest cell proliferation and induce cell differentiation 
ATRA 1 
2 
Fig. 18  Morphological appearance of 
TERA2.cl.SP12 human pluripotent 
stem cells exposed to 10 µM of ATRA, 
1, and 2 for 7 days. Note the similar 
appearance of cells treated with ATRA 
and 2, and the high cell numbers in  
the culture treated with 1, indicating 
continued proliferation rather than a 
commitment to differentiation.  
Scale bar represents 500 µm. 
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at the concentration used. The appearance of the cells after 14 days followed a similar 
trend, i.e. cell proliferation slowed in response to ATRA and compound 2, whereas 
cultures exposed to compound 1 became over-confluent due to continued cell 
proliferation (Fig. 19). 
                    
 
                                                                                                     
   
 
 
 
 
Cell viability assay 
After incubating for 7 days in compound-supplemented media, cells were prepared for 
an assay of cell viability by combining culture media containing any potentially 
detached or dead cells, with trypsinised live cells from each experimental condition. 
The resulting cell solution from each flask was centrifuged, then re-suspended in 0.1% 
BSA solution to allow cells to be counted. Cells from cultures exposed to ATRA and 
comppounds 1 and 2 were diluted in a staining solution, and the proportion of live 
(intact cytoplasmic membranes excluded the dye) to dead (compromised cell 
membranes stained positive for the dye) cells was determined using a Viacount assay 
on a Guava EasyCyte cytometer. The number of viable cells, percentage viability, and 
total cell counts were thus determined (Fig. 20).  
Fig. 19  Morphological appearance of 
TERA2.cl.SP12 human pluripotent 
stem cells exposed to 10 µM of 
ATRA, 1, and 2 for 14 days. Note the 
similar appearance of cells treated 
with ATRA and 2, and continued cell 
proliferation in the culture treated 
with 1. Scale bar represents 500 µm. 
1 
2 
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Fig. 20  TERA2.cl.SP12 EC stem cells incubated for 7 days in culture media 
supplemented with 10 µM of ATRA, compound 1, or compound 2. The number of 
viable cells, percentage viability, and total cell counts were determined using a 
Viacount assay and these are represented in graphical format (for reproducibility, 
results are the average of triplicate assays ± SEM for each culture condition, n = 3). 
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Continued cell proliferation in cultures treated with compound 1 was reflected in the 
high cell count and number of viable cells, whereas with ATRA and compound 2, these 
values were lower due to cells exiting the cell cycle and committing to differentiation. 
However, cells exposed to compound 1 proved less viable than those treated with 
ATRA and compound 2, which was consistent with suboptimal culture conditions due 
to high cell numbers and over-proliferation. The similarity of cell viability values 
observed in the cultures treated with ATRA and compound 2 supports the earlier 
observation from cell morphology that these compounds act in a comparable fashion 
when exposed to the TERA2.cl.SP12 EC cell line. 
Differentiated-cell assay 
In order to quantify the effects of the thiazole-containing compounds on inducing 
differentiation of the TERA2.cl.SP12 cell line, cells were analysed for expression of 
known markers for stem cell and differentiated cell phenotypes. Cells from each 
experimental condition were incubated with antibodies for the stem cell antigens 
SSEA-3 (globoseries stage-specific embryonic antigen-3) and TRA-1-60 (a keratin-
sulphate-associated glycoprotein stem surface marker). Following this, incubation with 
a secondary fluorescent antibody allowed the proportion of cells expressing the 
marker to be determined through flow cytometry (Fig. 21, SSEA-3 and TRA-1-60). 
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Fig. 21  TERA2.cl.SP12 EC cells were exposed to 10 µM of ATRA, 1, and 2 for 14 days and analysed 
for expression of stem cell markers (SSEA-3 and TRA-1-60) and a neural marker (A2B5). Expression 
of SSEA-3 and TRA-1-60 decreased significantly in cultures exposed to ATRA and compound 2, with 
a corresponding increase in A2B5 expression. Conversely, a high level of stem cell character was 
observed for compound 1, with minimal A2B5 expression, indicating the compound does not 
induce differentiation. After 14 days, spontaneous differentiation of cell cultures exposed to 
compound 1 could account for the reduced SSEA-3 and TRA-1-60 levels, along with the elevated 
expression of A2B5. (For reproducibility, results are the average of triplicate assays ± SEM for each 
culture condition, n = 3).   
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After 3 days, expression of SSEA-3 and TRA-1-60 in cultures treated with ATRA and 
compound 2 began to decrease compared to the negative DMSO control. This was 
especially clear for SSEA-3 where levels decreased by approximately 55% and 42% in 
the cultures exposed to ATRA and compound 2, respectively. These data provide a 
strong indication of TERA2.cl.SP12 stem cells committing to differentiate in response 
to these compounds. However, no significant change in expression of these stem cell 
markers was observed for cells exposed to compound 1, suggesting that these cells 
retained a more stem cell-like phenotype. After 7 days, expression of SSEA-3 and TRA-
1-60 in the cultures treated with ATRA and compound 2 was greatly reduced, and 
remained minimal after 14 days. At this point it was surprising to note also the 
dramatic reduction in TRA-1-60 expression in cells treated with compound 1, 
indicating that differentiating cells may be present in these cultures.  
Since TERA2.SP12 cells are known to form neurons in response to exposure to ATRA,111 
the expression of the antigen A2B5 (ganglioseries antigen marking early-stage neural 
cells), which is associated with differentiating neural cell types, was also monitored by 
flow cytometry (Fig. 21, A2B5). As expected, the expression of A2B5 increased in 
response to ATRA over the course of the study period. A very similar pattern of 
expression was recorded in cultures treated with compound 2, suggesting that the 
compound is capable of inducing differentiation of TERA2.cl.SP12 cells with a level of 
activity comparable to that of the natural retinoid. After 7 days, no significant increase 
in antigen expression was observed in response to compound 1, yet by day 14, an 
elevated A2B5 expression was recorded that was similar to the levels observed with 
ATRA and compound 2. It would appear that differentiated cell types were now 
present in these cultures; however, further investigation would be required to 
determine if this was the result of spontaneous differentiation in the cultures due to 
sub-optimal growth conditions, rather than due to any effects induced by compound 
1. Nonetheless, given the length of time required before a change in cell phenotype 
was observed, it was unlikely that compound 1 behaved as a true inducer of 
differentiation. 
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Effect on neurite outgrowth 
(Assay carried out by Daniel M. Tams) 
Since the thiazole retinoid-like small molecule 2 was shown to induce neural 
commitment by flow cytometric analysis, it was hypothesised that these differentiated 
stem cells would subsequently form neurites. Thus, to assess neurite outgrowth, a 
human model of neurite formation was used: suspension aggregates of TERA2.cl.SP12 
cells were differentiated with 0.1 μM of compound 2, ATRA, or EC23. The latter is a 
photo-stable synthetic retinoid that has been found to exhibit a higher level of activity 
towards the induction of neural differentiation compared to ATRA.115,116 After 21 days, 
neurospheres from each treatment group were placed on laminin and poly-D-lysine 
coated substrates to induce neurite formation. The neurospheres were maintained for 
10 days prior to analysis. 
 
 
To visualise neurite outgrowth from each cell aggregate, immunocytochemical analysis 
of the neuronal marker β-III-tubulin was performed: staining for the marker showed 
that in cultures treated with compound 2 or EC23, many individual neurites were 
formed that projected from the central neurosphere. Quantification of the neurite 
number revealed a significant enhancement of neuritogenesis in these treatment 
groups compared to ATRA and the undifferentiated control (Fig. 22). 
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Fig. 22  Neurite outgrowth from differentiated TERA2.cl.SP12 EC stem cells. Cell 
aggregates were differentiated with 0.1 µM ATRA, EC23, or compound 2 for 21 days. 
Differentiated aggregates were placed onto a laminin poly-D-lysine substrate for 10 days 
to allow neurites to form. Neurites were stained with the pan-neuronal marker β-III-
tubulin (green), and cell bodies were stained with DAPI (blue). Results are the average of 
triplicate assays. Error bars represent ± SEM, *p < 0.05. Scale bar represents 50 µm.  
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The ability of EC23 or compound 2 to promote neurite outgrowth in this model was 
likely due to the stability of these compounds, which could give rise to enhanced 
retinoic acid receptor activation. Furthermore, the lack, or reduced level, of 
metabolite formation could contribute to eliciting a more homogeneous biological 
response, along with a corresponding decrease in undesirable side effects: this could 
potentially constitute an interesting area for future investigation into the biological 
activities of these synthetic retinoids. 
 
2.4. Stability study 
 
ATRA is known to be susceptible to isomerisation and degradation, particularly when 
exposed to light. This is an important area where retinoid activity and potency may be 
compromised. While the structure of the thiazole-containing compounds does not 
suggest any potential for instability or isomerisation, a light experiment was 
nevertheless conducted in order to confirm their stability. Compounds 1 and 2 were 
dissolved in DMSO-d6 in NMR tubes, and exposed to a white fluorescent light source at 
a distance of 40 cm for a period of 30 days. 1H NMR spectra were recorded at various 
time intervals and compared to the spectrum from day 1. No signs of decomposition, 
or loss of integrity, of the signals were observed over the course of the investigation, 
and the compounds can therefore be considered stable towards light exposure. 
 
2.5. Conclusions and Outlook 
 
The experimental evidence demonstrates clearly that compound 2 is able to induce 
the differentiation of human TERA2.cl.SP12 EC stem cells on a level comparable to that 
of the natural retinoid ATRA. Furthermore, at 0.1 µM, compound 2 promotes 
enhanced neural commitment and neurite outgrowth over ATRA, with levels similar to 
that observed with the synthetic retinoid EC23. Further characterisation would be 
required to determine if compound 2 exhibits selectivity for a particular retinoic acid 
receptor subtype, and if this could account for the positive results observed. 
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Despite the alkoxythiazole-containing compound A having previously been identified 
as an RARβ2 agonist,102 earlier studies found that this molecule showed limited ability 
to modulate the differentiation of either the pluripotent TERA2.cl.SP12 or the 
neuroprogenitor ReNcell 197VM cell lines.106 Although RARβ2 signalling is understood 
to play a significant role in neurite outgrowth,66,69,70 activation of this receptor thus did 
not appear to result in a positive effect on neuritogenesis when compared to ATRA or 
EC23 under the conditions tested. It remains possible that activation of RARβ2 is a 
necessary, but not sufficient, factor for neuronal differentiation in these types of 
human cells. 
Overall, these results show how subtle modifications to the structures of small 
molecules, specifically the incorporation of bulky hydrophobic side chains, can have a 
significant impact on their biological activity. Such information concerning structure-
activity relationships will advance our ability to design new compounds for specific 
biological applications. 
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3.1. Cell imaging 
 
A great challenge of this post-genome age lies in determining the biological 
significance of intracellular molecules in living cells. The visualisation of cellular 
molecules will provide information concerning their location and function, and the 
design and synthesis of chemical tools which will be suitable for these purposes will, 
therefore, prove to be highly valuable areas for investigation and development. The 
field of cell imaging has become increasingly important in chemical biology research 
over the last two decades, and fluorescent molecules have thus been synthesised and 
successfully applied for imaging cellular structures,117 which has led to the 
commercialisation of many probes for a wide variety of biological applications. 
 
 
 
 
 
 
 
Fig. 23  Fluorescence image of a mouse NIH3T3 fibroblast cell 
fixed and stained for DNA (blue), and the major cytoskeletal 
filaments actin (red) and α-tubulin (green).
118
 
Reprinted from Acta Materialia, 55, S. Suresh, Biomechanics 
and biophysics of cancer cells, 3989-4014, copyright 2007, 
with permission from Elsevier. 
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3.2. Fluorescence 
 
Fluorescence is a form of luminescence in which a substance that has absorbed light or 
other electromagnetic radiation emits light from electronically excited states. The 
electromagnetic spectrum is outlined in Fig. 24, and gives the range of all possible 
frequencies of electromagnetic radiation. 
 
 
 
 
In fluorescence, the emitted light is usually of a longer wavelength (and lower energy) 
than the absorbed light. This phenomenon is known as Stokes shift, and is attributed 
to the loss of energy, usually via vibrational relaxation to the lowest energy level of the 
first excited state (S1), before an absorbed photon is emitted. The quantum yield gives 
the efficiency of the fluorescence process: it is defined as the ratio of the number of 
photons emitted to the number of photons absorbed (maximum value = 1, i.e. every 
absorbed photon results in an emitted photon). The fluorescence lifetime refers to the 
average length of time a molecule remains in an excited state before undergoing 
relaxation back to the ground state. In phosphorescence, a longer excited state 
Fig. 24  The electromagnetic spectrum. 
(Reproduced with permission from: http://www.cyberphysics.co.uk/topics/light/emspect.htm) 
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lifetime is observed, followed by radiative decay (i.e. photon emission) from an excited 
triplet state. A summary of the various transitions between the electronic states of a 
molecule is given in the Jablonski diagram (Fig. 25).  
 
 
 
 
Fluorescence has wide-ranging and important applications in a variety of fields such as 
minerology, gemology, geology, fluorescence spectroscopy, fluorescence labelling, 
microscopy, medicine, forensics, and most commonly, in fluorescent lamps. 
 
3.3. Fluorescence microscopy 
 
Fluorescence microscopy has become an important tool for investigating biological 
molecules, pathways, and processes in living cells, tissues, and organisms. The 
compatibility of fluorescence microscopy with live cells confers an advantage over 
other imaging techniques, and dynamic and non-invasive studies may be carried out. 
Fig. 25  Jablonski diagram. 
(Reproduced from: http://www.olympusmicro.com/primer/java/jablonski/jabintro/) 
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Specific applications employing fluorescence include cellular and molecular imaging, 
cell labelling and tracking, and DNA detection.119 
The sample is placed under the objective lens of a fluorescence microscope and 
illuminated with light of a specific wavelength. This is absorbed by the fluorophores 
(fluorescent chemical compounds, see section 3.4.) present in the sample, which 
subsequently emit light of longer wavelengths (i.e. different colours) to the absorbed 
light. A spectral emission filter separates the weaker emitted fluorescence from the 
illuminating light. Typical components of a fluorescence microscope include: a light 
source (commonly a xenon arc or mercury-vapour lamp, or, in more advanced 
instruments, high-power LEDs and lasers); the excitation filter; the dichroic mirror; and 
the emission filter (Fig. 26). Different filters and dichroic mirrors are selected based on 
the excitation and emission characteristics of the fluorophore. Hence, the distribution 
of each fluorophore in a sample may be visualised separately, and multi-colour images 
may be generated by overlaying the single-colour images. 
 
 
 
Fig. 26  Schematic diagram of the typical components of a fluorescence microscope, 
exemplified by the epifluorescence microscope, where excitation and emission of the 
sample are both focused by the objective lens. 
(Reproduced from: 
http://biologywiki.apps01.yorku.ca/index.php?title=Main_Page/BIOL_4160/Visualizing_the
_Photosynthetic_Apparatus) 
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Wide-field and confocal microscopy represent the two most widely used fluorescence 
imaging methods: In wide-field microscopy, the entire sample is evenly flooded in light 
from a mercury or xenon source, and the resulting fluorescence may be viewed 
directly by eye or projected onto a camera, along with a large unfocused background. 
Confocal microscopy uses a focused laser beam that is scanned laterally along the x 
and y axes of the sample; point illumination and a pinhole in an optically conjugate 
plane in front of the detector eliminate out-of-focus signals, offering improved optical 
resolution compared to conventional wide-field microscopy. However, since much of 
the fluorescence is blocked at the pinhole, long exposure times are often required in 
order to compensate for a reduced signal intensity.  
Autofluorescence is the natural emission of light by biological structures, such as 
mitochondria and lysosomes, when they have absorbed light. This can interfere with 
visualisation of samples using fluorescence microscopy, since the structures of interest 
may be less discernible as a result. Hence, it is desirable to use fluorescent markers 
which are easily detectable despite cellular autofluorescence, and the latter may be 
excluded in some microscopes by making use of the different excited state lifetimes of 
individual fluorophores. 
 
3.4. Fluorophores 
 
Fluorophores are fluorescent chemical compounds, usually organic small molecules 
(ranging from 200 to 1000 Dalton), and typically contain several aromatic groups or π-
bonds in conjugation; an ideal fluorophore has a high absorption and fluorescence 
quantum yield, shows steady emission intensity, is biocompatible and non-toxic to the 
sample, does not perturb the host molecule, and stays photoactive over a long period 
under intense illumination (i.e. is stable to photobleaching, see section 3.5.). The 
various classes of fluorophore used in cell imaging studies are considered in the 
following subsections. 
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Small organic dyes 
Synthetic organic dyes, such as fluorescein and its major derivatives (fluorescein 
isothiocyanate, FITC, and 6-FAM phosphoramidite; Fig. 27), were the first fluorescent 
compounds to be used in biological research. The small size of these fluorophores 
means they have versatile applications, and they may be cross-linked to 
macromolecules without interfering with normal biological functions.  
 
 
 
Cyanine and rhodamine dyes comprise the two important families of fluorophore 
currently employed in the majority of in vitro studies. These types of small organic 
fluorophores (<1 kDa) are covalently attached to the macromolecule of interest, and 
industrial optimisation has been in the areas of wavelength range, brightness, 
photostability, and reduction in self-quenching. Structural modifications to the small 
molecules include: the extension of double-bond conjugation, rigidification through 
Fig. 27  First fluorescent dyes: fluorescein (a), fluorescein isothiocyanate, FITC (b), and 6-FAM 
phosphoramidite (c), which is used in the preparation of fluorescein-labelled oligonucleotides. 
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extra rings, and the incorporation of electron-withdrawing or charged substituents, 
such as fluorines or sulfonates. Thus, hundreds of dyes with characteristic 
excitation/emission spectra and optimal quantum yields are commercially available for 
any fluorescence application. Such dyes are often used in conjunction with antibody 
labels in order to target specific proteins of interest in both fixed and permeabilised 
cells. 
Cy3 and Cy5 are the most popular cyanine dyes (Fig. 28): Cy3 dyes fluoresce yellow-
green (~550 nm excitation, ~570 nm emission), while Cy5 dyes absorb in the orange 
region (~649 nm), and are fluorescent in the red region (~650/670 nm).
120 The side 
chains may be non-identical, and usually consist of short aliphatic chains, one or both 
ending in highly reactive groups which may be chemically linked to nucleic acids or 
proteins for various applications, such as proteomics and RNA localisation. 
 
 
 
 
Popular dyes in the rhodamine family include tetramethylrhodamine, rhodamine 6G, 
Texas Red, and Alexa546 (Fig. 29). The excitation and emission spectra of these dyes 
span across 500-700 nm, and several exhibit high quantum yield, low intersystem 
crossing, and high photostability properties.121 Rhodamine dyes are generally toxic, 
and they are typically soluble in water, methanol, and ethanol. 
Fig. 28  General structure of the most popular cyanine dyes, Cy3 and Cy5. 
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Fluorescent proteins 
The use of autofluorescent proteins in cell-imaging studies can circumvent the 
modification and labelling steps that are required for attaching small organic dyes to 
structures of interest. The discovery, gene cloning, and heterologous gene expression 
of the green fluorescent protein (GFP) from the jellyfish Aequorea victoria has 
revolutionised fluorescence microscopy and its applications in cell biology.122 GFP is a 
protein consisting of 238 amino acid residues (26.9 kDa), and exhibits bright green 
fluorescence (at wavelength 509 nm) when exposed to light in the blue to ultraviolet 
range (major excitation peak at 395 nm, minor at 475 nm), with a high fluorescence 
quantum yield (0.79). GFP belongs to a large family of homologous fluorescent 
proteins (FPs),123,124 and different colours are observed due to variations in 
chromophore covalent structure and the nonconvalent environment.125  
Fig. 29  Examples of popular rhodamine dyes. 
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The low toxicity of fluorescent proteins means they are compatible in live-cell studies, 
and GFP labelling is particularly useful for the study of protein localisation and mobility 
in living cells. The GFP gene is spliced into the genome of the organism, in a region that 
encodes the target protein. GFP is subsequently expressed along with the protein of 
interest, resulting in production of the fluorescent protein, thus allowing for 
visualisation using fluorescence microscopy. 
 
 
 
The use of GFP has proved valuable in the area of retinoid research and discovery: in 
one study, a reporter assay system used two GFP derivatives, one (enhanced yellow 
fluorescent protein (EYFP)) to measure the induction of gene expression, and the other 
(enhanced cyan fluorescent protein (ECFP)) as an internal control. This enabled 
fluorescence measurements to be obtained in cells expressing the target protein in 
response to ligand-induced transcriptional activation, and after screening a library of 
over 140 compounds, several were identified as activators of RARs.127  
 
Fig. 30  Crystal structure of the Aequorea victoria green fluorescent protein.
126 
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Quantum dots 
Quantum dots (QDs) are inorganic nanocrystals typically consisting of a CdSe or CdTe 
core and ZnS shell, and range from 2-10 nm in diameter (Fig. 31). QDs possess good 
quantum yields, and fluoresce at sharp and discrete wavelengths depending on their 
size: hence, specific wavelengths of emission may be generated by modifying the core 
size, resulting in emission of any colour of light desired. This wavelength-tunable 
property of QDs is called the ‘size quantisation effect’. The high photostability of QDs 
allows for repeated imaging of single molecules, and in this respect QDs have been 
found to be superior to traditional organic dyes: it has been estimated that QDs are 20 
times brighter and 100 times more stable than conventional fluorescent labels.128 
Indeed, one study found that quantum dots were able to be observed in the lymph 
nodes of mice for more than 4 months.129 
 
 
 
 
The development of coatings to confer water soluble properties to QDs has expanded 
their role in biological applications, preventing quenching by water, and allowing 
conjugation to antibodies targeting specific proteins in live cell studies. However, the 
relatively large size of these conjugates (~10-30 nm) render them unsuitable for 
transmembrane transport studies, and permeabilised cells or extracellular proteins 
must be therefore be employed. Nevertheless, the far-reaching potential of QDs in the 
Fig. 31  General structure of quantum dots. 
(Reproduced from
 
http://ceramics.org; credit: H. R. Patel.) 
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study of intracellular processes, and in the areas of tumour targeting and diagnostics, 
have been highlighted.130   
In general, the low QD concentrations used in live-cell and animal studies have no 
reported adverse effects on cell viability, morphology, function, or development. 
However, higher concentrations appear to affect embryonic development,131 and 
when QDs with less protected cores were used, the release of Cd2+ or Se2- ions was 
observed, along with abnormalities in cell viability or function.132 Therefore, careful 
optimisation of the use of QDs in medical procedures will be required in order to avoid 
these undesired outcomes. 
 
3.5. Factors influencing fluorescence 
Photobleaching 
Photobleaching describes the irreversible destruction of a fluorophore, leading to loss 
of fluorescence, through photon-induced chemical damage and covalent modification. 
The susceptibility of a molecule towards photobleaching, therefore, affects its 
suitability for use in fluorescence imaging experiments. Loss of fluorescence may be 
attributed to an oxidation reaction between the excited triplet state of the 
fluorophore and a nearby reactive species,133,134 or excitation of the molecule already 
in the excited state, leading to an unstable form.135,136 The total number of photons 
emitted before photobleaching, Npb, is thus reduced, and this can be a limiting factor 
in time resolution imaging. Efforts to maximise Npb have been made, including the use 
of pulse excitation to avoid double excitation,
137
 removing reactive oxygen species 
through oxygen scavenger systems,138 and using triplet-state quenchers, such as β-
mercaptoethanol (BME) or Trolox, a water-soluble vitamin E analogue.139 The rate of 
photobleaching may also be controlled by reducing the intensity or time-span of light 
exposure, reducing the frequency (and hence the energy) of light, or using 
fluorophores that are less susceptible to photobleaching. Excited140 and ground141 
state transitions may also occur, resulting in reversible darkening of the fluorophore in 
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a process known as photoblinking; in such cases the molecule switches between a 
photoactive and photoinactive form. An example of the loss of fluorescence intensity 
due to photobleaching a GFP-tagged cell is shown in Fig. 32. 
 
 
 
 
 
 
Quenching 
Fluorescence emission of a fluorophore may also be influenced by its interaction with 
other fluorescent or non-fluorescent molecules, resulting in ‘quenching’ of 
fluorescence. This is an important area for consideration when choosing a fluorophore 
for performing experiments, either in solution, or in the aqueous media used for 
maintaining cell cultures. The extent of quenching depends on the nature of the 
quencher molecule, the type of interaction, and the wavelength of energy that is 
emitted by the fluorophore. The types of fluorescence quenching include fluorescence 
resonance energy transfer (FRET), contact quenching, and collision quenching (Fig. 33). 
 
 
 
Fig. 32  Protein fluorescence in a small area (box) of a COS-7 cell is bleached repetitively 
every 40 s. Loss of fluorescence in areas outside the box indicates that the fluorescent 
protein diffuses between the bleached and unbleached areas. After 18 min, the entire 
fluorescence was depleted, indicating the highly mobile nature of the GFP-tagged 
protein.
142
 
Reprinted by permission from Macmillan Publishers Ltd: NATURE REVIEWS MOLECULAR 
CELL BIOLOGY (J. Lippincott-Schwartz, E. Snapp and A. Kenworthy, 2001, 2, 444-456), 
copyright 2001. 
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Fluorescence resonance energy transfer (FRET) 
In FRET (also known as Förster resonance energy transfer), the photon emitted from 
the excited state of a donor fluorophore is absorbed by a neighbouring acceptor 
molecule. When a non-fluorescent acceptor is used, the emitted light from the donor 
is effectively quenched. In the case of a fluorescent acceptor molecule, if the absorbed 
photon is within the excitation wavelength range of the acceptor, the latter is raised to 
an excited state, and releases a photon at the wavelength corresponding to relaxation 
to its ground state. Thus, instead of observing fluorescence at the wavelength of the 
original fluorophore, the emission wavelength of the quenching fluorophore is now 
detected. FRET is extremely sensitive to small distances, since the efficiency of energy 
transfer is inversely proportional to the sixth power of the distance between donor 
and acceptor. The distance between two fluorophores may therefore be determined 
by measuring the FRET efficiency.143 
Contact quenching 
In contact quenching (also referred to as static quenching), the fluorophore is 
complexed with a quenching molecule prior to excitation. Upon excitation, the energy 
is immediately transferred to the contact molecule, and is subsequently lost as heat.  
Fig. 33  Types of fluorescence quenching. 
(Reproduced with permission from Thermo Fisher Scientific Inc.: 
http://www.piercenet.com/method/fluorescent-probes; copyright 2014.) 
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Collision quenching 
Collision, or dynamic, quenching occurs when the excited fluorophore reacts in 
solution with a quencher molecule, resulting in the immediate transfer of energy to 
the latter, and relaxation of the excited fluorophore. 
 
3.6. Tracking in live cells 
 
While the in vitro approach of analysing cells has been of great importance in 
developing the understanding of molecular reactions in cells, the use of processed cell 
solutions in these studies means that information concerning the effect of the 
endogenous cellular environment is often lost. The challenge that remains is to 
observe biochemical reactions in living cells, and optical imaging is a powerful 
technique for this purpose, offering millisecond time resolution and nanometer spatial 
precision, single-molecule sensitivity, and, crucially, biochemical specificity.144 
In order to visualise small molecules in living cells, several obstacles must be 
overcome: first, bright fluorophores should be employed to improve the signal to 
noise ratio (SNR), which would facilitate their detection over the high 
autofluorescence of the cell;145 exciting the cell with an evanescent wave may also 
minimise cellular autofluorescence. Second, given the crowded nature of the cell 
environment, high specificity in labelling the structure of interest is required. Third, in 
order to be able to discern molecules separately, a low concentration of fluorescent 
probe should be used to avoid co-localisation of fluorescing molecules within the 
diffraction limit. Finally, the rapid diffusion and translocation of molecules in three 
dimensions, as well as high ATP and oxygen concentrations, necessitate a high 
temporal resolution and low excitation level.146   
Nevertheless, advances have been made in the areas of probing gene expression, 
active transport, and metabolism in living cells through the application of optical 
imaging techniques (reviewed in ref. 144). 
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Membrane proteins 
Lateral diffusion 
Single green fluorescent protein molecules have been successfully imaged in living 
cells through linking GFPs to E-cadherin (E-cad-GFP), which is a calcium-dependent 
cell-cell adhesion molecule. Using objective-type total internal reflection fluorescence 
microscopy, it was possible to image individual E-cad-GFP molecules in the membrane 
of live cells (Fig. 34, bottom left).147 By measuring the fluorescence intensities of the 
GFP spots, it was found that more than 50% exhibited greater fluorescence compared 
to monomers, suggesting that the majority of E-cad-GFP molecules are in oligomeric 
complexes of sizes ranging from dimers to decamers, and that oligomerisation of E-
cadherin takes place before its assembly at cell-cell adhesion sites. It was suggested 
that enhanced membrane-tethering effects trap these E-cad-GFP oligomers in place on 
the free cell surface, thus accounting for the greatly reduced (by a factor of 10 to 40) 
translational diffusion rate observed. Similar characterisation for other 
transmembrane proteins has also been achieved,145 as well as for anchored proteins 
such as Ras, which were tagged with EYFP or GFP.  
 
 
 
Fig. 34  Live-cell imaging for tracking membrane proteins in lateral diffusion 
via total internal reflection microscopy.
146
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Improved SNR was achieved through the use of synthetic dyes: for example, dye-
labelled epidermal growth factor (EGF) was used to observe the movement and 
dimerisation of its receptor target as the latter bound the extracellular ligand (Fig. 34, 
bottom right).148 A similar approach was also used to study cAMP receptor systems149 
and peptide-binding proteins.150 Additional signal improvement was attained by 
tagging glycine receptors with QDs, which allowed tracking over extended periods (>20 
min).151 
Protein translation 
Many in vitro single-molecule experiments have provided valuable insights into the 
mechanistics of protein transcription152 and translation.153 However, the 3D nature of 
protein translation in the cytoplasm means that the process is more difficult to detect 
in live cells compared to the activity of a membrane protein. However, real-time 
observation of the production of single protein molecules has been achieved, recently 
in individual Escherichia coli cells.144 The YFP variant, Venus, was used, and in order to 
avoid excess fluorescence signals due to the rapid diffusion of the protein through the 
cytoplasm, a membrane protein, Tsr, was attached to the N-terminus of Venus (tsr-
venus): once produced, the YFP-fusion localises to the cell membrane where its 
fluorescence signal may be unambiguously detected with single-molecule sensitivity. 
Thus, a strain of E. coli was established containing a single copy of the tsr-venus gene 
in the E. coli chromosome, replacing the native lacZ gene, and production of YFP 
during cell growth was imaged through the use of an epifluorescence microscope and 
a charged-coupled device (CCD) camera. The fusion proteins were counted by 
photobleaching the fluorophores after their detection: it was found that cells from 
each cell cycle generally produced up to five fluorescent protein molecules per cell, 
and that these gene expression bursts lasted between 3 to 15 minutes. 
Cytoplasmic proteins 
Several studies have identified and tracked cytoplasmic proteins as they diffuse in the 
3D volume of the cell, these are highlighted in the following paragraphs.  
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Transcription factor binding 
Along with other transcription factors (TFs), the in vivo kinetics of the lac repressor has 
formerly been studied indirectly, through monitoring the gene products. Thus, 
information concerning the underlying dynamics of TF-mediated gene regulation is 
often lost. A recent study utilising living E. coli cells has followed the kinetics of gene 
binding and dissociation of the lac repressor (LacI) in response to a metabolic signal 
(Fig. 35, left).154 The repressor was expressed from the native chromosomal lacI locus 
as a fusion with the Venus YFP at the C-terminus, thereby allowing for DNA-binding at 
the N-terminal domain. Imaging with a wide-field fluorescence microscope and a CCD 
camera revealed that fluorescence from TFs that are not specifically bound to DNA 
were obscured by strong cellular autofluorescence due to rapid diffusion of the 
proteins throughout the cytoplasm. In contrast, fluorescence from single TFs 
specifically bound to the relatively stationary DNA proved visible above the 
background autofluorescence, and could be visualised from highly localised regions. 
Timescales for LacI binding to, and dissociation from, a DNA target sequence were 
measured by taking snapshots at 1 to 1000 ms time resolution intervals. As a result, it 
was observed that LacI spends approximately 90% of the time diffusing along DNA in a 
non-specific association, with a residence time of less than 5 ms. This approach may 
thus be applied for the study of other nucleic acid binding proteins. 
Transport through the nuclear pore complex 
Molecular transport between the nucleus and cytoplasm is made possible by the 
nuclear pore complexes (NPCs), which span across the double-membrane nuclear 
envelope (NE). While small molecules (less than ~20-40 kDa) may transit NPCs through 
a passive diffusion process, larger molecules and complexes (up to ~25-50 MDa) are 
transported via carrier-mediated, signal-dependent processes (facilitated 
translocation).155 Single-molecule fluorescence microscopy was used to monitor the 
nucleocytoplasmic transport process with import complexes (ICs), which consisted of 
the transport substrate and importin(s), through the NPC in permeabilised cells.156 A 
nuclear localisation sequence was tagged with synthetic dyes, and interaction with the 
NPC temporarily mobilised the molecule to within 200 nm, enabling the fluorescence 
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to be identified with high spatial (30 nm) and temporal (3 ms) resolution. Tracking of 
this fluorescence revealed that movement of ICs along the central pore axis is 
bidirectional and rapid, thus having the characteristics of a random walk. 
Motor proteins on linear tracks 
Fluorescence imaging with one nanometer accuracy (FIONA) was used to analyse 
organelle movement by kinesin and cytoplasmic dynein within a cell.157 These proteins 
are microtubule-dependent molecular motors that are responsible for intracellular 
trafficking and cell division (Fig. 35, right); long-distance organelle transport occurs in 
both directions along the microtubule tracks. A GFP-tagged peroxisome in culture 
Drosophila S2 cells were visualised to within 1.5 nm in 1.1 ms, which determined the 
average step size for movement of this organelle along the microtubule tracks to be 
approximately 8 nm for both kinesin and dynein. It was also found that the two 
proteins work in a cooperative manner, at a speed ten times greater compared to the 
previously observed speed in vitro. 
 
 
 
 
Fig. 35  Live cell imaging for detecting TF-binding onto DNA (left);
154
 for 
identifying the presence of mRNA in the cytoplasm (top);
158
 and for tracking a 
motor protein (right).
157
 (Image reproduced from ref. 146.) 
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Other Single Objects 
Detection of single molecules in live cells is not limited to proteins: by attaching many 
copies of a fluorophore to the same object, mRNA molecules and viruses are also able 
to be visualised and tracked by fluorescence microscopy.  
RNA transcript 
Most mRNA molecules can be found throughout the cytoplasm159 and their movement 
within the cell is essential for determining the spatial distribution of protein synthesis. 
Complex transport systems involving the cytoskeleton,160 and in some cases molecular 
motors,161 are necessary for the localisation and movement of mRNA. Since RNA 
molecules may not be covalently labelled with fluorophores, a method was developed 
for the real-time visualisation of single mRNA molecules in living mammalian cells, 
with the aim of elucidating the mechanism of movement of these molecules, and to 
provide information concerning their intracellular localisation.158  
A MS2 (coat protein) and GFP fusion (MS2-GFP) was used along with a reporter mRNA 
containing tandemly repeated MS2 binding sites: when these were coexpressed, MS2-
GFP that was bound to the reporter mRNA was exported to the cytoplasm (Fig. 35, 
top); when only the MS2-GFP fusion was expressed, the protein was confined to the 
nucleus by a nuclear localisation signal. Quantification of fluorescence revealed that 
most GFP-labelled mRNA particles contained 20-50 molecules of GFP. In addition, four 
types of motility of the mRNA reporters within a single living cell were observed: some 
molecules appeared to remain stationary; a minority of particles travelled linearly over 
long distances (>1.5 µm) and at a constant speed; some of the latter molecules 
occasionally changed direction abruptly and followed a second path of movement, 
which suggested the involvement of a motor protein; the remaining particles moved 
significantly, either around a central position, or exhibiting a diffusive pattern of 
movement, but never travelling more than 1.5 µm continuously in a single direction. 
Thus, the movement of single RNA transcripts was able to be followed with a time 
resolution of 10 ms. Individual mRNA molecules were observed frequently switching 
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among the movements described above, suggesting that they undergo continuous 
cycles of anchoring, diffusion, and active transport. 
Viruses 
The viral infection pathway begins with contact between the virus and cell membrane, 
resulting in transport of the virus into the nucleus and eventual gene expression. In 
order to effectively design antiviral drugs, and to assist in the development of gene 
therapy techniques, it is essential to understand the process of viral infection. In the 
past, electron microscopy was used for investigating the different stages of the 
infection pathway, however, it was not suitable for analysing living cells with high time 
resolution.162 The detection of viruses in fixed cells using conventional fluorescence 
microscopy was also possible, however, this required high concentrations of viruses 
and/or many copies of fluorophore, which not only masked the detection of single-
molecule processes, but which was also not representative of the real physiological 
conditions of virus-cell interaction.163 Thus, real-time visualisation of the infection 
pathway of single viruses in living cells was achieved by labelling each virus (adeno-
associated virus, AAV) with only one fluorescent dye molecule.164 The trajectories of 
single AAV-Cy5 particles in 74 living HeLa cells at different stages of infection were 
then analysed (Fig. 36). Ultimately, the tracing measurements allowed for a detailed 
observation and quantitative description of the infectious entry pathway of virus 
particles into living cells.  
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3.7. Summary 
 
Fluorescence imaging has rapidly become a powerful tool for investigating biological 
processes, particularly in living cells where cellular events may be observed in their 
physiological contexts. The development of single-molecule visualisation techniques 
has greatly enhanced the usefulness of fluorescence microscopy for such applications, 
enabling the tracking of proteins and small molecules in their endogenous 
environments, thus offering a new dimension to understanding their activity and 
function, at which in vitro experiments of the past have only hinted. Improvements in 
this field lie in the areas of conjugation chemistry, photophysics and photochemistry, 
and methodology and instrumentation. However, the great diversity of fluorescent 
probes, and the limitless potential for their modification to provide fluorophores with 
specific properties (wavelength, fluorescence intensity, and stability), will be a source 
of great interest for many years to come.  
Fig. 36  Trajectories of single AAV-Cy5 particles 
showing virus entry pathways into a living HeLa 
cell. Traces showing single diffusing virus particles 
were recorded at different times, and describe 
the different stages of infection: diffusion in 
solution (1 and 2); touching cell membrane (2); 
penetrating cell membrane (3); diffusion in the 
cytoplasm (3 and 4); penetrating nuclear 
envelope, and diffusion in the nucleoplasm (4).
164
 
From G. Seisenberger, M. U. Reid, T. Endreß, H. 
Büning, M. Hallek and C. Bräuchle, Science, 2001, 
294, 1929-1932 . Reprinted with permission from 
AAAS. 
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4.1. Background and Aims 
 
Doxorubicin (DOX) is a popular chemotherapeutic drug used in the treatment of a 
wide range of cancers,165 including leukaemia, Hodgkin’s lymphoma, bladder, breast, 
stomach, lung, ovarian, and thyroid cancers. The amphiphilic and amphoteric nature of 
the molecule means that the drug is able to bind to both cell membranes and proteins. 
The main mechanism of DOX cytotoxicity is proposed to be due to its ability to 
intercalate DNA and inhibit the enzyme topoisomerase II, which unwinds DNA for 
transcription, thus leading to cell death. 
 
 
Due to the inherent fluorescence of the compound, DOX has also become a popular 
research tool in the field of fluorescence imaging, and its distribution has accordingly 
been visualised in various cells and tissues. Since the fluorescence intensity of DOX 
was found to be dependent on its concentration and microenvironment,166,167 the 
intracellular uptake and trafficking of the drug in ovarian carcinoma A2780 cells was 
able to be characterised by taking into account its interaction with cellular 
components such as DNA, histones, and phospholipids.168 The ultimate aim was to 
enhance DOX targeting to tumours, to improve the therapeutic index of the drug, and 
to reduce systemic toxicity.  
At present, DOX is the only known molecule possessing intrinsic fluorescence emission 
along with significant biological activity. It was recognised that this is an area which 
has hitherto been unexplored in the field of retinoid research. Thus, if fluorescence 
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could be incorporated into a small molecule modulator of stem cell development, this 
would in itself constitute a powerful probe, and would negate the need for the use of 
fluorescent dyes, proteins, and quantum dots (reviewed in Chapter 3). In particular, 
the use of live-cell tracking techniques would provide invaluable information 
concerning cellular uptake and localisation, thereby offering new insights into retinoid 
activity and metabolism. Furthermore, since it would no longer be necessary to attach 
a large fluorescent entity to the molecule of interest, the latter may be followed in the 
physiological context of its natural environment.  
Thus, the aim of the project was to design and synthesise a stable fluorescent retinoid, 
after which its fluorescence emission in various solvents would be measured, the 
capacity for cellular detection and visualisation determined, and any biological effects 
induced would be assessed. If results proved favourable, synthesis of a library of 
fluorescent compounds could then be considered, firstly to derivatise our current set 
of synthetic retinoids, and then to develop other novel structures. 
 
4.2. Aza-EC23 
 
EC23 is a potent inducer of stem cell differentiation: biological evaluation in the 
embryonal carcinoma stem cell model TERA2.cl.SP12 revealed that this synthetic 
retinoid acts in a comparable fashion to ATRA, and induces a higher level of neural 
differentiation compared to the natural retinoid.115,116  
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In order to extend its application to the field of fluorescence imaging, a derivative of 
EC23 containing an N-methyl group within the hydrophobic core was proposed: aza-
EC23 (above). The presence of an electron donating and accepting group, as well as 
the resulting conjugation of electrons throughout the molecule, means that aza-EC23 
should, therefore, be fluorescent. 
Synthetic route 
 
 
 
Scheme 4  Synthetic route to aza-EC23. 
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Aza-EC23 was previously synthesised according to Scheme 4:169 alkylation of N-
methylaniline with 3,3’-dimethylallylbromide was followed by cyclisation with 
polyphosphoric acid (PPA) to provide the tetrahydroquinoline-type structure 14. 
Aromatic iodination was then performed, which allowed compound 15 to be coupled 
to alkyne 16 in a Sonogashira reaction. Saponification of ester 17 then afforded aza-
EC23 as a yellow crystalline solid. 
Light stability study 
An experiment was carried out to determine the stability of aza-EC23 towards light 
exposure: a sample of the compound in DMSO-d6 was placed under a white 
fluorescent light source at a distance of 40 cm for up to 28 days.170  
 
 
 
Fig. 37  
1
H NMR spectra of aza-EC23 in DMSO-d6 (recorded at 400 MHz), exposed to a 
white fluorescent light source at a distance of 40 cm: (a) 0 h; (b) 24 h; (c) 72 h; (d) 7 d; 
(e) 14 d; (f) 21 d; (g) 28 d. 
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1H NMR spectra were recorded at various time intervals, and the aromatic signals of 
aza-EC23 over the course of the study were compared in Fig. 37; substantial 
degradation of the signals was clearly observed, most notably after 7 days light 
exposure. It was thus clear that the stability of EC23 (in an analogous light experiment, 
no change in its 1H NMR signals was observed) was not retained in the aza analogue. 
Proposed degradation routes 
Several oxidation routes of the hydrophobic core of aza-EC23 were proposed (Scheme 
5), namely, to give N-oxide (18), enamine (19), and epoxide (20) structures. Such 
species have previously been reported as metabolites of important pharmaceutical 
compounds,171 and the biological effects of these N-alkyl derivatives have been 
studied, particularly the relationship between structure, antimicrobial, and cytolytic 
activity effects on the growth and metabolism of microorganisms. 172,173 It was, 
therefore, possible that oxidation of aza-EC23 could account for the loss of 1H NMR 
signals observed, and since the molecule was expected to be fluorescent, light may 
also have been a contributing factor in the degradation process. 
 
 
 
Scheme 5  Proposed degradation routes of the hydrophobic region of aza-EC23. 
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4.3. Synthesis of an aza-EC23 derivative (GZ108) 
 
Due to the instability of aza-EC23 towards exposure to light for extended periods, 
some modifications to the structure were proposed, involving the incorporation of a 
more bulky N-isopropyl moiety, as well as a methyl group on the aromatic ring 
(compound 21). These would be expected to stabilise the molecule by disfavouring N-
oxidation, as well as by increasing the electron-donating, and hence fluorescence, 
properties of the molecule. 
 
 
Construction of the hydrophobic core 
The synthetic route to compound 21 was proposed to be analogous to that for aza-
EC23. The first step involved the reaction of commercially-available o-toluidine with 2-
iodopropane in order to provide compound 24 (Equation 3). The use of sodium 
hydroxide in powder form, as opposed to pellets, was found to promote a faster 
reaction. 
 
 
 
Equation 3 
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It was observed by 1H NMR analyses on all repeats of the reaction that a small amount 
of the disubstituted product was formed (up to 15%), and attempts at separation by 
distillation was only successful in removing the lower boiling point unreacted 
iodopropane. The monosubstituted and disubstituted products were not effectively 
resolved, and appeared as one spot by TLC analysis when silica gel plates were used; 
however, on alumina plates, distinct Rf values for the two products were observed. 
Hence, compound 24 was obtained as a yellow oil in 82% yield following purification 
by column chromatography on basic alumina.  
A second N-alkylation was then carried out by heating compound 24 and 3,3’-
dimethylallylbromide with potassium carbonate (Equation 4); this hindered 
substitution reaction did not go to completion, and some unreacted starting material 
remained despite heating for an extended period (up to 2 days, after which additional 
side-products were observed). Therefore, after overnight reflux, an aqueous workup 
was performed, and the crude product was purified by column chromatography on 
basic alumina to afford compound 25 as a yellow oil in 70% yield. 
 
 
 
With compound 25 in hand, a cyclisation reaction was then performed using PPA 
(Equation 5). After heating to 120 °C for 24 h, with vigorous stirring due to the highly 
viscous mixture, an aqueous workup was carried out, and the residue was filtered 
through a pad of silica to afford compound 26 as a yellow oil in 78% yield.  
Equation 4 
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Direct iodination approach 
Despite the unreactive nature of iodine towards electrophilic substitution, procedures 
for successful aromatic iodination reactions have nevertheless been reported.174 Thus, 
direct iodination reactions using compound 26 were attempted: Firstly, as for the 
synthesis of aza-EC23, the starting material was stirred in a mixture of iodine and 
mercury(II) oxide in dichloromethane (Equation 6, Method A). At various timepoints, 
an aqueous workup was performed on an aliquot of the reaction mixture, and a 1H 
NMR analysis was obtained; however, only starting material was observed, despite 
stirring for up to 18 h. Secondly, a Lewis acid-catalysed method based on a reported 
procedure175 was also attempted (Equation 6, Method B); this was somewhat 
successful, and approximately 30% conversion to the desired product was observed by 
1H NMR analysis after stirring for 72 h. 
 
 
 
Various other iodination reactions using reported literature procedures were also 
attempted in order to synthesise the target iodide 27 (Table 1): No reaction was 
observed when compound 26 was heated with ICl in acetic acid (Table 1, Reaction 1). 
Equation 6   
Equation 5 
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a
Approx. value as observed by GC-MS analysis in comparison to starting material, mix of other 
products also apparent. 
b
Approx. value compared to starting material as observed by GC-MS analysis. 
Similarly, no iodide was formed when N-iodosuccinimide (NIS) and trifluoroacetic acid 
(TFA) were used (Table 1, Reaction 2).176 When compound 26 was treated with a 
mixture of KI and KIO3 in acetic acid (Table 1, Reaction 3),
177 approximately 30% 
conversion to the iodide was observed by GC-MS analysis; however, multiple side-
products were also present. Finally, equimolar amounts of compound 26, N-
chlorosuccinimide (NCS), and sodium iodide were stirred in 0.1 M acetic acid at room 
temperature:178 after 4 h, 25% conversion to the iodide was observed (Table 1, 
Reaction 4); however, when the reaction was stirred for 48 h, a minimal amount of 
product (approx. 5%) was observed by GC-MS analysis (Table 1, Reaction 5). Evidently, 
the reaction conditions assessed were insufficiently activating to promote iodination 
of compound 26. This was surprising, given that iodination of the N-methyl analogue 
(see synthesis of aza-EC23, Scheme 4) proceeded relatively easily. Thus, it can only be 
surmised that the presence of the additional methyl groups in compound 26 
deactivate the structure towards aromatic iodination. 
 
 
Reaction Reagents Solvent Temp. (°C) Time (h) 
Product 
observed? 
1 ICl (1.2 equiv.) AcOH 120 5 no 
2 
NIS (1.1 equiv.) 
TFA (0.3 equiv.) 
MeCN 20 4 no 
3 
KI (1.0 equiv.) 
KIO3 (1.0 equiv.) 
AcOH 80 2 30%a 
4 
NCS (1.0 equiv.) 
NaI (1.0 equiv.) 
AcOH 
(0.1 M) 
20 4 25%b 
5 
NCS (1.0 equiv.) 
NaI (1.0 equiv.) 
AcOH 
(0.1 M) 
20 48 5%b 
         
 
 
Table 1  Iodination reactions attempted with compound 26. 
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Aromatic bromination 
Given the difficulties in carrying out direct aromatic iodination of compound 26, the 
synthesis of bromide 28 was proposed (Equation 7), with the aim of then performing a 
halogen-exchange reaction to afford the desired iodide product. 
 
 
 
Bromination was initially carried out by cooling a flask containing a solution of 
compound 26 in chloroform to 0 °C, followed by the dropwise addition of 1.1 
equivalents of bromine. After 10 min, consumption of the starting material was 
apparent by 1H NMR analysis. The mixture was then washed with 1 M aqueous 
NaHCO3 solution, and the organic layer was dried over MgSO4. Following in vacuo 
solvent removal, the residue was filtered through a pad of alumina using 
hexane:EtOAc, 9:1, as eluent. However, in addition to the expected brominated 
product, an alkene species with a similar structure was also present (approx. 10% by 
1H NMR analysis), with two doublet signals at δ 6.02 and 4.87 in the 1H NMR spectrum. 
It became apparent that this species was inseparable from bromide 28, despite 
attempts at purifying the oil by column chromatography using different solvent 
systems. This mixture of products was used in subsequent reactions for synthesis of 
the target structure (compound 21); however, despite purification of the product from 
each step by column chromatography and recrystallisation, the characteristic doublet 
signals in the alkene region remained by 1H NMR analysis. 
It was deduced that the minor species must be the dehydrogenated side-product 
(compound 29) formed from bromide 28 during the course of the reaction. This would 
account for the similarity of the two products by TLC and 1H NMR analyses, and the 
difficulty in their separation by chromatographic means.  
Equation 7 
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It was proposed that once formed, bromide 28 undergoes an addition-elimination 
reaction in the presence of excess bromine to give an iminium ion, which subsequently 
eliminated during aqueous workup to give the enamine structure (Scheme 6). 
 
 
 
Since the relative integral peaks of major to minor product in the 1H NMR spectrum 
indicated approximately 10% of the enamine product was present, this would 
correlate with the 0.1 equivalents of excess bromine used for carrying out bromination 
of compound 26. Thus, in order to obtain pure bromide 28, the reaction was repeated 
using both 1 and 0.9 equivalents of bromine, at 0 °C and at room temperature, 
respectively. In both cases, formation of the enamine product was still observed: 
evidently, the side reaction appeared to be highly competitive. 
Scheme 6  Proposed mechanism for the formation of compound 29. 
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Pure bromide 28 was eventually obtained by cooling a stirred solution of compound 26 
in chloroform using a cryostat set to -60 °C, followed by the addition of 0.95 
equivalents of Br2 (Equation 8). The flask was warmed slowly to -30 °C over 1 h, after 
which 1H NMR analysis of an aliquot of the reaction mixture after aqueous workup 
showed the reaction to be complete, and no enamine side-product was observed. 
However, it was observed that if the crude product was stored without purifying, 
some side-product would be formed. Thus, in order to remove any residual oxidising 
bromine species, compound 28 was filtered through a pad of alumina using 
hexane:EtOAc, 9:1, as eluent, affording the pure bromide as a colourless oil in 62% 
yield. A fast flow rate was preferred in order to compensate for the tendency of the 
product to streak on the column, thereby reducing the number of fractions in which 
the bromide eluted. 
 
 
 
Synthesis of an enamine species 
It was recognised that if enamine 29 could be exclusively obtained, this could allow for 
the synthesis of another fluorescent retinoid derivative, compound 30.  
 
Equation 8 
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The additional double bond and increased conjugation present in this compound 
should result in enhanced fluorescence properties for this molecule compared to the 
tetrahydroquinoline structure. Thus, synthesis of enamine 29 was attempted using 2.2 
equivalents of bromine in order to ensure complete conversion to the desired product. 
The reaction was monitored by TLC analyses, and found to be complete after stirring 
at 30 °C overnight. 1H NMR analysis of the crude product following aqueous workup 
showed that, as expected, the starting material had been fully consumed, and two 
doublet peaks associated with the enamine double bond were observed. However, an 
additional unexpected singlet peak at 6.36 ppm was also present, which appeared to 
constitute the major product. GC-MS analysis of the mixture suggested that a 
dibrominated species was present, and the major product was, therefore, determined 
to be compound 31 (Equation 9). 
  
 
 
Chemical shift comparisons and mechanistic considerations (discussed below) 
suggested the bromine atom to be in the 3-position, rather than in the alpha-position 
(32). 
 
Equation 9 
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Synthesis of a dibromide species 
A review of NMR data from previous reactions in which enamine 29 was formed 
revealed that the dibromide compound was also present following aqueous workup of 
the bromination reactions. Thus, loss of the singlet peak associated with compound 31 
in 1H NMR analyses of the product following purification by column chromatography 
was likely due to the less-mobile dibromide remaining on the stationary phase. It 
would appear that excess bromine could react with the enamine product by adding 
across the double bond, which would give a tribromide species (33); Elimination of HBr 
during aqueous workup would then provide dibromide 31 (Scheme 7). 
 
 
 
Thus, in the presence of excess bromine as well as a base, enamine 29 would be 
expected to be a very reactive intermediate to undergo addition-elimination, and 
should be fully consumed during the course of the reaction. This was accordingly 
assessed by using 2,6-lutidine as an in situ base in order to promote elimination from 
the tribromide adduct, and to provide exclusively the dibromide species. Indeed, after 
stirring compound 26 with 2.2 equivalents of bromine and 2,6-lutidine overnight at 30 
Scheme 7  Proposed mechanism for formation of the dibromide species 31. 
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°C (Equation 10), no enamine was present by 1H NMR analysis. However, the 
dibromide species in fact constituted the minor product, and the major product was 
observed to be the monobromide (ratio of 1:2, respectively, as observed by 1H NMR 
analysis).  
 
 
It was recognised that dibromide 31 would provide scope for derivatisation and 
functionalisation of the molecule at the 3-position, making it an attractive synthetic 
target. A literature search revealed that if compound 31 could be exclusively obtained, 
this would provide an interesting, simple, and direct route to a biochemically 
important and novel dihydroquinoline-type structure.179 1,4-Dihydroquinolines have 
been employed as carriers for the delivery of biologically-active compounds to the 
brain, however, their use is hampered by poor stability towards oxidation and 
hydration reactions, which limit investigations in vivo.180 In this case, the fully 
substituted 4-position of compound 31 renders the molecule stable towards 
isomerisation, which is a major issue for synthetic control in dihydroquinolines (Fig. 
38).181 
 
 
Equation 10 
Fig. 38  Spontaneous isomerisation of 1,2 (34)- and 1,4 (35)-dihydroquinolines possessing electron-
withdrawing substituents in the 3-position. Compare with the ‘locked’ structure of the gem-dimethyl 
group in compound 31. 
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Thus, based on the mechanisms outlined in Schemes 6 and 7, it was concluded that 
the use of 3 equivalents of bromine should provide the desired dibromide product 31, 
and the inclusion of a hindered base such as 2,6-lutidine would also be expected to 
promote product formation via the intermediates. Accordingly, 3 equivalents each of 
bromine and 2,6-lutidine were added to a stirred solution of compound 26 in 
chloroform. The flask was maintained at 30 °C, and following overnight stirring, a 
mixture of products was observed by 1H NMR analysis (Fig. 39). It was determined that 
the major product was still the monobromide, with some dibromide compound 
present, as well as two distinctive doublets indicative of tribromide 33 (approximate 
ratio of 55:30:15, respectively; Table 2, Reaction 1).  
 
              
 
 
A few drops of lutidine were added to the NMR sample and mixed thoroughly, 
whereupon 1H NMR analysis showed that signals associated with the tribromide 
product had disappeared, which was consistent with the suggestion that the 
dibromide species was the product of basic elimination of HBr from the tribromide 
intermediate. 
  
 
  
   
Fig. 39  
1
H NMR spectrum showing distinctive signals associated with monobromide 28 
(circled); dibromide 31 (rectangle); tribromide 33 (hexagon) - recorded in CDCl3 at 400 MHz. 
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A series of reactions were then attempted in order to obtain exclusively the dibromide 
product, these are summarised below (Table 2). 
 
Reaction Br2 2,6-lutidine Temp. 
% mono 
28 
% di 
31 
% tri 
33 
1 3 equiv. 3 equiv. 30 °C 55 30 15 
2 1 equiv. x 3 1 equiv. x 3 30 °C 25 25 50 
3 4 equiv. 8 equiv. 30 °C 0 33 67 
4 4 equiv. 8 equiv. 60 °C 0 100 0 
 
 
 
Since the reaction to give the dibromide product evidently did not go to completion,  
despite using sufficient equivalents of bromine and 2,6-lutidine, the limiting factor was 
thought to be consumption of the base (namely, that a lutidine-bromide complex was 
formed during the course of the reaction). Thus, in order to promote a more efficient 
reaction, 1 equivalent each of bromine and 2,6-lutidine were added at 0, 4, and 8 h to 
a stirred solution of compound 26 at 30 °C (Table 2, Reaction 2). Following overnight 
reaction, the ratio of the mono-, di-, and tri-bromide products was observed by 1H 
NMR analysis to be 25:25:50, respectively. The addition of a further 1.5 equivalents of 
bromine followed by 5 equivalents of 2,6-lutidine only resulted in complete formation 
of the tribromide intermediate, and the addition of more base at this point was 
ineffective in promoting elimination to give exclusively the dibromide product. It 
would appear, therefore, that the tribrominated species was in fact more stable than 
previously expected. 
Next, a reaction employing 4 equivalents of Br2 was set up, and, for effective 
elimination from the tribromide, 8 equivalents of 2,6-lutidine were also used (Table 2, 
Reaction 3). After stirring overnight at 30 °C with 1 equivalent of compound 26, 1H 
NMR analysis of an aliquot of the reaction mixture (following aqueous workup to 
remove base and bromine species) showed that no monobromide product was 
Table 2  Approximate percentages of  monobromide 28, dibromide 31 and tribromide 33  as 
observed by 1H NMR analysis following reaction with bromine and 2,6-lutidine.  
In all cases, reagents were added to 1 equiv. of compound 26 in chloroform, and stirred for 18 h. 
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present. Instead, a 2:1 ratio of tribromide to dibromide products was observed, and 
subsequent addition of 2,6-lutidine to the reaction mixture was not successful in 
increasing the ratio of the dibromide product. Since there should have been more than 
sufficient bromine and base for formation of the dibromide product, the reaction was 
repeated with heating to 60 °C (Equation 11; Table 2, Reaction 4). 
 
 
 
After 18 h, an aqueous workup was performed, and complete conversion to dibromide 
31 was observed by 1H NMR analysis, with no monobromide or tribromide species 
present (Fig. 40). 
 
 
 
Equation 11 
Fig. 40  
1
H NMR spectrum of dibromide 31 (recorded in CDCl3 at 400 MHz) from 
Equation 11 after reaction workup. Note loss of signals associated with the  mono- 
and tri-bromide products. 
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Reactions of the dibromide species 
Dibromide 31 was synthesised according to Equation 11, and purification of the 
compound was performed by filtering the crude product through a pad of alumina. 
However, 1H NMR analysis of the residue following in vacuo removal of the solvent 
revealed that a species in addition to the expected product was present. The signals 
did not correlate with either the simple loss of a bromide ion from the product, or with 
the starting material. Evidently, the presence of the vinyl bromide in conjugation with 
the nitrogen atom conferred an element of instability to the molecule, which became 
apparent upon further handling and purification. Some proposed reactions of 
dibromide 31 are considered below. 
Addition-elimination? 
The most likely reaction of compound 31 would be the addition of water across the 
double bond, followed by elimination of HBr (Scheme 8). 
 
 
 
Thus, an overall loss of a bromine atom along with a gain of an oxygen atom would be 
expected, and GC-MS analysis of the mixture confirmed that this was the case. 
Scheme 8  Proposed mechanism for addition-elimination of compound 31. 
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Furthermore, a sharp carbonyl signal was present in the IR spectrum of the material 
(max 1723 cm
-1), with no peak indicative of a hydroxyl group. The product of the 
addition-elimination reaction was, therefore, deduced to be the amide compound 37, 
rather than the enol product (36).  
Radical migration? 
Compound 36 may undergo a further addition-rearrangement reaction, in which loss 
of a bromine radical would be stabilised by a 1,2-methyl migration as depicted in 
Scheme 9. 
 
 
 
 
Aldehyde species? 
It was clear from 1H NMR analyses that two coupled doublets at 9.52 and 3.63 ppm 
were present. The very low-field shift at 9.52 ppm suggested the presence of an 
aldehyde proton coupled to a proton on the neighbouring carbon atom. Additionally, 
the IR stretch at max 1723 cm
-1 was within the approximate range for an exocyclic 
aldehyde. The most likely structure that corresponded to these observations was thus 
determined to be aldehyde 39, and the proposed mechanism for its formation is 
Scheme 9  Proposed mechanism for radical elimination and methyl migration. 
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shown in Scheme 10. It was thought that the presence of a significant amount of 
moisture in the large volume of solvent required for eluting compound 31 from the 
alumina pad may have contributed to formation of the aldehyde product. 
 
 
 
 
The Brady’s test using 2,4-dinitrophenylhydrazine (DNPH, Equation 12) was performed 
in order to assess if the aldehyde was indeed present. However, after overnight 
stirring at room temperature, no precipitate (indicative of product formation) was 
observed, neither was the expected mass of the adduct (40) found by GC-MS analysis. 
This lack of reaction was perhaps unsurprising, due to the unfavourable hindered 
approach of DNPH to the purported aldehyde. It is recognised that conclusive 
structural proof for formation of compound 39 is still required. 
  
Equation 12 
Scheme 10  Proposed mechanism for formation of aldehyde 39. 
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Carbenoid species? 
It was also possible that dibromide 31 could possess a degree of carbene-like 
character, as shown in Scheme 11. 
  
 
Therefore, in order to examine the nature of 31, as well as to derivatise and/or 
stabilise the molecule, a substitution reaction with allyltrimethylsilane was attempted 
using various Lewis acids (Equation 13). 
 
 
 
Compound 31 was dissolved in dry dichloromethane under an inert argon atmosphere, 
after which 1 equivalent of Lewis acid was added, and the solution was stirred for 10 
min prior to the addition of 1 equivalent of allyltrimethylsilane. When BF3·OEt2 was 
used as the catalyst, TLC analyses after 1, 2.5, and 18 h showed only starting material 
was present. The mixture was then heated gently to reflux (40 °C): after 2 h, no 
product was observed by TLC analysis; after 6 h, there was substantial decomposition 
of dibromide 31 as observed in the 1H NMR spectrum, and the expected product peak 
of compound 42 was not detected by GC-MS analysis. Reactions using CuCl, Yb(OTf)3, 
Scheme 11  Proposed generation of a carbenoid species (41). 
Equation 13 
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Fe(OTf)2, or AgOAc as catalyst were similarly unsuccessful. This lack of reactivity of the 
enamine bromide was surprising, and necessitates further investigation. 
Future work 
There could be an inherent instability of dibromide 31 that accounted for the 
unexpected side-products observed: these may be formed spontaneously following 
reaction workup, or could be produced during the purification process, either due to 
exposure to light, air, or moisture, or by reaction with alumina. Further investigations 
would be necessary in order to ascertain how and at which point the side-products are 
formed, as well as to definitively determine their structures. Given these findings, 
perhaps the best course of action would be to repeat the synthesis of the dibromide, 
and to take precautions during purification, handling, and storage (i.e. where possible 
to exclude light, air, and moisture) in order to avoid side-product formation.  
The crude dibromide product was nevertheless employed for the synthesis of a 
bromine-containing retinoid (discussed in section 4.6.); however, it was not possible to 
achieve satisfactory purification of this compound. 
Synthesis of the polar terminus 
 
Scheme 12  Esterification reactions of 4-iodo (43)- and 3-iodo (44)-benzoic acid. 
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Preparation of the aryl alkyne region of the molecule was then carried out: 4-iodo- and 
3-iodo-benzoic acids were used, with the aim of producing retinoids containing the 
carboxylic acid terminus in the para- and meta-positions, respectively. Thus, 
esterification reactions of 4-iodo (43)- and 3-iodo (44)-benzoic acids were carried out 
by refluxing the starting material in methanol, along with a catalytic amount of 
concentrated sulphuric acid. After overnight reaction, the corresponding methyl esters 
(45 and 46) were obtained in excellent yields following aqueous workup and 
recrystallisation (Scheme 12). 
Next, Sonogashira coupling reactions were performed with esters 45 and 46 in order 
to afford the trimethylsilyl-protected aryl alkynes 47 and 48 in good yields (Scheme 
13). 
 
 
 
 
Finally, base deprotection of compounds 47 and 48 was carried out by stirring with 4 
equivalents of sodium carbonate in a solution of methanol and water at ambient 
Scheme 13  Sonogashira coupling reactions with trimethylsilylacetylene (TMSA). 
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temperature (Scheme 14). Alkynes 16 and 49 were thus obtained in good yields (79% 
and 63%, respectively). 
 
 
 
 
Halogen-exchange reaction 
Having probed the various outcomes of the aromatic bromination reaction, namely, 
formation of the enamine and dibromide side-products, efforts were then directed 
towards synthesis of the original fluorescent retinoid target (compound 21), using 
pure monobromide 28, which was synthesised according to Equation 8. Thus, a 
halogen-exchange reaction to produce the desired iodide was attempted, using a 
procedure which had been previously reported as successful for the conversion of 
aromatic bromides (Equation 14).182 
 
 
Scheme 14  Base deprotection reactions to provide alkynes 16 and 49. 
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Previously, when a sample of compound 28 containing approximately 10% of the 
enamine product (before conditions to obtain pure 28 were developed) was used in 
the halogen-exchange reaction, full conversion to iodide 27 was observed by GC-MS 
analysis. The subsequent Sonogashira coupling reaction with aryl alkyne 16 was 
successful in providing the desired (methyl-protected) retinoid compound, which, 
when dissolved in chloroform, was observed to be highly fluorescent under long-wave 
UV light. However, attempts at purification by column chromatography and 
recrystallisation were unsuccessful in separating the desired product from the 
enamine species. 
When pure compound 28 was used, the halogen-exchange reaction proved sluggish, 
and after heating for 3 days, predominately unreacted starting material was observed 
by GC-MS analysis. Various factors were considered that may have hindered the 
reaction, including moisture in the solvent and/or reagents, the presence of oxygen, 
and stirring issues. However, even after these issues were addressed, less than 20% 
conversion to iodide 27 was observed by GC-MS analysis after 3 days. The addition of a 
further 5 mol% CuI and 10 mol% N,N’-DMEDA, followed by overnight heating, 
improved product conversion slightly to 30%. Addition of more catalyst and ligand (up 
to 15 mol% CuI and 30 mol% N,N’-DMEDA), as well as heating for up to 1 week, 
produced an eventual 90% conversion to the iodide compound. Evidently, given the 
high catalyst and ligand loadings, as well as the long reaction time required, this was 
an inefficient means of producing the desired product. It would appear, therefore, that 
the success of the procedure depended on a number of factors, and efforts to 
Equation 14 
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optimise the reaction proved insufficiently effective. Furthermore, due to their similar 
Rf values, it was not possible to separate iodide 27 from the bromide starting material. 
Sonogashira reactions with an aromatic bromide 
Since synthesis of the desired iodide proved unsuccessful, alternative routes for 
obtaining the target fluorescent retinoid 21 were considered, and these are discussed 
in the following paragraphs.  
 
 
Reaction with aryl alkyne 16  
First, a Sonogashira reaction between bromide 28 and alkyne 16 was attempted 
(Equation 15). The reaction was expected to be slow given the electron-rich nature of 
compound 28, as well as the decreased reactivity of the aryl alkyne; nevertheless, if 
successful, this would provide a more direct route to the desired target retinoid. In 
order to improve reactivity, 10 mol% of CuI and Pd(PPh3)2Cl2 catalysts, as well as 50 
mol% triphenylphosphine (as a catalyst stabiliser), were employed. However, after 
heating to 80 °C for 3 days, no conversion to the product was observed by GC-MS 
analysis, and only starting materials were present. This lack of reaction was thought to 
be due to the deactivating nature of the inductively donating N-isopropyl and ring 
methyl groups, rendering bromide 28 a poor substrate for the Sonogashira reaction. 
 
Equation 15 
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Reaction with TMSA 
Next, a Sonogashira reaction between bromide 28 and TMSA was attempted (Equation 
16). The procedure was based on the synthesis of EC23,115 and the bromide was 
expected to be more amenable to coupling with this more reactive alkyne.  
  
 
 
In addition to 3 equivalents of TMSA, 1 equivalent of PPh3 was used along with 10 
mol% of Cu(OAc)2 and PdCl2 catalysts. The mixture was heated to 80 °C, and the 
reaction was monitored by GC-MS analysis: after 4 days, 99% conversion to alkyne 51 
was observed. Following in vacuo solvent removal, the residue was filtered through a 
pad of silica, and the crude product was obtained as a dark yellow oil/low melting 
point solid. This material consisted mainly of compound 51 and triphenylphosphine 
oxide (Ph3P=O), and slowly crystallised over a period of a few days. There was some 
evidence of instability at this point, as the enamine-type structure 52 was observed 
after leaving the oil for a few days at room temperature. It remains to be seen if this 
may be attributed to an inherent instability of the compound, or if the presence of 
oxidising impurities may have promoted loss of H2 from the structure.  
 
Equation 16 
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The significant quantity of Ph3P=O produced as a result of using 1 equivalent of PPh3 in 
the coupling reaction proved problematic to separate from the desired product: Co-
elution of Ph3P=O with alkyne 51 was observed during attempts at purification by 
silica-gel chromatography. Recrystallisation from various polar and non-polar solvents 
also did not effectively separate Ph3P=O. Finally, recrystallisation of compound 51 
from ethanol provided some pure product in the form of yellow needle-like crystals, 
albeit in a low yield (16%). When the reaction was repeated and the residue 
recrystallised from hexane, an improved yield of 59% was obtained; however, 1H NMR 
analysis showed that the enamine product 52 was also present (approx. 10%). Thus, in 
future, the reaction and subsequent purification steps should be performed as quickly 
as possible in order to minimise the potential for oxidation. When PPh3 was not used 
in the coupling reaction, poor conversion to alkyne 51 was observed by GC-MS analysis 
after 96 h reaction. It would appear that in this case, PPh3 played an important role in 
the coupling reaction, possibly in stabilising the catalyst. Since the presence of Ph3P=O 
was not expected to affect subsequent reactions, crude 51 was used for the synthesis 
of the target retinoid compound (see Equation 18).  
Microwave-assisted method 
In order to reduce the reaction time required for the Sonogashira reaction between 
bromide 28 and TMSA, as well as to reduce the amount of PPh3 required, microwave 
(MW) conditions were also assessed (Equation 17). 
 
 
 
Equation 17 
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After heating to 100 °C for 6 h, 75% conversion to product 51 was observed by GC-MS 
analysis. Repeating the reaction with more catalyst, alkyne, as well as increasing the 
reaction time did not significantly improve conversion to the product. After in vacuo 
removal of Et3N, filtration of the residue through a pad of silica (hexane:EtOAc, 9:1, as 
eluent) was effective in purifying the product, and some triphenylphosphine oxide still 
remained. Evidently there is scope for reaction optimisation, and the use of a polymer-
supported PPh3, or an alternative reagent, should be considered for ease of 
separation. 
Base desilylation 
Stirring compound 51 at room temperature with 4 equivalents of Na2CO3 in a solution 
of MeOH/Et2O and 10% H2O was ineffective in removing the trimethylsilyl group, so a 
stronger base, NaOH, was employed which resulted in complete conversion to 
compound 53 (Equation 18). Due to the presence of residual Ph3P=O from the 
previous Sonogashira reaction, it was not possible to carry out satisfactory purification 
of compound 53. 
  
 
 
 
Second Sonogashira coupling 
Synthesis of ester 50 was achieved by combining alkyne 53, 0.95 equivalents of aryl 
iodide 45, and 1 mol% of CuI and Pd(PPh3)2Cl2 catalysts in Et3N in a nitrogen-filled 
glovebox (Equation 19). After stirring at room temperature for 72 h, complete 
conversion to ester 50 was observed by GC-MS analysis. Following in vacuo removal of 
Equation 18 
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the solvent, the residue was recrystallised from hexane to provide bright yellow 
needle-like crystals of pure compound 50. 
 
 
 
Ester hydrolysis 
Compound 50 was hydrolysed according to Equation 20; following aqueous workup 
and recrystallisation from ethanol, the target retinoid was obtained in the form of 
neon-yellow fluffy crystals in high yield (89%). 
  
Equation 19 
Equation 20 
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4.4. Stability and purification of GZ108 
Photodehydrogenation 
Upon completed synthesis of target retinoid 21, a side-product resulting from the loss 
of H2 from the molecule to give an enamine-type structure (30, Scheme 15) was 
observed, and constituted approximately 10% of the mixture.  
 
 
 
 
 
 
Scheme 15  Loss of H2 from retinoid 21 to give the enamine-type structure 30. 
Fig. 41  Representative 
1
H NMR spectrum of compound 21 in CDCl3 (recorded at 
400 MHz) exposed to a white fluorescent light source at a distance of 40 cm. Note 
the presence of doublet peaks in the alkene region, consistent with enamine 30, 
the relative integral values of which increased over the course of the light 
experiment. 
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Steps had previously been taken to avoid this oxidation reaction during synthesis of 
the intermediates; however, it was now apparent that this could be an inherent 
instability of the molecule. It was thought that the dehydrogenation process could be 
induced by exposure to light: in order to test this theory, a sample of compound 21 
was dissolved in CDCl3 and placed under a white fluorescent lamp at a distance of 40 
cm for up to 30 days; 1H NMR analyses were carried out at various time intervals (Fig. 
41).  
By plotting a graph of the relative integral values of enamine 30 (two doublet peaks in 
the alkene region, as well as two singlets at 5.02 and 6.26 ppm, possibly due to 
intermediate side-products) compared to those for retinoid 21, it was evident that the 
proportion of side-product in the sample increased steadily over the 30 day 
observation period (Fig. 42). 
 
 
 
 
Fig. 42  Plot of the relative integral values of 
1
H NMR peaks of the enamine side-product 
when a sample of retinoid 21 in CDCl3 was exposed to a white fluorescent light source at 
a distance of 40 cm for up to 30 days. 
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An occurrence known as photo-dehydrogenation has previously been reported in the 
literature, whereby loss of H2 from dihydropyrimidinones (54) was observed after 
irradiating samples that had been dissolved in chloroform (Equation 21).183 
 
 
 
 
Interestingly, while reactions carried out in an oxygen atmosphere produced complex 
mixtures, an argon atmosphere provided the desired product (55), with chloroform 
being an important electron transfer agent; thus, a proposed route for photo-
dehydrogenation was suggested (Scheme 16). This mechanism was supported by 
analysis of the acidity of the solution following irradiation, as well as detection of 
dichloromethane by GC analysis. 
 
 
 
 
It was, therefore, feasible that such a process could account for the light-induced 
dehydrogenation observed with retinoid 21. Since this occurrence was assumed to be 
due to the purported redox potential of chloroform, an analogous light study with 
Equation 21 
Scheme 16  Proposed mechanism for dehydrogenation via light-induced electron-transfer. 
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compound 21 dissolved in DMSO-d6 was established in order to ascertain if 
photodehydrogenation would still be observed (Fig. 43). 
 
 
 
 
1H NMR analyses were carried out over a period of 30 days, and a plot of the relative 
integral values of the doublet peaks associated with the side-product showed quite 
clearly that dehydrogenation was still occurring in DMSO-d6 at a rate comparable to 
that of the compound in CDCl3. (It was interesting to note, however, that in this 
solvent, no singlet peaks associated with a second side-product/intermediate were 
observed.) From these findings, it can be inferred that the major promoting factor for 
enamine formation was the presence of light, rather than any effects induced by the 
solvent. Indeed, when a sample of retinoid 21 in CDCl3 was stored in the dark for a few 
weeks, no increase in the relative integrals of the side-product(s) was apparent by 1H 
NMR analysis.  
Despite the susceptibility of compound 21 towards light-induced dehydrogenation, the 
integrity of the structure remained otherwise intact, with no significant degradation 
observed over the course of the light experiments. However, when the NMR sample 
y = 0.0139x + 0.2008 
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Fig. 43  Plot of the relative 
1
H NMR integral values of the side-product formed when a sample of 
retinoid 21 in DMSO-d6 was exposed to a white fluorescent light source at a distance of 40 cm for 
up to 30 days. 
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was exposed to light for up to three months in an attempt to promote complete 
conversion to the enamine product, a more complex proton NMR spectrum was 
observed, which was indicative of product degradation or side-product formation. In 
any case, given the slow process, this was evidently an inefficient means of obtaining 
the desired product. 
Proposed light-promoted radical mechanisms 
Due to their unsaturated nature, retinoids are believed to be efficient scavengers of 
peroxyl radicals, which could account for their antioxidant properties.184 Since 
formation of enamine 30 was proposed to occur in response to light and air, a 
mechanism for this process is outlined below, involving the formation of a 
hydroperoxyl radical (Schemes 17 and 18). 
 
 
 
 
Scheme 17  Proposed mechanism for light-induced interaction of compound 21 with triplet oxygen. 
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Since the extended conjugated structure of retinoid 21 meant that the molecule was 
particularly susceptible to excitation by light, it was proposed that the α-hydrogen 
could be activated towards reaction with molecular oxygen, to form a radical-type 
structure (56, Scheme 17). The hydroperoxyl radical formed as a result could either be 
involved in a β-elimination (Scheme 18, green arrows), or an E1 elimination from the 
addition product 57 (Scheme 18, purple arrows).  
 
 Scheme 18  Proposed mechanisms for generation of enamine 30 through reaction with a 
hydroperoxyl radical. 
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These could be plausible mechanisms for formation of the quinoline-type structure 30. 
Given that the radical reaction steps were expected to be fast, the rate-limiting step 
was, therefore, likely to be excitation of the chromophore by light, thereby accounting 
for the slow dehydrogenation process observed. 
In order to affirm if the mechanism suggested above was the process through which 
dehydrogenation of retinoid 21 occurred, a test for the presence of peroxides in the 
reaction mixture could be performed. If positive, the exclusion of oxygen from future 
experiments could be carried out, which should prevent oxidation to the enamine 
species. In addition, direct light irradiation of retinoid 21 (rather than through the glass 
of the NMR tube) using a photolysis lamp could be attempted as a more efficient 
method for synthesising enamine 30. 
Oxidation reactions 
In order to ascertain if complete elimination from the tetrahydroquinoline core could 
be achieved, direct synthesis of the enamine product was attempted using oxidising 
agents. Given the availability of starting materials, these reactions were carried out 
using bromide 28. First, 1 equivalent of the mild oxidising agent N-bromoacetamide 
(NBA) was added to a solution of compound 28 in chloroform (Equation 22). 
  
 
After stirring for 2 h at room temperature, an aqueous workup was performed on an 
aliquot of the reaction mixture, and a mixture of products was evident by 1H NMR 
analysis, with signals corresponding to the starting material 28, and compounds 31 
and 33. When the reaction was repeated with heating to 60 °C, only the starting 
material and dibromide 31 were observed by 1H NMR analysis, and no enamine 
Equation 22 
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product 29 was present (this observation may be explained by the mechanisms 
outlined in section 4.3. [see schemes 6 and 7]). 
 
Oxidation of compound 28 using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) 
was then attempted (Equation 23): a flask containing the bromide and 1 equivalent of 
DDQ was evacuated and filled with argon three times, after which dry 
dichloromethane was added and the mixture stirred at room temperature. 
 
 
DDQ was still present by TLC analyses after 2, 4, and 6 h, and had not been consumed 
in the reaction. The mixture was then heated to reflux overnight, however, no change 
was observed by TLC analysis. After removal of the solvent, 1H NMR analysis showed a 
mixture of products, with no enamine product present. Similarly, using 2 equivalents 
of DDQ also did not provide the desired product. It would be interesting to repeat 
these reactions with retinoid 21, to assess if the presence of the extended conjugated 
system would induce a more favourable result. 
Separation by HPLC 
Given that synthetic routes to the enamine product 29 proved unyielding, efforts then 
turned towards purification of compound 21 and its enamine side-product 30 via 
HPLC. This would enable the fluorescence characterisation and biological testing of the 
Equation 23 
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two compounds to be performed separately, thereby enabling definitive conclusions 
to be drawn concerning the properties of the individual compounds. Since the sample 
(consisting of a mixture of compound 21 and approximately 10% of enamine 30) 
proved insoluble in either acetonitrile or methanol, it was first dissolved in a minimal 
volume of dichloromethane prior to making up to a 1 mL solution in methanol for 
HPLC analysis.  
 
 
Elution with acetonitrile 
When the sample was run using a standard gradient of acetonitrile (water:acetonitrile, 
90:10  water:acetonitrile, 10:90, over 20 min), compounds 21 and 30 were observed 
as two peaks in the mass spectrum, with similar retention times (11.77 and 12.23 min, 
respectively). A second analysis using a gradient of acetonitrile:water (50:50)  
acetonitrile (100%) over 10 min was used in order to reduce the retention times, and 
led to the elution of compounds 21 and 30 after 9.29 and 10.26 min, respectively. The 
similar, as well as late, elution times observed with the acetonitrile solvent systems 
were not ideal, and the products risked being lost in the column wash. 
Elution with methanol 
A 50  100% gradient of methanol (with water as co-solvent) over 10 min was also 
trialled; however, long retention times were again observed (10.88 min and 11.34 min 
for compounds 30 and 21, respectively). When the sample was run with 90% isocratic 
methanol, enamine 30 eluted more quickly, with a retention time of 2.80 min, and 
compound 21 at 3.58 min. With 85% isocratic methanol, compound 21 eluted after 
8.09 min, and enamine 30 eluted at both 6.01 and 9.06 min (in order to avoid this, the 
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less polar solvent tetrahydrofuran, rather than dichloromethane, should be used for 
initial dissolution of the sample). Given these findings, 87% isocratic methanol should, 
therefore, prove the best solvent system for satisfactory product elution time and 
separation.  
However, before HPLC could be carried out on a preparative scale in order to provide 
sufficient quantities of the compounds for fluorescence and biological evaluation, 
retinoid 21 needed to be synthesised via a route that would employ a Sonogashira 
reaction with an iodide substrate (see sections 4.7. and 4.8.). This was expected to be 
a more facile and higher-yielding reaction than the original procedure of using a 
bromide compound, and thus eliminate the need for use of triphenylphosphine as a 
catalyst stabiliser. 
 
4.5. Initial fluorescence data and biological evaluation  
 
This section outlines findings from Alex Palmer (Chemistry) and Rachel Wilson 
(Biological Sciences) as part of their BSI summer projects, with the co-operation of Dr. 
Carrie Ambler (Department of Biological Sciences) and Prof. John Girkin (Department of 
Physics) of Durham University. Full information concerning experimental procedures 
may be found in their respective project reports.185,186 
Due to the difficulties in synthesising, purifying, and separating compounds 21 and 30 
(discussed in the previous section), a sample containing a mixture of products (approx. 
10% of the enamine compound) was used for initial fluorescence characterisation and 
stem cell testing. Given their highly similar nature, the activities of both compounds 
were not expected to be significantly different.  
Fluorescence spectra of ester 50 and acid 21 (the latter containing approx. 10% of the 
enamine product) were obtained in various solvents (Fig. 44 and 45, respectively). The 
fluorescence of the compounds was easily detected, and solvent-dependent effects 
were observed (i.e. fluorescence maxima shifted to longer wavelengths as solvent 
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polarity increased), with significant fluorescence quenching observed in the more 
polar solvents (for example, in ethanol, DMSO, and cell culture media). This meant 
that when applied to cells, the fluorescence of the compounds could be expected to 
be discernable in discrete cellular locations, depending on the local polarity. 
 
 
 
 
 
 
 
 
 
   
 
    
 
Fig. 44  Fluorescence emission spectra of ester 50 recorded in various solvents 
(excitation wavelength: 350 nm).
185 
Fig. 45  Fluorescence emission spectra of retinoid 21 recorded in various solvents 
(excitation wavelength: 350 nm).
185 
Wavelength (nm) 
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Next, a preliminary cell-culture experiment was performed in which keratinocyte stem 
cells were incubated on glass cover slips using media supplemented with different 
concentrations of the sample - retinoid 21 with 10% enamine 30 - (1, 10, 25 and 100 
µg/mL). The initial objectives were as follows: firstly, to determine if, at the 
concentrations used for cell testing, fluorescence may still be observed; then, to 
ascertain the extent, if any, of cellular uptake of the sample, and finally, to assess if the 
sample demonstrated any ability to induce changes in cell growth and morphology. 
Collectively, this information would enable a decision to be made regarding the 
viability of the compound as a visual cellular probe.   
In the event of cell differentiation, keratinocyte cells would be expected to detach 
from the growth substratum; therefore, in order to ensure some cells may still be 
collected for visualisation (rather than risk losing cells into the incubation media), 
some of the keratinocytes exposed to 1 and 100 µg/mL of the retinoid sample were 
fixed and sealed onto microscope slides after 3 h exposure. After 18 h, the remaining 
cover slips were also fixed and sealed. 
The slides were viewed using a fluorescence microscope fitted with a 20/0.75 
objective lens. The findings were as follows: 
 At the lowest concentration used (1 µg/mL), the fluorescence of the sample 
was still highly visible. 
 After 3 h, cellular uptake of the sample was apparent, and at lower doses the 
compound(s) had not yet reached the nucleus.  
 After 18 h, localisation of the sample within the nucleus was evident. 
 Cells treated with higher doses of the sample appeared less healthy than those 
at lower concentrations: nuclei appeared saturated with the sample, fewer cell 
numbers were observed, and there was evidence of dead ‘exploded’ cells. 
 When lower concentrations of the sample were used, increased cell numbers 
were observed, and distinct changes in cell morphology were apparent.  
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However, the limitations of this initial study were fully recognised: namely, the need 
for negative (untreated cells) and positive (cells treated with a retinoid known to 
induce differentiation) controls. Also, any cells that may have detached (and, by 
extension, differentiated in response to retinoid treatment) need also to be collected 
for analysis.  
             
             
 
Fig. 46  Fluorescence images of keratinocyte cells incubated with 100 µg/mL of 
compound 21 (containing approx. 10% of the enamine product 30) in the culture media 
for 3 h (a), and 18 h (b). 
(a) 
(b) 
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These initial studies demonstrated that the sample of compound 21 (with 10% of 
enamine 30) was indeed able to act as a fluorescent probe in cell-culture experiments, 
which, in future, will allow for more extensive testing to be carried out, including 
visualisation at the organelle level, and assessment of the effects of the compound on 
inducing cell differentiation. Since the compounds appeared to be stable to 
photobleaching, this will likely greatly assist in the acquisition of fluorescence images, 
as well as in following the uptake and transport of the compound in live-cell tracking 
studies. 
 
4.6. Synthesis of a bromine-containing retinoid 
 
The dibromide compound 31 was successfully synthesised (see section 4.3., Equation 
11), despite difficulties in purification, as well as in derivatising and stabilising the 
structure at the 3-position. It was nevertheless recognised that this moiety could be 
used to obtain the bromine-containing retinoid (59, Scheme 19), using a route 
analogous to that for the synthesis of retinoid 21. This could potentially provide a 
structure possessing novel properties, and it would be interesting to determine to 
what extent the presence of a bromine atom would affect both the fluorescence and 
biological activity of the molecule.  
 
 
 
Scheme 19  Use of dibromide 31 to synthesise the bromine-containing retinoid, 59. 
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Thus, a Sonogashira reaction with compound 31 and TMSA was performed. When an 
oil bath was used to heat the mixture to 80 °C, the reaction required 60 h for 
completion, and it was difficult to obtain the product in pure form (crude yield of 47%, 
estimated from 1H NMR analysis). A greatly improved reaction time was achieved 
when a microwave-assisted method was used: after 6 h, 84% conversion to alkyne 60 
was observed by GC-MS analysis (Equation 24). 
 
 
In addition to the desired product, some unreacted starting material (31) was present 
(8%), as well as the dicoupled product 61 (8%). Triethylamine was removed in vacuo, 
and the residue was filtered through a pad of silica (hexane:EtOAc, 9:1, as eluent, with 
1% Et3N). 
1H NMR and GC-MS analyses of the material obtained following in vacuo 
solvent removal showed that a 50:50 ratio of compound 60 and the debrominated 
product 52 was present.  
 
It was thought that debromination was triggered by purification on silica gel, thus, the 
Sonogashira reaction was repeated, and crude alkyne 60 was used in the subsequent 
reactions, with purification to be attempted following the last step in order to obtain 
Equation 24 
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retinoid 59 in pure form. Thus, removal of the trimethylsilyl group from crude product 
60 was carried out according to Equation 25 in order to provide the free alkyne (62). 
 
 
 
A Sonogashira reaction was then performed using alkyne 62 and 4-iodobenzoic acid 
methyl ester 45 (Equation 26).  
 
 
 
Equation 25 
Equation 26 
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Formation of ester 63 was confirmed by 1H NMR analysis, and TLC analyses on both 
alumina and silica gel plates (hexane:EtOAc, 9:1, as eluent, with and without 1% Et3N) 
were performed to determine the appropriate solvent system for purification. 
Visualisation of the plates under long-wave UV light showed that, as expected, the 
material was highly fluorescent; however, significant streaking and spotting was 
observed on the plates regardless of the solvent system used, and was indicative of 
product instability towards purification by chromatographic means. 
Despite this, purification of ester 63 was performed via vacuum filtration through a 
short pad (3 cm height, 4 cm diameter) of silica with solvent (hexane:EtOAc, 9:1, as 
eluent) that had been chilled in the freezer for 30 min before use. These steps were 
intended to reduce the extent of compound degradation, and to improve product 
recovery; however, 1H NMR analysis showed no significant improvement in purity was 
attained when compared to the crude material, and a mixture of products remained. 
Perhaps, as appropriate equipment and purification systems become available, 
separation of compound 63 may be possible at a future date. 
 
4.7. Synthesis of a fluorescent retinoid via an N-acetyl compound 
 
Given that it was not possible to synthesise iodide 27 via a halogen-exchange reaction 
with bromide 28, or direct iodination with compound 26 (Scheme 20; for a discussion, 
see section 4.3.), as well as the difficulty in carrying out the Sonogashira cross-coupling 
reaction using the bromide (requiring high loadings of PPh3, palladium and copper 
catalysts, in addition to heating at a high temperature for a prolonged period), an 
alternative route to the desired iodide 27 was considered. 
 
Scheme 20 
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Proposed synthetic route 
Since iodination of the N-methyl derivative (for synthesis of aza-EC23, see section 4.2.) 
proceeded relatively easily, it was thought that the presence of the N-isopropyl 
moiety, as well as a methyl group on the aromatic ring, deactivated compound 26 
towards electrophilic aromatic substitution (a proposed explanation for this 
observation that takes into account the lowest energy conformations of the molecules 
is provided at the end of this section). Thus, the synthetic route to iodide 27 via an N-
acetyl compound is outlined in Scheme 21: with the acetyl group in place of the 
isopropyl, the propensity for compound 66 to undergo aromatic iodination could then 
be assessed. Following removal of the acetyl group, alkylation with 2-iodopropane 
would then provide iodide 27, the desired substrate in the Sonogashira coupling 
reaction for synthesis of the target fluorescent retinoid (21; GZ108).  
 
The ability to remove the acetyl group would also enable the tetrahydroquinoline core 
to be derivatised on the nitrogen atom, thus allowing for the synthesis of new retinoid 
compounds. In addition, by attaching long alkyl chains (C12-C18) at this position, 
structures with emulsion-type properties could also be produced, and would enable 
investigation into the area of targeted retinoid delivery to specific cell types.  
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Acetylation 
Acetylation of o-toluidine was achieved by the dropwise addition of a solution of 
acetyl chloride (1.1 equivalents) in dichloromethane to a stirred solution of the amine 
and pyridine (2.5 equivalents) in dichloromethane, with the flask maintained at 0 °C 
(Equation 27). The reaction was monitored by TLC analysis, and found to be complete 
after stirring for 2 h. The product was obtained as a fluffy white crystalline solid 
following aqueous workup and recrystallisation. For a larger scale preparation (>10 g), 
residual pyridine proved difficult to remove completely by evaporation, becoming 
Scheme 21  Proposed synthetic route to iodide 27 via N-acetylation of o-toluidine. 
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trapped with the product as a hard residue at the bottom of the flask. In this case, a 
trituration was performed in which the product, along with residual pyridine, was 
redissolved in dichloromethane, and an equal volume of hexane was added. 
Dichloromethane was then removed in vacuo, at which point compound 64 
crystallised from hexane, and was filtered out. 
 
 
 
Alkylation 
N-Alkylation of compound 64 with 3,3’-dimethylallyl bromide 12 using K2CO3 as base 
(as for the reaction with the N-isopropyl analogue) was not successful in promoting 
product formation. Thus, a stronger base, sodium hydride, was added slowly to a 
solution of compound 64 in dry DMF, and the mixture heated to 65 °C for 1 h. 3,3’-
Dimethylallyl bromide (1.2 equivalents) was then added to the cooled solution, and 
the mixture was heated to 70 °C overnight. Following aqueous workup and purification 
by silica-gel chromatography, product 65 was obtained as a brown oil, albeit in poor 
yield (28%). 
 
 
 
 
Equation 27 
Equation 28 
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Compound 65 was finally obtained by heating a suspension of compound 64, K2CO3 
(1.1 equivalents), NaOH (1.1 equivalents), (CH3)4NBr (3 mol%), and 3,3’-dimethylallyl 
bromide (1.2 equivalents) in toluene to 70 °C overnight with vigorous stirring 
(Equation 28). An aqueous workup was then performed, and the crude product 
purified by column chromatography on silica gel to give compound 65 in 75% yield 
(Fig. 47). 
 
 
 
Cyclisation 
A literature procedure employing AlCl3 in chlorobenzene was attempted for cyclisation 
of compound 65 (Equation 29).187 However, after heating with 2.2 equivalents of the 
Lewis acid to 110 °C for 1 h, only starting material was present by 1H NMR analysis. 
Heating for a further 5 h succeeded in converting approximately 10% of the starting 
material; similarly, heating to reflux (130 °C) overnight only resulted in a slight increase 
in conversion (15%). 
Fig. 47  
1
H NMR spectrum of allylated product 65 (recorded in CDCl3 at 400 MHz). 
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The reaction was repeated with heating to 120 °C, and consumption of the starting 
material was monitored by TLC analysis: after 5 h, a single product spot was observed. 
Following aqueous workup, 1H NMR and COSY analyses of the red/brown residue 
showed a complex spectrum in which two major products were observed in a 3:1 ratio 
(Fig. 48).  
 
 
 
GC-MS analyses of the crude material found two peaks possessing the same mass: the 
two products should therefore be isomers, and it was possible that, as well as a methyl 
shift, a 5-membered ring compound could have been formed (i.e. resulting in the 
possible structures 70 to 72; Fig. 49). 
Fig. 48  
1
H NMR spectrum of material obtained (following aqueous workup) from heating 
compound 65 with 2.2 equivalents of AlCl3 in chlorobenzene to 120 °C for 5 h in chlorobenzene - 
recorded in CDCl3 at 400 MHz. 
Equation 29 
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Purification of this mixture by silica-gel chromatography was attempted, using 
hexane:EtOAc, 9:1, as eluent. Coloured fractions were initially obtained, which 
provided an orange oil and a red solid; however, the desired product 66 was not 
present by 1H NMR analysis. The polarity was increased (hexane:EtOAc, 3:1, as eluent), 
and a single product eluted over more than twenty fractions (Fig. 50). This compound 
was obtained in 25% yield (compared to the starting material), and 1H NMR analyses of 
subsequent fractions from the column showed that the original mixture of products 
remained, which were not easily separated.  
 
 
 
Fig. 50  
1
H NMR spectrum of product obtained (following column chromatography) from the 
attempted cyclisation of compound 65 by heating to 120 °C for 5 h in chlorobenzene with 2.2 
equivalents AlCl3 - recorded in CDCl3 at 400 MHz. 
Fig. 49  Possible isomers from cyclisation of compound 65. 
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1H NMR analysis of the pure product showed that, while the alkane/alkene region of 
this material differed to that of the starting material, indicating that reaction had 
occurred, the five separate multiplet peaks that each integrated to one proton were 
inconsistent with the spectrum expected for the cyclised product. 
The presence of the acetyl group may produce diastereotopic protons on the adjacent 
carbon atom, thereby accounting for the non-equivalent proton signals observed; 
however, no discernible coalescence of peaks was observed when variable 
temperature 1H NMR studies were carried out with the compound in DMSO-d6 (up to 
80 °C), suggesting a fixed, stable, or rigid conformation. Notwithstanding this 
observation, the aromatic region of the product remained unchanged from the 
starting material, and still integrated to four protons, suggesting that cyclisation onto 
the ring had not occurred. Thus, alternative ways in which compound 65 may have 
reacted in the presence of AlCl3 were considered.  
Particularly interesting was a literature reference188 that proposed a Lewis acid-
promoted intramolecular carbonyl-ene reaction, and Scheme 22 outlines an analogous 
reaction with compound 65.  
 
 
 
The resulting product (compound 73) would therefore contain a 4-membered ring, 
along with an isolated double bond and a carbinolamine. To determine if the latter 
was indeed present, a few drops of D2O were added to the NMR tube containing the 
purified product of the AlCl3-catalysed cyclisation reaction (Fig. 50); however, no 
exchangeable protons were observed. Given the strained 4-membered ring system 
present in the structure, as well as the probable instability of carbinolamines, further 
Scheme 22  Proposed Lewis acid-catalysed 4-exo-trig cyclisation of compound 65. 
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reaction of compound 73, specifically, an intramolecular ring expansion followed by 
dehydration, could also be possible (Scheme 23).  
 
 
 
While the reactions outlined in Schemes 22 and 23 were feasible, none of the 
expected products from these transformations were identified by 1H NMR analysis. A 
more simple explanation for the presence of the five individual proton peaks in the 
purified material could be the addition of H2 across the alkene double bond to give the 
reduced product (76). HRMS analysis of the material supported this suggestion; 
however, given that no reducing agent was present in the reaction mixture, the 
mechanism for such an occurrence remains unknown. 
 
Scheme 23  Proposed ring expansion of compound 73 followed by dehydration. 
Equation 30 
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*No solvent: AlCl3 heated to 130 °C until molten, followed by addition of 
compound 65 and reducing the temperature to 85 °C. 
 
In an effort to produce the desired cyclised product 66, various reactions were set up 
between compound 65 and AlCl3 under different conditions in dichloromethane (Table 
3). The reactions were assessed for completion by 1H NMR analysis of the reaction 
mixtures following aqueous workup. Despite using different numbers of equivalents of 
the Lewis acid, as well as varying the reaction time and temperature, in all cases where 
a reaction had occurred, the same 3:1 ratio of major to minor product was always 
observed by 1H NMR analysis (see Fig. 48). 
 
Reaction AlCl3 Temp. Time (h) 
3:1 mix of 
products? 
1 3 equiv. r.t. 2.5 yes 
2 3 equiv. r.t. 1 yes 
3 2 equiv. r.t. 1 yes 
4 2 equiv. -78 °C 1 no reaction 
5 2 equiv.  0 °C 0.5 yes 
6 1 equiv. r.t. 0.5 no reaction 
7 1 equiv. r.t. 1 mainly 65 
8 1 equiv. r.t. 2 
65 (major) +  
3:1 mix (minor) 
 9* 1 equiv. 130 - 85 °C 2 yes 
 
 
Evidently, it was not possible to control the reaction outcome, and LCMS analysis of 
the mixture found that no chloride 77 (the result of simple addition of HCl across the 
alkene double bond) was present. Furthermore, given that the components of the 
mixture could not be easily separated (except to obtain, in low yield, the purported 
reduced compound shown in Fig. 50), the structures of the products from the reaction 
of compound 65 with AlCl3 thus remain undetermined. 
 
Table 3  Cyclisation conditions attempted with compound 65. 
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Cyclisation of compound 65 using PPA was also attempted; however, the reaction 
proved to be slow, and 1H NMR analyses of the mixture showed that the reaction did 
not go to completion, despite heating to 120 °C for up to one week. 
 
 
A modified approach was used: PPA was heated to 120 °C prior to the addition of neat 
compound 65. After stirring for 15 min, an aqueous workup was performed to obtain 
an orange-coloured oil in approximately 40% yield (compared to the starting material), 
which was observed to be a single product by 1H NMR analysis (Fig. 51).  
Equation 31 
4. Fluorescent Retinoids 
 
121 
 
 
 
 
Nonetheless, a comparison of the spectrum to the aromatic region of compound 65 
led to the conclusion that cyclisation onto the ring had not occurred. The presence of 
an exchangeable proton signal, at approx. 2.5 ppm, suggested that attack of the acetyl 
group may instead have occurred (Scheme 24). 
 
 
 
However, simple addition of H2O across the double bond could also be possible 
(Scheme 25). 
Fig. 51  
1
H NMR spectrum of product obtained from the reaction of compound 65 with 
PPA for 15 min at 120 °C - recorded in CDCl3 at 400 MHz. 
Scheme 24  Proposed cyclisation of compound 65 to give compound 78. 
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This would then be consistent with the 13C NMR spectrum of the material, which 
indicated that a carbonyl group was present; HRMS analysis also supported the 
structure of compound 79 as the product. As previously suggested, the presence of 
the acetyl group could give rise to the individual alkane proton peaks observed, and 
the great disparity between the proton chemical shifts (namely at 3.25 and 4.25 ppm, 
Fig. 51) could be further explained by hydrogen bonding within the molecule (Fig. 52), 
which would mean that the substituents on the nitrogen atom could remain in a 
relatively fixed conformation, and the alkane protons in question would experience 
considerably different chemical environments than if free bond rotation were possible.   
 
 
  
Scheme 25  Hydrolysis of compound 65 to give compound 79. 
Fig. 52  Proposed hydrogen-bonding conformations of hydrolysis product 79, with the 
less hindered (i.e. favoured) conformation shown on the left. 
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In order to determine if compound 79 would eventually react to provide the desired 
cyclised product, the reaction was repeated with heating for a longer period: 
compound 65 was added to a flask containing PPA that had been heated to 120 °C, 
and the mixture was stirred for 2 h. The resulting black/brown viscous oil was difficult 
to extract; however, some material was isolated following aqueous workup (approx. 
50%), and three separate peaks, each integrating to one proton, were observed in the 
aromatic region of the 1H NMR spectrum (Fig. 53). It appeared, therefore, that 
cyclisation had indeed occurred; however, it was apparent that the product had also 
deacetylated to give compound 80. 
 
 
 
Since cyclisation of compound 65 using AlCl3 and PPA had proved unsuccessful, 
alternative methods were considered: a literature procedure of cyclising a similar 
compound using concentrated sulphuric acid was attempted (Equation 32).189 
Fig. 53  
1
H NMR spectrum of product obtained from the reaction of compound 65 with PPA 
for 2 h at 120 °C - recorded in CDCl3 at 400 MHz. (Note change in aromatic region - residual 
ethyl acetate present). 
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The reaction mixture was stirred at 0 °C for 1 h, and an aqueous workup was 
performed. The resulting yellow oil proved to be a complex mixture of products as 
observed by 1H NMR analysis. Perhaps, given the presence of the acetyl group, a 
strong acid was not an appropriate reagent to use for cyclisation of compound 65. 
Cyclisation using the weaker Lewis acid BF3·OEt2 was also attempted (Equation 33): 
however, despite refluxing the mixture for 2 h, no reaction was observed by 1H NMR 
analysis, and only starting material was recovered. 
 
 
 
 
Finally, cyclisation of compound 65 was attempted using a catalytic amount of Sc(OTf)3 
(Equation 34), but this likewise proved unyielding, with only starting material present 
by 1H NMR analysis. 
 
Equation 32 
Equation 33 
Equation 34 
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Iodination 
Various iodination reactions were attempted on material that was originally thought 
to be the cyclised product (compound 66); however, it was later apparent that the 
substrate used was in fact likely to be compound 78, or more likely, the hydrolysis 
product 79 (see Fig. 51 for 1H NMR spectrum).  
 
 
 
The iodination conditions attempted are outlined in Table 4; in all cases, care was 
taken to exclude light from the reactions. Following aqueous workup of the reaction 
mixtures, 1H NMR analyses were performed to assess if iodination had occurred. A 
literature-reported method of using ICl and In(OTf)3 to carry out mild and efficient 
direct aromatic iodination of acid-sensitive substrates190 was attempted, both with 
and without heating (Table 4, Reactions 1-3), but only the starting material was 
observed by 1H NMR analysis. Similarly, stirring the substrate with equimolar amounts 
of iodine and mercury(II) oxide (Table 4, Reactions 4 and 5), using iodine (Table 4, 
Reactions 6 and 7), or N-iodosuccinimide (Table 4, Reaction 8), were all ineffective in 
Equation 35 
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*NIS - N-iodosuccinimide 
 
promoting formation of the desired product: evidently, the substrate appeared to be 
highly deactivated towards electrophilic aromatic substitution. 
 
Reaction Reagents Solvent 
Temp. 
(°C) 
Time  
(h) 
Product 
observed? 
1 
In(OTf)3 (1.0 equiv.) 
ICl (1.5 equiv.) 
MeCN 20 0.5 no 
2 
In(OTf)3 (1.0 equiv.) 
ICl (1.5 equiv.) 
MeCN 85 2.5 no 
3 
In(OTf)3 (1.0 equiv.) 
ICl (1.0 equiv.) 
MeCN 20 24 no 
4 
I2 (1.0 equiv.) 
HgO (1.0 equiv.) 
DCM 20 0.5 no 
5 
I2 (1.0 equiv.) 
HgO (1.0 equiv.) 
DCM 20 18 no 
6 I2 (0.95 equiv,) CH3Cl -60 to -30 1 no 
7 I2 (0.95 equiv,) CH3Cl 20 60 no 
8 NIS (1.1 equiv.) MeCN 85 2.5 no 
 
 
Low-energy conformation calculations 
Spartan 10 was used to perform an equilibrium conformation calculation (with AM1 
semi-empirical settings - which, on systems consisting of only C, H, N and O, provides 
sufficient accuracy to give a good indication of geometry vs energy - to generate 5000 
conformers) to predict the lowest energy conformation for compound 79 (Fig. 54). As 
expected, hydrogen bonding between the carbonyl and hydroxyl groups was evident, 
and the alkyl chain was arranged away from the aromatic methyl group in order to 
reduce steric crowding. As a result of this arrangement, the lone pair of the nitrogen 
atom was in an orthogonal position relative to the aromatic π-system, and, therefore, 
seemed unable to activate the molecule towards electrophilic iodination (by donating 
electron density into the aromatic ring). This likely accounted for the lack of reactivity 
Table 4  Iodination conditions attempted with the purified product from the 
reaction of compound 65 with PPA (see Fig. 51). 
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of the compound, and a similar orthogonal arrangement of the nitrogen lone-pair 
could also be expected for the 5-membered ring-containing compound, 78. 
 
                                                                       
 
 
AM1 (as implemented in Spartan 10) was also used to predict the lowest energy 
conformations of the tetrahydroquinoline structures 14 and 26, in order to determine 
whether a similar explanation could be made for the great difficulty in performing an 
aromatic iodination reaction with the latter more substituted compound compared to 
its less substituted analogue.  
Thus, the favoured low-energy conformations are shown in Fig. 55. In compound 26, it 
could clearly be observed that the N-isopropyl moiety was arranged in a pseudo-axial 
position in order to reduce steric effects with the neighbouring ortho-methyl group. 
The latter thus appeared to play a significant role in deactivating compound 26 
towards iodination, since the resulting conformation meant that the nitrogen lone-pair 
was less available to donate into the π-system, thereby rendering the molecule less 
susceptible towards electrophilic aromatic substitution. Conversely, in compound 14, 
without the steric-hindering effects of an aromatic methyl substituent, the N-methyl 
group was able to lie in a more equatorial position. In this case, the activating effects 
Fig. 54  Predicted lowest energy conformation of tertiary alcohol 79, as calculated by Spartan 10. 
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of the nitrogen lone-pair may be expected to come into play, thereby accounting for 
the relative ease with which this substrate undergoes aromatic iodination. 
                                              
 
                                              
 
 
 
It was further noted that, in compound 26, due to the pseudo-axial arrangement of the 
N-isopropyl group, the nitrogen lone-pair was consequently more available for 
performing nucleophilic attack (for example, of oxidising species), which would explain 
the susceptibility of the molecule for forming an enamine side-product (discussed in 
section 4.3.).  
 
Fig. 55  Predicted lowest energy conformations of compounds 14 and 26, as calculated by 
Spartan 10. Note the pseudo-axial position of the N-isopropyl group in compound 26, 
compared to the more equatorial position of the N-methyl group of compound 14. 
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4.8. Synthesis of an amide-containing retinoid  
 
 
 
 
A series of heteroarotinoids (Fig. 57) was synthesised and evaluated for biological 
activity and RAR/RXR receptor specificity. The presence of the two-atom linkers (C-O) 
between the two aromatic rings increased the flexibility of the heteroarotinoids, and 
Fig. 56  Predicted lowest energy conformation of the oxidised derivative of compound 26, 
as calculated by Spartan 10.  
Fig. 57  Flexible heteroarotinoids in which hydrophobicity of the molecule was increased 
through the incorporation of additional methyl groups.
191
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these compounds were found to possess increased potency and specificity for retinoic 
acid receptors compared with analogues containing alkenyl linkers.85 Synthesis of 
these heteroarotinoids were via cyclic amide structures, which were subsequently 
reduced to provide the tetrahydroquinoline cores.  
Target hydrophobic core 
Thus, synthesis of the cyclic amide-containing compound 87 (Fig. 58) was proposed, 
which was thought to possess desirable properties for incorporation into retinoids 
developed for fluorescence imaging applications.  
 
 
 
 
 
Iodide - better substrate 
for Sonogashira reaction. No potential for oxidation 
to enamine due to 
presence of C=O group. 
group. 
Hydrophobicity increased by 
additional methyl groups. 
Fig. 58  Desired target substrate 87 for Sonogashira coupling reaction, which, if 
desired, may be reduced to provide the original target iodide 27.
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With compound 87 in hand, synthesis of retinoid 88 would then be possible, and it 
would be interesting to evaluate the fluorescence and biological properties of the 
amide-containing molecule.  
 
N-Alkylation 
Reaction with acetone 
The proposed reaction scheme for the synthesis of iodide 87 was based on a similar 
procedure reported in the literature (Scheme 26).191  
         
 Scheme 26 
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4-Iodo-2-methylaniline (89) may be purchased from Sigma-Aldrich, however, it was 
synthesised via a straightforward procedure employing o-toluidine and 3 equivalents 
of iodine in a solution of pyridine and dioxane (Equation 36).192 After stirring for 1 h at 
0 °C, the mixture was allowed to warm to room temperature and stirred for a further 1 
h. An aqueous workup was then performed, and the desired product was obtained in 
61% yield after recrystallisation. 
  
 
 
In order to synthesise the N-isopropyl compound 90, 1.5 equivalents of acetone and 1 
equivalent of Ti(IV)oiPr were stirred with iodide 89 in ethanol for 24 h. However, a TLC 
analysis followed by a ninhydrin stain showed that only (the primary amine) starting 
material was present. The temperature was increased to 35 °C, and the mixture was 
stirred for a further 2 h; however, no product was observed by TLC analysis. The 
addition of more acetone (1.5 equivalents) followed by stirring at 35 °C for 5 h, also did 
not result in product formation. Given that this was reported as a successful procedure 
for performing N-alkylation of 4-bromoaniline, perhaps the presence of the ortho-
methyl group played a role in hindering the approach of the electrophile, thereby 
disfavouring product formation.  
Reaction with acryloyl chloride 
An alternative route was then considered, which involved first performing N-alkylation 
of iodide 89 using 3,3’-dimethylacryloyl chloride,85 after which cyclisation of the 
product may be carried out, and finally an N-isopropylation reaction would provide 
substrate 87. Accordingly, the first N-alkylation reaction of compound 89 was 
performed according to Equation 37, and product 92 was obtained as a white 
Equation 36 
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crystalline solid in 79% yield following aqueous workup and recrystallisation (Equation 
37). 
      
 
Cyclisation reactions 
Cyclisation of compound 92 according to the reported literature method was then 
attempted (Equation 38).85 This involved heating the starting material to 130 °C, prior 
to the addition of 1.5 equivalents of AlCl3 over 1 h. The flask was then cooled to 80 °C, 
and a further 0.2 equivalents of AlCl3 were added. The mixture for stirred for 30 min, 
then cooled to room temperature, and an aqueous workup was performed. However, 
1H NMR analysis revealed significant deiodination had taken place so that the desired 
compound 93 and the deiodinated product 94 were obtained in approx. 1:2 ratio, 
respectively (as observed by 1H NMR analysis), which were not easily separated by 
column chromatography. 
 
 
In order to obtain compound 93 as the sole product, iodination of the mixture of 
compounds 93 and 94 was attempted by the addition of 1.1 equivalents of ICl in acetic 
acid. Following overnight stirring at room temperature, this was successful in 
Equation 37 
Equation 38 
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increasing the proportion of the iodide product to approximately 62%. When the 
reaction was left stirring for a further 72 h, up to 78% of compound 93 was observed 
by 1H NMR analysis.  
It was thought that the iodination reaction may proceed more efficiently if carried out 
on a single compound, rather than with a mixture of products; therefore, reaction of 
o-toludine with 3,3-dimethylacryloyl chloride was performed according to Equation 39, 
which provided compound 95 as a white crystalline solid in 89% yield following 
aqueous workup and recrystallisation. 
 
 
 
Next, cyclisation of compound 95 using AlCl3 was carried out, with dichloromethane as 
the solvent (Equation 40). This was preferred over the solvent-free method, since the 
reaction proceeded more quickly, and given that no viscous black oil was produced, 
the product proved more facile to extract. Thus, pure compound 94 was obtained in 
91% yield following aqueous workup and recrystallisation. 
 
 
 
Compound 94 was then stirred with 1.1 equivalents of ICl in acetic acid at room 
temperature: following overnight reaction, approximately 62% conversion to the 
Equation 39 
Equation 40 
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iodide product was observed by 1H NMR analysis. When the reaction was repeated 
using 2 equivalents of ICl, an improved conversion to the desired product 
(approximately 81%) was observed following overnight stirring. However, again, due 
to the highly similar nature of the starting material and product, it was not possible to 
obtain iodide 93 in pure form. 
 
 
 
At this point, it was recognised that cyclisation of the iodine-containing compound 92 
could likewise be performed with AlCl3 using a solvent. Perhaps, by avoiding high 
temperatures (as in the solvent-free method), deiodination may be less likely to occur. 
Compound 92 was accordingly stirred with 2 equivalents of AlCl3 in dry 
dichloromethane for 1 h at room temperature: following aqueous workup, only 10% 
deiodination was observed by 1H NMR analysis. Compound 93 was eventually 
obtained as the sole product when 1.5 equivalents of AlCl3 were used; in this case, the 
reaction proceeded more slowly, and required 3 h for completion (Equation 42).  
 
 
 
 
Equation 41 
Equation 42 
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Derivatisation reactions 
Next, reduction and N-alkylation of compound 93 were attempted in order to assess 
the ease of performing such reactions (Equation 43). 
 
 
 
Reduction of the carbonyl group with borane-dimethyl sulfide was successful, and 
provided compound 68 in 83% yield after reaction workup. This was then used for the 
subsequent alkylation reaction with 2-iodopropane, with K2CO3 as base; however, 
following heating to 60 °C in DMF for 5 h, only starting material was recovered. A 
stronger base, such as sodium hydride, may be more effective in promoting formation 
of the N-alkylated product. 
Sonogashira coupling and hydrolysis  
A Sonogashira reaction was carried out between iodide 93 and alkyne 16 in order to 
provide the cyclic amide-containing ester 96 (Equation 44). Following overnight 
heating, the mixture was filtered, and the solvent was removed in vacuo. The product 
proved unstable to purification via chromatographic means (streaking on the column 
was observed, and only a minimal amount of the product was recovered, regardless of 
the solvent system used), therefore, trituration of the product was performed using 
ethanol as the solvent, and compound 96  was thus obtained in 66% yield.  
 
 
 
Equation 43 
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Next, ester hydrolysis was carried out according to Equation 45: after 4 h, some 
starting material was still observed by TLC analysis, so the reaction was heated for a 
further 4 h, after which a second TLC analysis showed only a single product spot was 
present.  
 
 
 
Equation 44 
Equation 45 
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An aqueous workup was performed by adding diethyl ether and water to the cooled 
reaction mixture, followed by acidification of the aqueous layer to pH 1 using 1 M HCl. 
At this point, an insoluble white precipitate was formed, which did not dissolve when 
the mixture was extracted with diethyl ether. The combined organic extracts were 
dried over MgSO4, however, following in vacuo removal of the solvent, only a minimal 
amount (approx. 15%) of product was recovered. A significant quantity of the insoluble 
material remained in the aqueous portion, and did not dissolve in any of the organic 
solvents that were added to the mixture (methanol, ethanol, diethyl ether, ethyl 
acetate, dichloromethane, acetone). Thus, it was thought that ring-opening of the 
cyclic amide must have occurred. 
Given that the product of the hydrolysis reaction of compound 96 proved insoluble in 
any of the organic solvents used in an attempt to dissolve the material, the product 
was thought to exist in the zwitterionic form (Fig. 59).  
 
 
 
1H NMR analysis of the material in DMSO-d6 revealed that a low-field singlet peak (at 
9.66 ppm, which was consistent with a proton of a carboxylic acid group) 
corresponding to one proton was present, which disappeared when a D2O exchange 
was carried out. An additional singlet peak was also present (at 3.87 ppm) that 
integrated to approximately 1.5 protons. However, in a D2O exchange experiment, this 
signal remained unchanged, even after leaving the sample for a few days. It was, 
therefore, unlikely that this signal was caused by a proton attached to an oxygen or 
nitrogen atom. It was interesting to note, however, that the chemical shift value of this 
Fig. 59  Proposed ammonium carboxylate salt produced from the hydrolysis reaction 
of compound 96. An intramolecular hydrogen-bonded structure is suggested.
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singlet peak, along with its corresponding 13C NMR signal, were highly similar to those 
observed for the methyl ester group in the starting material. The products of the 
hydrolysis reaction could, therefore, be the ring-opened compound 97 and its methyl 
ester analogue. Despite the 1H NMR spectrum of the material giving no indication that 
a second product was present, it could be feasible that, due to their highly similar 
structure, the two compounds would appear essentially identical by 1H NMR analysis. 
N-Isopropyl derivative 
Synthesis of the original target compound 87 was carried out by performing N-
alkylation of compound 93 according to Equation 46. 
 
 
Next, a Sonogashira coupling reaction between compound 87 and alkyne 16 was 
performed: following overnight heating, the mixture was filtered, and the solvent was 
removed in vacuo. It was possible to purify this N-substituted compound by silica-gel 
chromatography, and pure compound 98 was thus obtained in 89% yield. 
Equation 46 
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Ester hydrolysis of compound 98 was attempted using the conditions shown in 
Equation 48. However, in both cases, an insoluble material was obtained that proved 
to be consistent with the amide ring-opened product by 1H NMR analysis.  
Equation 47 
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4.9. Synthesis of an amide retinoid via an oxazoline compound 
 
Since hydrolysis of the methyl ester compounds in the previous section resulted in 
ring-opening of the cyclic amide, the synthesis of an oxazoline-containing analogue, 
which may be converted to the desired carboxylic acid product using milder 
conditions, is outlined in Scheme 27. 
Equation 48 
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Reaction of compound 45 with ethanolamine, followed by cyclisation of compound 99 
using tosyl chloride and 4-dimethylaminopyridine, proved straightforward, and 
provided the oxazoline-containing aryl iodide 100 in a good yield (72%) following 
purification by silica-gel chromatography. 
Next, a Sonogashira coupling reaction between compound 100 and TMSA was 
attempted according to the previously-established method of heating with palladium 
and copper catalysts in neat triethylamine. However, this led to a poor product 
recovery, and it was later thought that this was likely due to decomposition of the 
oxazoline moiety in the highly basic environment. The reaction was repeated using 
DMF as the solvent, with 2 equivalents of triethylamine as base. In addition, an acidic 
workup should be avoided for future repeats of the reaction, since the oxazoline group 
also appeared unstable to a 5% HCl wash. Nevertheless, removal of the trimethylsilyl 
group was carried out on the crude material to provide the free alkyne, compound 
102. 
Scheme 27  Synthetic route to oxazoline compound. 
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A final Sonogashira reaction was then carried out to obtain the oxazoline retinoid 
analogue 103 (Equation 49; for improved product yield, heating in neat triethylamine 
should be avoided for future repeats of this reaction). 
 
 
 
Conversion of compound 103 to the desired carboxylic acid product was attempted 
according to a reported literature method of stirring with NBu4HSO4 and 5% NaOCl in 
ethyl acetate at room temperature (Equation 50).193 However, the reaction was slow, 
requiring a long reaction time (96 h) for consumption of the starting material. 
Following aqueous workup, an insoluble material was recovered, and it was apparent 
from 1H NMR analysis that this was again the amide ring-opened product. 
Equation 49 
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4.10. Conclusions and Outlook 
 
It is evident that the synthetic route towards a cyclic amide-containing retinoid 
requires some optimisation in order to provide the desired carboxylic acid product, 
without causing ring-opening of the hydrophobic part of the molecule. Thus, a 
screening of procedures for milder hydrolysis of the methyl ester compounds could be 
carried out, as well as assessing different methods for conversion of the oxazoline 
group to the carboxylic acid. With the amide-containing retinoid in hand, it would then 
be possible to perform an evaluation of the stability, fluorescence, and biological 
properties of the molecule. 
 
Equation 50 
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5.1. Concluding remarks 
 
These studies have demonstrated that minor changes to the structure of small 
molecules can have profound impacts on their biological activity. This was clear from 
evaluation of the thiazole-containing molecules A, 1, and 2: while the alkoxy (A)- and 
phenyl (1)-containing derivatives did not induce differentiation of TERA2.cl.SP12 EC 
cells, the more bulky tetramethyltetrahydronaphthyl (2)-substituted analogue 
displayed significant retinoid activity in this cell line, and promoted enhanced neurite 
outgrowth compared to ATRA. The relationship between activation of a particular 
receptor and the inducement of specific biological outcomes remains to be fully 
elucidated, and could provide an interesting area for further study. 
In addition, the synthesis, characterisation, and initial biological evaluation of the 
fluorescent retinoid, GZ108, provided encouraging results to support the concept that 
fluorescence incorporated within an active small molecule could constitute a highly 
useful tool for the unprecedented real-time visual exploration of retinoid uptake, 
transport, and activity in biological cells and systems. 
 
Nevertheless, the propensity of the molecule for forming an enamine side product 
remains to be fully understood. This occurrence was proposed to be due to exposure 
of the fluorophore to light, resulting in overall dehydrogenation via a purported 
radical-mediated process. Furthermore, the predicted low-energy conformations 
calculated by Spartan 10 revealed the surprising effects of the N-substituent, which 
should be taken into account for future synthetic work. Briefly, the presence of the N-
isopropyl group appeared to have a significant impact on the resulting conformation of 
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the molecule: in order to reduce steric effects with the aromatic methyl group, the 
isopropyl moiety was arranged such that the nitrogen lone-pair was no longer in 
conjugation with the rest of the molecule, and could not, therefore, play an electron 
donating/activating role. This would account for the great difficulty in performing 
aromatic iodination reactions with the hydrophobic core, which in turn affected the 
ease of carrying out the remaining reactions in the synthetic scheme, leading to a 
suboptimal product yield. Perhaps a simple substitution of an N-methyl group would 
be sufficient to stabilise the molecule towards N-oxidation or degradation, while 
allowing the nitrogen lone-pair to lie in a coplanar conformation.  
Finally, the synthetic route to a cyclic-amide containing retinoid was successful; 
however, reactions to remove the protecting group (methyl or oxazoline moiety) in 
order to provide the free carboxylic acid terminus resulted in ring-opening of the cyclic 
amide; it is hoped that reaction optimisation would lead to a more favourable result. 
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5.2. Future work 
 
Based on the findings from this project, the synthesis of novel structures to 
incorporate into fluorescent retinoid design is proposed in Fig. 60. The presence of the 
additional methyl groups adjacent to the nitrogen atom (compounds 105-107) would 
increase the hydrophobicity, as well as stabilise the molecule by preventing oxidation 
to an enamine structure. The incorporation of a second aromatic group (compounds 
107 and 108) is based on the structures of known RARβ-selective ligands, and the 
additional conjugation would be expected to increase the fluorescence properties of 
the molecule. 
Fig. 60  Proposed novel building blocks for synthesis of fluorescent retinoids. The 
additional methyl groups increase hydrophobicity of the molecule while preventing 
oxidation to the enamine product. Fluorescence is increased by the additional 
conjugation in compounds 106-108. The more bulky structures of compounds 107 
and 108 are expected to provide selectivity for RARβ.
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6.1. General experimental 
Reagents were purchased from Sigma-Aldrich, Acros or Alfa-Aesar, and used without 
further purification unless otherwise stated. Dry solvents were purchased from the 
supplier. Where indicated, reagents were combined in an Innovative Technology Inc. 
(UK; http://www.innovative-technology.co.uk) nitrogen-filled (BOC, UK; 
http://www.boconline.co.uk) glovebox. All glassware was oven-dried (130 °C) prior to 
use and cooled under a positive pressure of argon. Microwave (MW)-assisted 
reactions were carried out in an Emrys™ Optimizer (Personal Chemistry, Biotage, 
Sweden; http://www.biotage.com) in septum-containing, crimp-capped, sealed vials 
with automatic wattage adjustment to maintain the desired temperature for a 
specified period of time. Reactions were monitored in situ by TLC, GC-MS or 1H NMR 
spectroscopy to ensure consumption of starting materials before reaction workup. 
Thin layer chromatography (TLC) was performed on Polygram SIL G/UV254 plastic-
backed silica gel plates with visualisation achieved using a UV lamp. Column 
chromatography was performed with Davisil Silica gel, 60 mesh. GC-MS was 
performed using an Agilent Technologies 6890 N gas chromatograph equipped with a 
5973 inert mass selective detector and a 10 m fused silica capillary column (5% cross-
linked phenylmethylsilicone) using the following operating conditions: injector 
temperature 250 °C, detector temperature 300 °C, oven temperature was ramped 
from 70 °C to 280 °C at 20 °C min−1. UHP helium was used as the carrier gas. All NMR 
spectra were recorded on either Bruker Avance-400, Varian Mercury-400, Varian 
Inova-500 or Varian VNMRS 700 spectrometers at the following frequencies: 1H: 200, 
400, 500 and 700 MHz; 13C: 126, 151 and 176 MHz; 19F: 658.4 MHz. NMR spectra were 
recorded in CDCl3 (where tetramethylsilane (TMS) was used as the internal standard), 
CD3OD, or DMSO-d6. The chemical shifts are reported in ppm relative to the residual 
protic solvent peak as reference, and spin multiplicities are indicated by the following 
symbols: s (singlet), d (doublet), dd (doublet of doublets), ddd (doublet of doublet of 
doublets), t (triplet), m (multiplet); J coupling constants are given in Hz. ES-MS was 
performed by the Durham University departmental service using an Acquity TQD 
(Waters UK Ltd) mass spectrometer and accurate mass measurements were obtained 
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on a Thermo LTQ-FT spectrometer. Elemental analyses were carried out using an 
Exeter Analytical E440 machine. Samples for HPLC analysis were submitted to the 
Durham University departmental service, and run on a C18 column at 20 °C, with a 
flow rate of 1 mL/min, and a wavelength of 254 nm was used for sample detection. IR 
spectra were recorded on a Perkin Elmer FT-IR spectrometer with an ATR attachment. 
Melting point values were measured on a Sanyo Gallenkamp apparatus and are 
uncorrected. Predicted low-energy conformation calculations were performed using 
Spartan 10, version 1.1.0 (Wavefunction Inc., 18410 Von Karman Ave., Suite 370, 
Irvine, CA 92612, USA; www.wavefun.com).  
 
6.2. Synthetic procedures for thiazole-containing retinoids  
4-(4-Hydroxy-5-methyl-thiazol-2-yl)-benzoic acid ethyl ester (5)  
 
Ethyl 4-cyanobenzoate (1.29 g, 7.4 mmol), 2-mercaptopropionic acid (0.64 mL, 7.4 
mmol) and pyridine (0.59 mL, 7.4 mmol) were thoroughly mixed in a MW vial and 
heated at 150 °C for 75 min (5 × 15 min periods). The resulting yellow solid was 
dissolved in ethyl acetate (60 mL). Undissolved material was removed by filtration, and 
recrystallisation from ethyl acetate produced yellow crystals that were washed with 
acetonitrile to provide compound 5 as a yellow crystalline solid (1.50 g, 77%): m.p. 
203-205 °C; 
A: 1H NMR (700 MHz; CDCl3) δ 8.11 (unsymmet. d, J = 8.4, 2H, H3+3’), 7.88 (unsymmet. 
d, J = 8.4, 2H, H4+4’), 4.40 (q, J = 7.0, 2H, H10), 2.36 (s, 3H, H9), 1.42 (t, J = 7.0, 3H, H11); 
13C NMR (176 MHz; CDCl3) δ 166.0 (C1), 159.3 (C6), 158.7 (C7), 136.5 (C5), 131.1 (C2), 
130.3 (C3+3’), 125.4 (C4+4’), 105.6 (C8), 61.7 (C10), 14.3 (C11), 9.4 (C9); 
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B: 1H NMR (700 MHz; CDCl3) δ 8.20-8.13 (m, 4H, H3+4), 4.41 (q, J = 7.0, 2H, H10), 4.29 (q, 
J = 7.0, 1H, H9), 1.76 (d, J = 7.0, 3H, H9), 1.43 (t, J = 7.0, 3H, H11); 
13C NMR (176 MHz, 
CDCl3) δ 193.8 (C7), 165.3 (C1), 159.1 (C6), 135.9 (C5), 135.5 (C2), 130.0 (C3+3’), 128.6 
(C4+4’), 61.7 (C10), 49.4 (C8), 18.1 (C9), 14.2 (C11); 
 IR (neat) max/cm
-1 2980w (C-Haliphatic), 1709s (C=Oester), 1580w (C=Car.), 1514w (C=Car.), 
1466w (C=Car.), 1271s (C-Oester), 1104s (C-Oester), 856m (C-Har.); MS (ES): m/z = 264 [M + 
1]+;  UV-vis (EtOH) max/nm (/M
-1 cm-1): 204 (5 770), 244 (4 950), 356 (5 000). Anal. 
calcd for C13H13NO3S: C, 59.30; H, 4.98; N, 5.32. Found: C, 58.99; H, 4.97; N, 5.34. 
 
4-(5-Methyl-4-trifluoromethanesulfonyloxy-thiazol-2-yl)-benzoic acid ethyl ester (6) 
 
N,N-Diisopropylethylamine (2.65 mL, 15.2 mmol) was added to a stirred solution of 4-
(4-hydroxy-5-methyl-thiazol-2-yl)-benzoic acid ethyl ester 5 (2.0 g, 7.60 mmol) in 
dichloromethane (30 mL). The flask was cooled to -78 °C, after which 
trifluoromethanesulfonic anhydride (4.4 g, 15.2 mmol) was carefully added. The 
reaction was allowed to warm slowly to room temperature and was stirred overnight 
under a nitrogen atmosphere. Dichloromethane (30 mL) and water (30 mL) were 
added, and the product extracted with dichloromethane (3 x 50 mL). The organic 
extracts were combined and washed three times with water (3 x 100 mL). After drying 
with MgSO4, the solvent was removed in vacuo and the brown residue purified by 
flash chromatography to give a yellow oil, Rf. 0.32 (hexane:EtOAc, 8:2, as eluent). 
Recrystallisation from hexane provided compound 6 as an off-white crystalline solid 
(2.1 g, 70%): m.p. 48-50 °C; 1H NMR (700 MHz; CDCl3) δ 8.10 (unsymmet. d, J = 8.4, 2H, 
H3+3’), 7.91 (unsymmet. d, J = 8.4, 2H, H4+4’), 4.40 (q, J = 7.0, 2H, H10), 2.49 (s, 3H, H9), 
1.42 (t, J = 7.0, 3H, H11); 
13C NMR (176 MHz; CDCl3) δ 165.9 (C1), 161.2 (C6), 148.3 (C7), 
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136.2 (C5), 132.4 (C2), 130.4 (C3+3’), 125.7 (C4+4’), 122.4 (C8), 119.7 (C12), 61.5 (C10), 14.5 
(C11), 10.2 (C9); 
19F NMR (658.4 MHz; CDCl3) δ 72.5; IR (neat) max/cm
-1 1712s (C=Oester), 
1550m (C=Car.), 1422s (C=Car.), 1274m (C-Oester), 1221s (C-Oester), 1137s (C-F), 1093s (C-
F), 769s (C-Har.), 694s (C-Har.) , 602s (C-Har.); MS (ES
+): m/z = 263 [M - CF3SO2]
+, 396 [M + 
1]+, 418 [M + Na]+;  UV-vis (EtOH) max/nm (/M
-1 cm-1): 312 (23 100). Anal. calcd for 
C14H12F3NO5S2: C, 42.53; H, 3.06; N, 3.54. Found: C, 42.50; H, 3.07; N, 3.48. 
 
4-(5-Methyl-4-phenyl-thiazol-2-yl)-benzoic acid ethyl ester (9) 
 
4-(5-Methyl-4-trifluoromethanesulfonyloxy-thiazol-2-yl)-benzoic acid ethyl ester 6 
(500 mg, 1.26 mmol), phenylboronic acid pinacol ester (284 mg, 1.39 mmol), K3PO4 
(537 mg, 2.53 mmol) and Pd(dppf)Cl2 (28 mg, 0.0383 mmol, 3 mol%) were combined in 
DMF and H2O (10 mL, 10:1) in a Schlenk tube under an inert nitrogen atmosphere and 
heated at 80 °C for 18 h. The mixture was dissolved in diethyl ether and washed twice 
with water. The organic layer was dried using MgSO4 and the solvent removed in 
vacuo to give an orange/brown residue that was purified by column chromatography 
(3→5% EtOAc:hexane) to give a white solid following in vacuo removal of the solvent, 
Rf. 0.28 (hexane:EtOAc, 9:1, as eluent). Recrystallisation from ethanol provided 
compound 9 as a white crystalline solid (246 mg, 60%): m.p. 85-87 °C; 1H NMR (700 
MHz; CDCl3) δ 8.10 (unsymmet. d, J = 8.4, 2H, H3+3’), 8.03 (unsymmet. d, J = 8.4, 2H, 
H4+4’), 7.73 (unsymmet d, J = 7.0, 2H, H11+11’), 7.47 (unsymmet. t, J = 7.7, 2H, H12+12’), 
7.38 (unsymmet. t, J = 7.7, 1H, H13), 4.40 (q, J = 7.0, 2H, H14), 2.64 (s, 3H, H9), 1.42 (t, J = 
7.0, 3H, H15); 
13C NMR (176 MHz; CDCl3) δ 166.3 (C1), 162.4 (C6), 152.8 (C7), 137.7 (C5), 
135.0 (C10), 131.3 (C2), 130.3 (C3+3’), 129.8 (C8), 128.8 (C11+11’), 128.6 (C12+12’), 127.9 
(C13), 126.2 (C4+4’), 61.3 (C14), 14.5 (C15), 13.1 (C9); IR (neat) max/cm
-1 1706s (C=Oester), 
1278s (C-Oester), 1101s (C-Oester), 860s (C-Har.), 768s (C-Har.), 699s (C-Har.) ; MS (ES
+): m/z 
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= 324 [M + 1]+, 325 [M + 2]+, 670 [2M + Na]+; UV-vis (EtOH) max/nm (/M
-1 cm-1): 254 
(22 400), 330 (18 100). Anal. calcd for C19H17NO2S: C, 70.56; H, 5.30; N, 4.33. Found: C, 
70.62; H, 5.32; N, 4.44. 
 
4-[5-Methyl-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-thiazol-2-yl]-
benzoic acid ethyl ester (10) 
 
4-(5-Methyl-4-trifluoromethanesulfonyloxy-thiazol-2-yl)-benzoic acid ethyl ester 6 
(500 mg, 1.26 mmol), 1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthylboronic acid 
pinacol ester (477 mg, 1.52 mmol), K3PO4 (537 mg, 2.53 mmol) and Pd(dppf)Cl2 (28 
mg, 0.0383 mmol, 3 mol%) were combined in DMF and H2O (10 mL, 10:1) in a Schlenk 
tube under an inert nitrogen atmosphere. After heating to 80 °C for 18 hours, the 
cooled mixture was dissolved in diethyl ether (20 mL) and washed with water (2 x 20 
mL) and the organic layer was dried using MgSO4. The solvent was removed in vacuo, 
and the residue was purified by flash chromatography, Rf. 0.33 (hexane:EtOAc, 9:1, as 
eluent). Following in vacuo removal of the solvent, recrystallisation of the resulting 
white solid from ethanol afforded the title product in the form of fluffy white crystals 
(410 mg, 75%): m.p. 161-162 °C; 1H NMR (700 MHz; CDCl3) δ 8.09 (unsymmet. d, J = 
8.4, 2H, H3+3’), 8.03 (unsymmet. d, J = 8.4, 2H, H4+4’), 7.61 (d, J = 1.4, 1H, H11), 7.49 (dd, 
J = 8.4 and 2.1, 1H, H12), 7.40 (unsymmet. d, J = 8.4, 1H, H13), 4.40 (q, J = 7, 2H, H22), 
2.63 (s, 3H, H9), 1.73 (s, 4H, H18+19), 1.42 (t, J = 7, 3H, H23), 1.34 (s, 6H, H17+17’), 1.32 (s, 
6H, H21+21’); 
13C NMR (176 MHz; CDCl3) δ 166.3 (C1), 162.1 (C6), 153.3 (C7), 144.9 (C15), 
144.7 (C10), 137.9 (C5), 132.1 (C14), 131.2 (C2), 130.2 (C3+3’), 129.2 (C8), 127.0 (C11), 
126.9 (C13), 126.2 (C4+4’), 126.0 (C12), 61.3 (C22), 35.2 (C18+19), 34.5 (C16), 34.4 (C20), 32.1 
(C17+17’), 32.0 (C21+21’), 14.5 (C23), 13.1 (C9); IR (neat) max/cm
-1 1707s (C=Oester), 1270s 
(C-Oester), 1102s (C-Oester), 772s (C-Har.); MS (ES
+): m/z = 434 [M + 1]+; UV-vis (EtOH) 
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max/nm (/M
-1 cm-1): 262 (27 400), 335 (17 600). Anal. calcd for C27H31NO2S: C, 74.79; 
H, 7.21; N, 3.23. Found: C, 74.67; H, 7.22; N, 3.17. 
 
4-(5-Methyl-4-phenyl-thiazol-2-yl)-benzoic acid (1)  
 
4-(5-Methyl-4-phenyl-thiazol-2-yl)-benzoic acid ethyl ester 9 (100 mg, 0.31 mmol) and 
LiOH·H2O (39 mg, 0.93 mmol) were mixed in THF:H2O (2 mL, 3:1 ratio) in a MW vial 
and irradiated at 160 °C for 15 min, after which the cooled reaction mixture was 
acidified with 1 M HCl and ethyl acetate (5 mL) was added. The organic layer was 
washed with brine (2 x 5 mL) and dried with MgSO4. After in vacuo solvent removal, 
the residue was recrystallised from ethanol to give the title compound as a white 
crystalline solid (81 mg, 88%): m.p. 267-269 °C; 1H NMR (500 MHz; DMSO-d6) δ 8.05 (s, 
4H, H3+4), 7.76 (dd, J = 8.0 and 1.5, 2H, H11+11’), 7.51 (td, J = 7.5 and 1.5, 2H, H12+12’), 
7.42 (tt, J = 7.5 and 1.5, 1H, H13), 2.64 (s, 3H, H9): 
13C (125.6 MHz, DMSO-d6) 167.7 (C1), 
162.3 (C6), 152.5 (C7), 137.5 (C5), 135.3 (C10), 131.2 (C2), 131.1 (C8), 129.4 (C11), 129.2 
(C12), 128.8 (C13), 126.8 (C3+4), 13.6 (C9); IR (neat) max/cm
-1 2847s (O-H), 1674s (C=O), 
1284s (C-O), 858s (C-Har.), 771s (C-Har.), 700s (C-Har.), 681s (C-Har.); MS (ES
-): m/z = 294 
[M - H]-; UV-vis (EtOH) max/nm (/M
-1 cm-1): 255 (23 000), 329 (19 000). Anal. calcd for 
C17H13NO2S: C, 69.13; H, 4.44; N, 4.74. Found C, 68.79; H, 4.46; N, 4.74. 
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4-[5-Methyl-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-thiazol-2-yl]-
benzoic acid (2)  
 
4-[5-Methyl-4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-thiazol-2-yl]-
benzoic acid ethyl ester 10 (100 mg, 0.23 mmol) and LiOH·H2O (29 mg, 0.69 mmol) 
were mixed in THF:H2O (2 mL, 3 : 1 ratio) in a MW vial. After irradiation at 160 °C for 
15 min, the reaction mixture was acidified with 1 M HCl and ethyl acetate (5 mL) was 
added. The organic layer was washed with brine (2 x 5 mL) and dried with MgSO4. 
After in vacuo removal of the solvent, the residue was recrystallised from ethanol to 
give the title compound as a white crystalline solid (80 mg, 85%); m.p. 276-278 °C; 1H 
NMR (500 MHz; DMSO-d6) δ 8.07-8.02 (m, 4H, H3+4), 7.63 (d, J = 2, 1H, H11), 7.49 (dd, J 
= 8.0 and 2.0, 1H, H12), 7.44 (unsymmet. d, J = 8.5, 1H, H13), 2.62 (s, 3H, H9), 1.69 (s, 4H, 
H18+19), 1.31 (s, 6H, H17+17’), 1.29 (s, 6H, H21+21’); 
13C NMR (125.6 MHz; DMSO-d6) δ 
166.8 (C1), 161.2 (C6), 152.1 (C7), 144.3 (C15), 144.1 (C10), 136.6 (C5), 131.6 (C14), 130.3 
(C2), 129.7 (C3+4), 126.6 (C8), 126.3 (C11), 125.9 (C13), 125.7 (C12), 34.6 (C18+19), 34.5 (C16), 
34.0 (C20), 31.7 (C17+17’), 31.6 (C21+21’), 12.7 (C9); IR (neat) max/cm
-1 2929s (O-H), 1681s 
(C=O), 1279s (C-O), 773s (C-Har.); MS (ES
+): m/z = 404 [M + H]+; UV-vis (EtOH) max/nm 
(/M-1 cm-1): 261 (27 000), 333 (17 000). Anal. calcd for C25H27NO2S: C, 74.04; H, 6.71; 
N, 3.45. Found: C, 73.42; H, 6.75; N, 3.53. 
 
6.3. Biological procedures 
Tissue culture 
Stock solutions of ATRA (Sigma-Aldrich, UK), EC23 (Reinnervate, Sedgefield, UK), 
compound 1, and compound 2 were prepared in dimethyl sulfoxide (DMSO, Sigma) to 
concentrations of 10 mM. Aliquots of these stock solutions were stored at -80 °C in the 
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dark and thoroughly defrosted in a water bath set at 37 °C prior to use. Unless 
otherwise stated, all plastic-ware was purchased from Becton, Dickinson and 
Company. Phase contrast images of cultures were obtained using a light microscope 
(Nikon Diaphot 300) and photomicrographs were captured using digital photography 
(Nikon). Scale bars were calibrated and added to images using ImageJ. Human 
pluripotent TERA2.cl.SP12 embryonal carcinoma stem cells were cultured in DMEM 
(Sigma) supplemented with 10% FCS (Lonza, UK; http://www.lonza.com), 2 mM L-
glutamine (Lonza) and 100 active units each of penicillin and streptomycin (Lonza). 
Cells were maintained in a humidified atmosphere of 5% CO2 in air at 37 °C in a Sanyo 
CO2 incubator and handled under sterile conditions in a Class 1 microbiological safety 
cabinet. Cultures were passaged using sterile acid-washed glass beads (VWR, UK; 
https://uk.vwr.com) or trypsinised using a solution of 0.25% (w/v) trypsin (Life 
Technologies, UK; https://www.lifetechnologies.com) and 2 mM EDTA in PBS to obtain 
a single-cell suspension for counting. 96-Well plates were used for cell viability studies, 
and cultures intended for flow cytometric analyses were set up in T25 flasks. Human 
neural progenitor ReNcell 197VM cells (Millipore, UK; http://www.millipore.com) were 
maintained under the laboratory conditions described above. Before establishing cell 
cultures, a 20 μg mL−1 concentration of laminin solution was applied to all plastic-ware, 
which was incubated at 37 °C for 6 h then rinsed once with culture medium. Cells were 
maintained in serum-free conditions with DMEM:F12 (1:1, Gibco, Life Technologies) 
supplemented with B27 (Invitrogen, Life Technologies), 2 mM L-glutamine, gentamycin 
(Gibco), and 50 mg mL−1 heparin solution (Sigma). For proliferation, 10 ng mL−1 
fibroblast growth factor (FGF) and 20 ng mL−1 epidermal growth factor (EGF) were 
added to the culture media before applying to cells. Cells were trypsinised as 
described above. 
Neurite outgrowth assay 
TERA2.cl.SP12 EC cells were maintained as described above. Aggregates of 
TERA2.cl.SP12 EC cells were produced by creating a single-cell suspension and adding 
1.5 × 106 cells per 20 mL of maintenance media to a 90 mm un-treated Petri dish. The 
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cells were left to aggregate overnight and subsequently treated with the test 
compound. Aggregates were cultured for 21 d in the presence of the test compound to 
induce neural commitment and the production of neurospheres prior to analysis of 
neurite outgrowth. To induce neurite outgrowth, a 48-well tissue culture plate was 
used: the well was coated with a solution of 10 μg mL−1 laminin (Sigma) and poly-D-
lysine (Sigma) overnight. The tissue culture was washed three times with sterile PBS 
prior to the addition of the neurospheres, which were added to the permissive 
substrate in the presence of the mitotic inhibitors: 5-fluoro-2-deoxyuridine (10 μM), 
uridine (10 μM), and cytosine-arabinoside (1 μM) in the TERA2.cl.SP12 maintenance 
media described previously, and incubated at 37 °C under 5% CO2 for 10 d. 
Neurospheres where then fixed in 4% PFA and visualised by immunocytochemical 
staining of the TUJ-1 antibody. Neurites were imaged using the Nikon Diaphot 300 and 
quantified using Image J. 
Cell viability assay 
Cells were assessed for viability by combining a single-cell suspension (achieved by the 
addition of 1 mL, 0.25% trypsin/EDTA solution) of live cells with detached dead cells 
contained in the culture medium from each flask. Cell numbers were determined using 
a haemocytometer. Cells were required to be diluted 1:20 in a staining solution for the 
Viacount assay and added to a 96-well plate. The number of viable cells, percentage 
viabilities, and total cell numbers were recorded in triplicate for each experimental 
condition. 
Flow cytometric analysis of pluripotent TERA2.cl.SP12 EC cells 
At each time point (except for the negative control flasks, which were processed for 
analysis after 3 d), cultures were washed with PBS and treated with trypsin to obtain a 
single-cell suspension as described above. Cells were washed three times with PBS to 
ensure complete removal of trypsin. After centrifugation of the cell mixture and 
removal of the supernatant, the cell pellet was re-suspended in 0.1% bovine serum 
albumin (BSA) solution and counted using a haemocytometer. 200 000 cells per well 
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were added to a 96-well plate according to the experimental plan. After centrifugation 
of the plate at 1000 rpm for 3 min, and removal of the supernatant, cells were re-
suspended in 50 μL of the appropriate primary antibody. Each triplicate set of culture 
conditions (ATRA, compounds 1 and 2, as well as the DMSO-supplemented flasks [on 
day 3 only]) was analysed at each time point for expression of the following three 
antigens: SSEA-3 (antibody diluted 1:5 in 0.1% BSA), TRA-1-60 (diluted 1:10) and A2B5 
(diluted 1:40). These primary monoclonal antibodies were used as they recognise 
specific cell surface antigens associated with globoseries glycolipids, glycoproteins and 
ganglioseries, displaying highly regulated expression profiles in response to 
differentiation of human EC cells. One well containing undifferentiated control cells 
was incubated with the mouse myeloma marker anti-P3X as a negative control. The 
plate was incubated on ice for 1 h, after which excess unbound antibody was removed 
by the addition of 100 μL ice-cold 0.1% BSA, centrifugation was performed as above 
and the supernatant was removed. Two further washings were carried out with 180 μl 
0.1% BSA, after which cells were re-suspended with the fluorescent secondary 
antibody FITC (fluorescein isothiocyanate-conjugated) goat anti-mouse IgM (ICN 
Pharmaceuticals, Inc.; Aurora, OH; http://www.icnpharm.com) diluted 1:100 in 0.1% 
BSA. After incubating the plate in the dark for 1 h on ice, cells were washed three 
times with 0.1% BSA as described above, and re-suspended in 200 μL 0.1% BSA for 
analysis. Cell surface antigen expression on TERA2.cl.SP12 stem cells and their 
compound-induced derivatives was observed by indirect immunofluorescence and 
quantified using a flow cytometer (Guava Easycyte). A fluorescence threshold was set 
such that cells fluorescing with a greater intensity than approximately 95% of the cells 
incubated with the negative control antibody P3X were counted as antigen positive. 
Immunocytochemistry with human pluripotent TERA2.cl.SP12 EC cells and 
neuroprogenitor ReN197 VM cells  
Cells were fixed in 4% paraformaldehyde (PFA) in PBS (Sigma) for 30 min at r.t. and 
rinsed with PBS. Cell membranes were permeabilised by treatment with 1% Triton-X-
100 (Sigma) in PBS for 10 min at r.t. Non-specific labelling was blocked by incubation 
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on a bench-top shaker (Fisher Scientific, UK; http://www.fisher.co.uk) for 1 h at r.t. 
with a solution of 1% goat serum (Sigma) containing 0.2% Tween-20 (Sigma) in PBS. 
Primary antibodies were diluted in blocking solution and incubated with cells for 1 h at 
r.t. [β-III tubulin antibody (TUJ1, Covance, UK; http://www.covance.com, diluted 
1:600); NF-200 antibody (AbCam, Cambridge, MA; http://www.abcam.com, diluted 
1:200)]. After washing three times for 15 min with PBS cells were incubated for 1 h in 
the dark with FITC-conjugated (anti-mouse Alexafluor 488, Invitrogen, diluted 1:600), 
Cy3-conjugated (anti-rabbit Cy3, JacksonLabs, UK; http://www.jireurope.com, diluted 
1:600) fluorescently-labelled secondary antibodies and Hoechst 33342 nuclear staining 
dye (Molecular Probes, Life Technologies, diluted 1:1000) in blocking solution. Cells 
were washed twice more with PBS and left in the final wash for immediate imaging. 
Fluorescence micrographs, including Hoecsht 3342, were acquired using the 
appropriate filter sets and an adapted digital camera (Nikon). 
 
6.4. Synthetic procedures for a fluorescent retinoid 
2-Methyl-N-(propan-2-yl)aniline (24) 
 
2-Iodopropane (40 mL, 400 mmol) was added to a refluxing mixture (105 °C) of o-
toluidine (21.4 mL, 200 mmol) and powdered sodium hydroxide (20 g, 500 mmol). This 
was heated to reflux for 12 h under an inert argon atmosphere. The mixture was 
filtered, diluted with diethyl ether (100 mL), and washed with water (3 x 30 mL). The 
solvent was removed in vacuo and the residue purified by column chromatography on 
basic alumina (hexane:EtOAc, 95:5, as eluent), to afford compound 24 as a yellow oil 
(24.6 g, 82%): Rf. 0.51 (hexane:EtOAc, 95:5, as eluent); 
1H NMR (500 MHz; CDCl3) δ 
7.18 (dt, J = 7.5 and 1.5, 1H, H3), 7.11 (dd, J = 7.5 and 0.5, 1H, H5), 6.71-6.67 (m, 2H, 
H2+4), 3.74 (septet, J = 6.5, 1H, H8), 3.36 (br s, 1H, NH), 2.18 (s, 3H, H7), 1.31 (d, J = 6.5, 
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6H, H9+9’); 
13C NMR (176 MHz; CDCl3) δ 145.5 (C1), 130.3 (C5), 127.2 (C3), 121.8 (C6), 
116.5 (C2), 110.3 (C4), 44.1 (C8), 23.3 (C9+9’), 17.7 (C7); IR (neat) max/cm
-1 2965m (C-
Hmethyl), 1606s (C=Car.), 1512s (C=Car.), 1478m (C=Car.), 1382m (C-Hmethyl); MS (ES
+): m/z 
= 150 [M + H]+; UV-vis (CHCl3) max/nm (/M
-1 cm-1): 246 (42 900), 297 (11 000); HRMS 
(ES) calcd for C10H16N [M + H]
+: 150.1279, found: 150.1283. 
 
2-Methyl-N-(3-methylbut-2-en-1-yl)-N-(propan-2-yl)aniline (25) 
 
2-Methyl-N-(propan-2-yl)aniline 24 (11.3 g, 76 mmol) and 3,3-dimethylallyl bromide 
(9.7 mL, 84 mmol) were dissolved in acetonitrile (200 mL). Powdered potassium 
carbonate (11.6 g, 84 mmol) was added and the flask heated to reflux (70 °C) overnight 
under an inert argon atmosphere. The mixture was filtered and the solvent removed in 
vacuo to give a dark residue that was purified by column chromatography on basic 
alumina, providing compound 25 as a yellow oil (11.5 g, 70%): Rf. 0.55 (hexane as 
eluent); 1H NMR (700 MHz; CDCl3) δ 7.19 (unsymmet. d, J = 7.7, 1H, H5), 7.11 
(unsymmet. t, J = 7.7, 1H, H3), 7.04 (unsymmet. d, J = 7.7, 1H, H2), 6.96 (unsymmet. t, J 
= 7.7, 1H, H4), 5.02 (t, J = 6.3, 1H, H11), 3.60 (d, J = 6.3, 2H, H10), 3.22 (septet, J = 7.0, 
1H, H8), 2.31 (s, 3H, H7), 1.61 and 1.60 (s, 3H, H13+13’), 1.10 (d, J = 7.0, 6H, H9+9’); 
13C 
NMR (176 MHz; CDCl3) δ 150.1 (C1), 135.7 (C6), 132.6 (C12), 130.9 (C5), 125.6 (C3), 123.7 
(C2), 123.1 (C4), 123.0 (C11), 53.0 (C8), 44.2 (C10), 25.8 and 18.5 (C13+13’), 19.7 (C9+9’), 18.5 
(C7); IR (neat) max/cm
-1 2968s (C-Hmethyl), 2929m (C-Hvinyl), 1598m (C=Car.), 1490s 
(C=Car.), 1449m (C=Car.), 1380m (C-Hmethyl), 1360m (C-Hmethyl); MS (ES
+): m/z = 218 [M + 
H]+; UV-vis (CHCl3) max/nm (/M
-1 cm-1): 260 (13 700), 243sh (11 600); HRMS (ES) calcd 
for C15H24N [M + H]
+: 218.1903, found: 218.1906. 
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1-Isopropyl-4,4,8-trimethyl-1,2,3,4-tetrahydroquinoline (26) 
 
2-Methyl-N-(3-methylbut-2-en-1-yl)-N-(propan-2-yl)aniline 25 (10.6 g, 49 mmol) and   
polyphosphoric acid (60 g) were heated to 120 °C for 24 h. The mixture was diluted 
with water (50 mL), and aqueous potassium hydroxide carefully added until neutral. 
The reaction mixture was extracted with diethyl ether (500 mL) , and the combined 
organic layers were washed with water (3 x 100 mL). After drying with MgSO4, the 
mixture was filtered, and the solvent removed in vacuo to give a crude oil which was 
purified by flash chromatography on silica gel (hexane:EtOAc, 9:1, as eluent), to afford 
compound 26 as a yellow oil (8.2 g, 78%): Rf. 0.64 (hexane:EtOAc, 9:1, as eluent); 
1H 
NMR (700 MHz; CDCl3) δ 7.15 (dd, J = 7.7 and 1.4, 1H, H3), 6.97 (dd, J = 7.0 and 0.7, 1H, 
H5), 6.79 (t, J = 7.7, 1H, H4), 3.55 (septet, J = 7.0, 1H, H8), 3.15-3.12 (m, 2H, H10), 2.26 (s, 
3H, H7), 1.68-1.65 (m, 2H, H11), 1.28 (s, 6H, H13+13’), 1.15 (d, J = 7.0, 6H, H9+9’); 
13C NMR 
(176 MHz; CDCl3) δ 146.0 (C1), 138.0 (C2), 130.1 (C6), 129.6 (C5), 124.1 (C3), 120.0 (C4), 
53.0 (C8), 38.5 (C10), 37.8 (C11), 32.5 (C12), 32.2 (C13+13’), 20.8 (C9+9’), 20.5 (C7); IR (neat) 
max/cm
-1
 2959s (C-Hmethyl), 1591w (C=Car.), 1464s (C=Car.), 1426s (C=Car.), 1130s (C-N); 
MS (ES+): m/z = 218 [M + H]+; UV-vis (CHCl3) max/nm (/M
-1 cm-1): 261 (20 000), 298sh 
(6 600); HRMS (ES) calcd for C15H24N [M + H]
+: 218.1903, found: 218.1904. 
 
6-Bromo-1-isopropyl-4,4,8-trimethyl-1,2,3,4-tetrahydroquinoline (28) 
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A stirred solution of 1-isopropyl-4,4,8-trimethyl-1,2,3,4-tetrahydroquinoline 26 (2.30 g, 
10.6 mmol) in chloroform (20 mL) was cooled in an acetone bath fitted with a cryostat 
set at a temperature of -60 °C. Bromine liquid (515 μl, 10.1 mmol, 0.95 equiv.) was 
then added dropwise to the stirred reaction mixture. The temperature was raised 
gradually to -30 °C over a period of 1 h, after which the mixture was washed with a 
saturated solution of NaHCO3 (3 x 20 mL), and the organic phase dried with MgSO4. 
Following in vacuo removal of the solvent, the crude oil was purified by filtering 
through a pad of neutral alumina (hexane:EtOAc, 9:1, as eluent). Monobromide 28 was 
obtained as a colourless oil (1.95 g, 62%) after in vacuo removal of the solvent: Rf. 0.46 
(hexane as eluent); 1H NMR (600 MHz; CDCl3) δ 7.21 (d, J = 2.4, 1H, H3), 7.08 (d, J = 2.4, 
1H, H5), 3.48 (septet, J = 6.6, 1H, H8), 3.12-3.09 (m, 2H, H10), 2.22 (s, 3H, H7), 1.65-1.62 
(m, 2H, H11), 1.26 (s, 6H, H13+13’), 1.13 (d, J = 6.6, 6H, H9+9’); 
13C NMR (151 MHz; CDCl3) δ 
145.2 (C1), 140.2 (C2), 132.4 (C6), 132.0 (C5), 126.8 (C3), 112.6 (C4), 53.1 (C8), 38.4 (C10), 
37.3 (C11), 32.8 (C12), 31.9 (C13+13’), 20.7 (C9+9’), 20.3 (C7); IR (neat) max/cm
-1 2960s (C-
Hmethyl), 1468s (C=Car.), 860s (C-Har.), 829m (C-Har.), 742m (C-Har.); MS (EI): m/z = 296 
and 298 [M + H]+; UV-vis (EtOH) max/nm (/M
-1 cm-1): 272 (16 500); HRMS (ES) calcd 
for C15H23BrN [M + H]
+: 296.1014, found: 296.1004. 
 
3,6-Dibromo-1-isopropyl-4,4,8-trimethyl-1,4-dihydroquinoline (31) 
 
2,6-Lutidine (2.23 mL, 19.1 mmol) and Br2 liquid (490 μl, 9.57 mmol) were added to a 
stirred solution of 1-isopropyl-4,4,8-trimethyl-1,2,3,4-tetrahydroquinoline 26 (520 mg, 
2.39 mmol) in chloroform (20 mL). The mixture was heated to 60 °C and stirred 
overnight. Starting material consumption was indicated by 1H NMR analysis, after 
which chloroform (50 mL) was added and the organic layer washed with 2.5% aqueous 
HCl (3 x 50 mL), and 1M aqueous NaHCO3 (3 x 50 mL). After drying with MgSO4, and 
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removal of the solvent in vacuo, a brown oil was obtained (976 mg) consisting mainly 
of dibromide 31: 1H NMR (400 MHz; CDCl3) δ 7.21 (d, J = 1.6, 1H, H3), 7.13 (d, J = 1.6, 
1H, H5), 6.35 (s, 1H, H10), 3.59 (septet, J = 6.4, 1H, H8), 2.24 (s, 3H, H7), 1.49 (s, 6H, 
H13+13’), 1.20 (d, J = 6.4, 6H, H9+9’); 
13C NMR (176 MHz; CDCl3) δ 140.2 (C1), 138.0 (C2), 
132.7 (C5), 130.4 (C6), 128.4 (C10), 127.6 (C3), 115.7 (C11), 115.5 (C4), 53.7 (C8), 39.7 
(C12), 32.1 (C13+13’), 20.4 (C9+9’), 20.2 (C7); IR (neat) max/cm
-1 2972s (C-Hmethyl), 1464s 
(C=Car.), 1432s (C=Car.), 754s (C-Har.); MS (ES
+): m/z = 296 [M - Br]+; UV-vis (EtOH) 
max/nm (/M
-1 cm-1): 296 (4 900). 
 
Methyl 4-iodobenzoate (45) 
 
4-Iodobenzoic acid (12.2 g, 49 mmol) was dissolved in methanol (300 mL) with 
concentrated H2SO4 (2 mL), and refluxed at 70 °C overnight. Water (250 mL) was 
added and the mixture extracted with diethyl ether (3 x 150 mL). The organic layers 
were combined, washed with water (2 x 200 mL), dried over MgSO4 and the solvent 
removed in vacuo to afford compound 45 in the form of white needles (12.5 g, 97%), 
which were sufficiently pure to be used without further purification: m.p. 116-117 °C 
(lit.,194 115-116 °C); Rf. 0.30 (hexane:EtOAc, 9:1, as eluent); 
1H NMR (700 MHz; CDCl3) δ 
7.80 (unsymmet. d, J = 8.4, 2H, H5+5’), 7.74 (unsymmet. d, J = 8.4, 2H, H4+4’), 3.91 (s, 3H, 
H1); 
13C NMR (176 MHz; CDCl3) δ 166.8 (C2), 137.9 (C5+5’), 131.2 (C4+4’), 129.8 (C3), 100.8 
(C6), 52.4 (C1); IR (neat) max/cm
-1 2948w (C-Hmethyl), 1710s (C=Oester), 1585s (C=Car.), 
1436s (C=Car.), 1284s (C-Hmethyl), 1272s (C-Oester), 1107s (C-Oester), 845s (C-Har.), 827s (C-
Har.); MS (EI): m/z = 262 [M]
+, 231 [M - OCH3]
+; UV-vis (EtOH) max/nm (/M
-1 cm-1): 256 
(12 100). Anal. calcd for C8H7IO2: C, 36.67; H, 2.69. Found: C, 36.76; H, 2.71. 
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Methyl 3-iodobenzoate (46) 
 
Procedure as for compound 45, using 3-iodobenzoic acid (10.2 g, 41 mmol) to provide 
ester 46 as a white crystalline solid (10.2 g, 95%), which was sufficiently pure to be 
used without further purification: m.p. 49-50 °C (lit.,195 49-50 °C); Rf. 0.40 
(hexane:EtOAc, 9:1, as eluent); 1H NMR (500 MHz; CDCl3) δ 8.38 (t, J = 1.5, 1H, H4), 
8.00 (dt, J = 7.5 and 1.5, 1H, H5), 7.88 (dt, J = 7.5 and 1.5, 1H, H7), 7.19 (t, J = 7.5, 1H, 
H6), 3.92 (s, 3H, H1); 
13C NMR (126 MHz; CDCl3) δ 165.8 (C2), 141.9 (C7), 138.6 (C4), 
132.2 (C3), 130.2 (C6), 128.9 (C5), 93.9 (C8), 52.5 (C1); IR (neat) max/cm
-1 2948w (C-
Hmethyl), 1704s (C=Oester), 1589w (C=Car.), 1567m (C=Car.), 1440s (C=Car.), 1277s (C-
Hmethyl), 1299s (C-Oester), 1115s (C-Oester), 740s (C-Har.), 704s (C-Har.); MS (EI): m/z = 262 
[M]+; UV-vis (EtOH) max/nm (/M
-1 cm-1): 200 (19 700), 220 (22 400). Anal. calcd. for 
C8H7IO2: C, 36.67; H, 2.69. Found: C, 36.75; H, 2.68.  
 
Methyl 4-((trimethylsilyl)ethynyl)benzoate (47) 
 
Methyl 4-iodobenzoate 45 (12.5 g, 48 mmol), Cu(I)I (0.09 g, 0.48 mmol), and 
Pd(PPh3)2Cl2 (0.33 g, 0.48 mmol) were slurried in triethylamine (200 mL) in a nitrogen 
purged flask. Nitrogen gas was bubbled through the mixture for 10 min prior to the 
addition of TMSA (5.4 g, 55 mmol) under a nitrogen atmosphere. The flask was sealed, 
and the mixture left to stir overnight at room temperature. Reaction completion was 
monitored by GC-MS, after which the solvent was removed under a high vacuum. The 
residue was dissolved in hexane and filtered through a silica pad (hexane:EtOAc, 9:1, 
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as eluent). After in vacuo removal of the solvent, compound 47 was obtained in the 
form of yellow needles (9.7 g, 87%), which were sufficiently pure to be used without 
further purification: m.p. 56-57 °C (lit.,196 55-56 °C); Rf. 0.35 (hexane:EtOAc, 9:1, as 
eluent); 1H NMR (700 MHz; CDCl3) δ 7.97 (unsymmet. d, J = 8.4, 2H, H4+4’), 7.52 
(unsymmet. d, J = 8.4, 2H, H5+5’), 3.91 (s, 3H, H1), 0.26 (s, 9H, H9+9’+9’’); 
13C NMR (176 
MHz; CDCl3) δ 166.7 (C2), 132.0 (C5+5’), 129.8 (C3), 129.5 (C4+4’), 127.9 (C6), 104.2 (C7), 
97.8 (C8), 52.4 (C1), 0.0 (C9+9’+9’’); IR (neat) max/cm
-1 2953m (C-Hmethyl), 2160m 
(C≡Cdisub.), 1718s (C=Oester), 1603s (C=Car.), 1560w (C=Car.), 1497w (C=Car.), 1443s 
(C=Car.), 1275s (C-Oester), 1246s (C-Hmethyl), 1110s (C-Oester), 837s (C-Har), 759s (C-Har); 
MS (GC): m/z = 232 [M]+, 217 [M - CH3]
+; UV-vis (EtOH) max/nm (/M
-1 cm-1): 200 (33 
200), 268 (29 400). Anal. calcd. for C13H16O2Si: C, 67.20; H, 6.94. Found: C, 67.25; H, 
6.96. 
 
Methyl 3-((trimethylsilyl)ethynyl)benzoate (48) 
 
Procedure as for compound 47, using methyl 3-iodobenzoate 46 (4.5 g, 17 mmol) to 
give compound 48 as a pale yellow solid (2.7 g, 68%), which was sufficiently pure to be 
used without further purification: m.p. 52-53 °C (lit.,197 52 °C); Rf. 0.43 (hexane:EtOAc, 
9:1, as eluent); 1H NMR (700 MHz; CDCl3) δ 8.14-8.13 (m, 1H, H4), 7.97 (dt, J = 7.7 and 
1.4, 1H, H5), 7.63 (dt, J = 7.7 and 1.4, 1H, H7), 7.38 (t, J = 7.7, 1H, H6), 3.92 (s, 3H, H1), 
0.26 (s, 9H, H11+11’+11’’); 
13C NMR (176 MHz; CDCl3) δ 166.5 (C2), 136.2 (C7), 133.3 (C4), 
130.5 (C3), 129.6 (C5), 128.5 (C6), 123.8 (C8), 104.0 (C9), 95.5 (C10), 52.4 (C1), 0.0 
(C11+11’+11’’); IR (neat) max/cm
-1 2956m (C-Hmethyl), 2159m (C≡Cdisub.), 1725s (C=Oester), 
1598w (C=Car.), 1578w (C=Car.), 1484w (C=Car.), 1429m (C=Car.), 1298s (C-Oester), 1208s 
(C-Oester), 845s (C-Har.), 749s (C-Har.); MS (EI): m/z = 232 [M]
+, 217 [M - CH3]
+; UV-vis 
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(EtOH) max/nm (/M
-1 cm-1): 228 (37 300), 260 (20 100). Anal. calcd. for C13H16O2Si: C, 
67.20; H, 6.94. Found: C, 67.43; H, 7.03. 
 
Methyl 4-ethynylbenzoate (16) 
 
Methyl 4-((trimethylsilyl)ethynyl)benzoate (47, 9.2 g, 40 mmol) and sodium carbonate 
(17.0 g, 160 mmol) were mixed in 10:1 methanol and water (330 mL) and stirred 
overnight at room temperature. The mixture was diluted with diethyl ether (300 mL) 
and washed with water (2 x 150 mL). The aqueous phase was extracted with diethyl 
ether (2 x 150 mL) and the combined organic layers were dried over MgSO4. After in 
vacuo removal of the solvent, alkyne 16 was obtained as a yellow crystalline solid (5.0 
g, 79%), which was sufficiently pure to be used without further purification: m.p. 94-95 
°C (lit.,196 93-94 °C); Rf. 0.27 (hexane:EtOAc, 9:1, as eluent); 
1H NMR (700 MHz; CDCl3) δ 
7.99 (unsymmet. d, J = 8.4, 2H, H4+4’), 7.54 (unsymmet. d, J = 8.4, 2H, H5+5’), 3.92 (s, 3H, 
H1), 3.22 (s, 1H, H8); 
13C NMR (176 MHz; CDCl3) δ 166.6 (C2), 132.2 (C5+5’), 130.3 (C3), 
129.6 (C4+4’), 126.9 (C6), 82.9 (C7), 80.2 (C8), 52.4 (C1); IR (neat) max/cm
-1 3242s (C-
Halkyne), 2952w (C-Hmethyl), 2104w (C≡Cterm.), 1702s (C=Oester), 1607m (C=Car.), 1560w 
(C=Car.), 1434s (C=Car.), 1288s (C-Hmethyl), 1278s (C-Oester), 1109s (C-Oester), 860s (C-Har.), 
772s (C-Har.), 721s (C-Har.), 678s (C-Har.); MS (EI): m/z = 342 [2M + Na]
+; UV-vis (EtOH) 
max/nm (/M
-1 cm-1): 256 (22 300). Anal. calcd. for C10H8O2: C, 74.99; H, 5.03. Found: 
C, 74.84; H, 5.14. 
 
Methyl 3-ethynylbenzoate (49) 
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Procedure as for compound 16, using methyl 3-((trimethylsilyl)ethynyl)benzoate 48 
(1.8 g, 8 mmol) to give alkyne 49 as a yellow solid (0.79 g, 63%), which was sufficiently 
pure to be used without further purification: m.p. 55-56 °C (lit.,197 54-55 °C); Rf. 0.27 
(hexane:EtOAc, 9:1, as eluent); 1H NMR (600 MHz; CDCl3) δ 8.17 (t, J = 1.8, 1H, H4), 
8.02 (dt, J = 7.8 and 1.2, 1H, H5), 7.67 (dt, J = 7.8 and 1.2, 1H, H7), 7.41 (t, J = 7.8, 1H, 
H6), 3.93 (s, 3H, H1), 3.12 (s, 1H, H10); 
13C NMR (151 MHz; CDCl3) δ 166.4 (C2), 136.4 
(C7), 133.4 (C4), 130.6 (C3), 129.9 (C5), 128.6 (C6), 122.7 (C8), 82.7 (C9), 78.3 (C10), 52.5 
(C1); IR (neat) max/cm
-1 3255s (C-Halkyne), 2956m (C-Hmethyl), 2109w (C≡Cterm.), 1714s 
(C=Oester), 1598w (C=Car.), 1582m (C=Car.), 1482m (C=Car.), 1433s (C=Car.), 1294s (C-
Oester), 1274s (C-Hmethyl), 1197s (C-Oester), 749s (C-Har.), 716s (C-Har.), 664s (C-Har.); MS 
(EI): m/z = 343 [2M + Na]; UV-vis (EtOH) max/nm (/M
-1 cm-1): 220 (32 800), 248 (16 
700), 272 (18 500). Anal. calcd. for C10H8O2: C, 74.99; H, 5.03. Found: C, 75.31; H, 5.10. 
 
1-Isopropyl-4,4,8-trimethyl-6-((trimethylsilyl)ethynyl)-1,2,3,4-tetrahydroquinoline 
(51) 
 
6-Bromo-1-isopropyl-4,4,8-trimethyl-1,2,3,4-tetrahydroquinoline 28 (523 mg, 1.77 
mmol), PPh3 (463 mg, 1.77 mmol), PdCl2 (31 mg, 0.18 mmol) and Cu(OAc)2 (32 mg, 
0.18 mmol) were added to a Schlenk tube, which was then evacuated and filled with 
argon. This was repeated a further two times followed by addition of dry triethylamine 
(30 mL). After bubbling argon through the mixture for 10 min, trimethylsilylacetylene 
(754 μl, 5.30 mmol) was added. Argon was bubbled through the mixture for a further 5 
min before the tube was sealed and heated at 80 °C. After 4 days, approximately 95% 
conversion to the product was found by GC-MS analysis. After in vacuo removal of the 
solvent, the residue was redissolved in hexane:ethyl acetate (95:5, with 1% Et3N), and 
filtered through a silica pad to remove catalyst residue. Purification by column 
6. Experimental 
 
169 
 
chromatography was performed on silica gel treated with 1% Et3N (hexane:EtOAc, 
95:5, as eluent). Significant co-elution with PPh3=O occurred, however, fractions 
containing mainly the desired product were obtained and provided the crude product 
as a yellow solid (345 mg, 62%) following in vacuo removal of the solvent. 
Recrystallisation from ethanol afforded some pure compound 51 as yellow needle-like 
crystals (88 mg, 16%), which was used for characterisation purposes: m.p. 78-80 °C; Rf. 
0.46 (hexane:EtOAc, 95:5, with 1% Et3N, as eluent); 
1H NMR (600 MHz, CDCl3) δ 7.25 
(d, J = 1.8, 1H, H3), 7.10 (d, J = 1.8, 1H, H5), 3.58 (septet, J = 6.6, 1H, H8), 3.13-3.11 (m, 
2H, H10), 2.21 (s, 3H, H7), 1.64-1.62 (m, 2H, H11), 1.26 (s, 6H, H13+13’), 1.12 (d, J = 6.6, 6H,  
H9+9’), 0.23 (s, 9H, H16+16’+16’’); 
13C NMR (176 MHz; CDCl3) δ 146.9 (C1), 137.7 (C2), 133.4 
(C5), 129.2 (C6), 127.8 (C3), 113.3 (C4), 106.8 (C14), 91.5 (C15), 52.9 (C8), 38.2 (C10), 37.5 
(C11), 32.5 (C12), 31.6 (C13+13’), 20.5 (C9+9’), 20.5 (C7), 0.4 (C16+16’+16’’); IR (neat) max/cm
-1 
2957s (C-Hmethyl), 2140w (C-Calkyne); MS (EI): m/z = 314 [M + H]
+; UV-vis (EtOH) max/nm 
(/M-1 cm-1): 304 (39 800). Anal. calcd. for C20H31NSi: C, 76.61; H, 9.97; N, 4.47. Found: 
C, 76.63; H, 10.09; N, 4.41. 
 
6-Ethynyl-1-isopropyl-4,4,8-trimethyl-1,2,3,4-tetrahydroquinoline (53) 
 
1-Isopropyl-4,4,8-trimethyl-6-((trimethylsilyl)ethynyl)-1,2,3,4-tetrahydroquinoline 51 
(177 mg, 0.56 mmol) was dissolved in MeOH:Et2O (1:1, 30 mL) followed by addition of 
NaOH (18 mg, 0.45 mmol) and H2O (1 mL). After overnight stirring, a TLC analysis 
indicated that the starting material had been consumed. Diethyl ether (50 mL) was 
added, the organic layer was washed with H2O (3 x 50 mL), dried with MgSO4, and the 
solvent removed in vacuo to give the crude product 53 as a brown oil (142 mg, 109%): 
1H NMR (700 MHz, CDCl3) δ 7.29 (s, 1H, H3), 7.11 (s, 1H, H5), 3.60 (septet, J = 6.3, 1H, 
H8), 3.14-3.12 (m, 2H, H10), 2.98 (s, 1H, H15), 2.23 (s, 3H, H7), 1.66-1.64 (m, 2H, H11), 
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1.26 (d, J = 0.7, 6H, H13+13’), 1.15 (dd, J = 6.3 and 0.7, 6H, H9+9’); 
13C NMR (176 MHz; 
CDCl3) δ 147.1 (C1), 137.7 (C2), 133.4 (C5), 129.4 (C6), 128.0 (C3), 112.3 (C4), 85.1 (C14), 
75.0 (C15), 52.9 (C8), 38.2 (C10), 37.5 (C11), 32.5 (C12), 31.7 (C13+13’), 20.6 (C9+9’), 20.6 (C7); 
IR (neat) max/cm
-1 2954s (C-Hmethyl), 2125w (C-Calkyne); MS (ES
+): m/z 242 [M + H]+. 
 
Methyl 4-((1-isopropyl-4,4,8-trimethyl-1,2,3,4-tetrahydroquinolin-6-yl)ethynyl) 
benzoate (50) 
 
In a nitrogen-filled glovebox, crude 6-ethynyl-1-isopropyl-4,4,8-trimethyl-1,2,3,4-
tetrahydroquinoline 53 (140 mg, 0.58 mmol), methyl 4-iodobenzoate (144 mg, 0.55 
mmol), Pd(PPh3)Cl2 (4 mg, 1 mol%) and CuI (1 mg, 1 mol%) were dissolved in 
triethylamine (10 mL) in a Schlenk flask. The flask was sealed and the mixture stirred at 
room temperature for 3 days, after which GC-MS analysis showed complete 
conversion to the product. The solvent was removed in vacuo to give a golden-yellow 
solid (92 mg, 40%) consisting mainly of the desired ester, which, for characterisation 
purposes was recrystallised from hexane to give yellow needle-like crystals of pure 
ester 50 (40 mg, 18%): m.p. 126-127 °C; 1H NMR (700 MHz; CDCl3) δ 7.99 (unsymmet. 
d, J = 8.4, 2H, H18+18’), 7.55 (unsymmet. d, J = 8.4, 2H, H17+17’), 7.33 (s, 1H, H3), 7.17 (s, 
1H, H5), 3.92 (s, 3H, H21), 3.63 (septet, J = 6.3, 1H, H8), 3.17-3.13 (m, 2H, H10), 2.25 (s, 
3H, H7), 1.68-1.65 (m, 2H, H11), 1.29 (s, 6H, H13+13’), 1.16 (d, J = 6.3, 6H, H9+9’); 
13C NMR 
(176 MHz; CDCl3) δ 166.9 (C20), 147.3 (C1), 137.9 (C2), 133.2 (C5), 131.3 (C17+17’), 129.6 
(C18+18’), 129.4 (C6), 129.1 (C16), 128.8 (C19), 127.7 (C3), 112.8 (C4), 94.3 (C14), 87.2 (C15), 
53.0 (C8), 52.3 (C21), 38.2 (C10), 37.5 (C11), 32.6 (C13+13’), 31.6 (C12), 20.7 (C7), 20.6 (C9+9’); 
IR (neat) max/cm
-1 2957s (C-Hmethyl), 2196s (C-Calkyne), 1716s (C=Oester), 1272s (C-Oester); 
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MS (ES+): m/z = 376 [M + H]+; UV-vis (EtOH) max/nm (/M
-1 cm-1): 360 (42 900). Anal. 
calcd. for C25H29NO2: C, 79.96; H, 7.78; N, 3.73. Found: C, 79.56; H, 7.65; N, 3.62. 
 
Methyl 4-((1-isopropyl-4,4,8-trimethyl-1,2,3,4-tetrahydroquinolin-6-yl)ethynyl) 
benzoic acid (21) 
 
Methyl 4-((1-isopropyl-4,4,8-trimethyl-1,2,3,4-tetrahydroquinolin-6-yl)ethynyl) 
benzoate 50 (40 mg, 0.1 mmol) was dissolved in THF (2 mL) and 20% aq. NaOH (2 mL). 
The mixture was heated to reflux (70 °C) for 20 h under an inert argon atmosphere to 
give a colourless solution and a TLC analysis indicated consumption of the ester. 
Diethyl ether (10 mL) and H2O (10 mL) were added and the solution acidified to pH 1 
with 1 M HCl upon which yellow crystals precipitated out of the aqueous layer. Diethyl 
ether was added (30 mL) to extract the product, the organic layer was separated, dried 
using MgSO4 and the solvent removed in vacuo to give a yellow solid. This was 
recrystallised from ethanol to provide acid 21 as a neon-yellow crystalline solid (32 mg, 
89%): 1H NMR (600 MHz; CDCl3) δ 8.06 (unsymmet. d, J = 8.4, 2H, H18+18’), 7.58 
(unsymmet. d, J = 8.4, 2H, H17+17’), 7.34 (s, 1H, H3), 7.19 (s, 1H, H5), 3.64 (septet, J = 6.0, 
1H, H8), 3.18-3.13 (m, 2H, H10), 2.26 (s, 3H, H7), 1.69-1.65 (m, 2H, H11), 1.30 (s, 6H, 
H13+13’), 1.17 (d, J = 6.0, 6H, H9+9’); 
13C NMR (176 MHz; CDCl3) δ 169.9 (C20), 147.4 (C1), 
137.9 (C2), 133.3 (C5), 131.4 (C17+17’), 130.2 (C18+18’), 130.1 (C16), 129.4 (C6), 127.7 (C3), 
127.6 (C19), 112.7 (C4), 95.0 (C14), 87.2 (C15), 53.0 (C8), 38.2 (C10), 37.5 (C11), 32.6 (C12), 
31.6 (C13+13’), 20.7 (C7), 20.6 (C9+9’); IR (neat) max/cm
-1 2962br (O-Hacid), 2190s (C-
Calkyne), 1683s (C=Oacid), 1592s (C=Car.), 1470m (C=Car.), 1273 (C-Oacid); MS (ES
+): m/z = 
362 [M + H]+; UV-vis (CHCl3) max/nm (/M
-1 cm-1): 371 (45 600). Anal. calcd. for 
C24H27NO2: C, 79.74; H, 7.53; N, 3.87. Found: C, 79.18; H, 7.53; N, 3.75. 
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6.5. Synthetic procedures for a bromine-containing retinoid 
3-Bromo-1-isopropyl-4,4,8-trimethyl-6-((trimethylsilyl)ethynyl)-1,4-dihydroquinoline 
(60) 
 
A Schlenk tube was charged with 3,6-dibromo-1-isopropyl-4,4,8-trimethyl-1,4-
dihydroquinoline 31 (1.0 g, 2.7 mmol), PPh3 (350 mg, 1.3 mmol), Pd(PPh3)2Cl2 (190 mg, 
0.3 mmol) and CuI (50 mg, 0.3 mmol), then evacuated and filled with argon. This was 
repeated a further two times, after which dry triethylamine (35 mL) was added. The 
mixture was stirred for 10 min before the dropwise addition of trimethylsilylacetylene 
(1.1 mL, 8.0 mmol). The flask was then sealed and heated to 80 °C for 60 h, after which 
a GC-MS analysis of the reaction mixture was performed to confirm reaction 
completion. The solvent was removed in vacuo to give crude 60 as a brown oil (1.21 g, 
crude yield estimated from 1H NMR analysis: 47%): 1H NMR (700 MHz; CDCl3) δ 7.24 
(d, J = 2.1, 1H, H3), 7.14 (d, J = 2.1, 1H, H5), 6.35 (s, 1H, H10), 3.64 (septet, J = 6.3, 1H, 
H8), 2.23 (s, 3H, H7), 1.49 (s, 6H, H13+13’), 1.19 (d, J = 6.3, 6H, H9+9’), 0.24 (s, 9H, 
H16+16’+16’’); 
13C NMR (176 MHz; CDCl3) δ 141.6 (C1), 136.0 (C2), 134.0 (C5), 128.6 (C3), 
128.1 (C10), 127.9 (C6), 117.1 (C4), 116.1 (C11), 105.5 (C14), 93.0 (C15), 53.6 (C8), 39.6 
(C12), 32.2 (C13+13’), 20.5 (C9+9’), 20.2 (C7), 0.2 (C16+16’+16’’); IR (neat) max/cm
-1 2960s (C-
Hmethyl), 2147s (C≡Cdisub.), 1470s (C=Car.), 1436s (C=Car.); MS (GC): m/z = 389 [M
79Br - H]- 
and 391 [M81Br - H]-. 
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3-Bromo-6-ethynyl-1-isopropyl-4,4,8-trimethyl-1,4-dihydroquinoline (62) 
 
3-Bromo-1-isopropyl-4,4,8-trimethyl-6-((trimethylsilyl)ethynyl)-1,4-dihydroquinoline 
60 (500 mg, 1.28 mmol), NaOH (41 mg, 1.02 mmol) and H2O (0.8 mL) were dissolved in 
MeOH:Et2O (1:1, 40 mL), and the mixture stirred at room temperature overnight, after 
which GC-MS analysis revealed the reaction to be complete. Diethyl ether (40 mL) was 
added and the organic layer washed with water (3 x 30 mL), dried with MgSO4 and the 
solvent removed in vacuo to provide crude 62 as a brown viscous oil (420 mg, crude 
yield estimated from 1H NMR analysis: 72%): 1H NMR (700 MHz; CDCl3) δ 7.27 (d, J = 
1.4, 1H, H3), 7.15 (d, J = 1.4, 1H, H5), 6.36 (s, 1H, H10), 3.66 (septet, J = 7.0, 1H, H8), 2.24 
(s, 3H, H7), 1.49 (s, 6H, H13+13’), 1.21 (d, J = 7.0, 6H, H9+9’); 
13C NMR (176 MHz; CDCl3) δ 
141.8 (C1), 136.0 (C2), 133.9 (C5), 128.9 (C3), 128.1 (C10), 128.0 (C6), 116.1 (C4), 115.9 
(C11), 84.0 (C14), 76.2 (C15), 53.5 (C8), 39.5 (C12), 32.2 (C13+13’), 20.5 (C9+9’), 20.3 (C7); IR 
(neat) max/cm
-1 2961s (C-Hmethyl), 2060w (C≡Cterm.), 1469s (C=Car.), 1436s (C=Car.); MS 
(GC): m/z = 317 [M79Br - H]- and 319 [M81Br - H]-. 
 
Methyl 4-((3-bromo-1-isopropyl-4,4,8-trimethyl-1,4-dihydroquinolin-6-
yl)ethynyl)benzoate (63) 
 
A Schlenk tube was charged with 3-bromo-6-ethynyl-1-isopropyl-4,4,8-trimethyl-1,4-
dihydroquinoline 62 (200 mg, 0.63 mmol), 4-iodobenzoic acid methyl ester (156 mg, 
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0.60 mmol), Pd(PPh3)2Cl2 (4 mg, 0.006 mmol) and CuI (1 mg, 0.006 mmol). After thrice 
evacuating and filling the flask with argon, dry triethylamine (10 mL) was added. The 
sealed flask was heated to 50 °C for 72 h, with reaction completion monitored by GC-
MS analysis. The solvent was removed in vacuo to give crude 63 as a brown oil (307 
mg, 108%): 1H NMR (700 MHz; CDCl3) δ 7.80 (unsymmet. d, J = 8.4, 2H, H18+18’), 7.74 
(unsymmet. d, J = 8.4, 2H, H17+17’), 7.33 (d, J = 2.1, 1H, H3), 7.22 (d, J = 2.1, 1H, H5), 6.38 
(s, 1H, H10), 3.92 (s, 3H, H21), 3.69 (septet, J = 6.3, 1H, H8), 2.28 (s, 3H, H7), 1.53 (s, 6H, 
H13+13’), 1.23 (d, J = 6.3, 6H, H9+9’); 
13C NMR (176 MHz; CDCl3) δ 166.7 (C20), 141.8 (C1), 
137.8 (C2), 136.2 (C5), 133.6 (C17+17’), 132.0 (C18+18’), 131.4 (C6), 131.2 (C16), 129.7 (C19), 
129.6 (C3), 129.5 (C10), 115.9 (C4), 92.9 (C14), 88.0 (C15), 53.6 (C8), 39.6 (C12), 32.2 
(C13+13’), 20.6 (C9+9’), 20.3 (C7); IR (neat) max/cm
-1 2966s (C-Hmethyl), 2198w (C≡Cdisub.), 
1720s (C=Oester), 1604s (C=Car.), 1470m (C=Car.), 1435s (C=Car.); MS (GC): m/z = 451 
[M79Br - H]- and 453 [M81Br - H]-. 
 
6.6. Synthetic procedures for N-acetyl compounds 
N-o-Tolylacetamide (64) 
 
Acetyl chloride (22 mL, 308 mmol) was added slowly dropwise to a stirred solution of 
o-toluidine (30 g, 280 mmol) and pyridine (59 mL, 728 mmol) in dichloromethane (300 
mL). The flask was maintained at 0 °C in an ice and methanol bath, and after stirring 
for 2 h, the mixture was allowed to warm to room temperature, then washed with 
water (180 mL), brine (2 x 180 mL), and the organic layer dried over MgSO4. After 
filtering the mixture, a trituration was performed in which hexane (300 mL) was added 
to the filtrate, followed by in vacuo removal of dichloromethane. The resulting 
suspension was filtered to obtain the title compound as a fluffy white crystalline solid 
(33 g, 80%): m.p. 109-111 °C; 1H NMR (700 MHz; CDCl3) δ 7.77 (d, J = 7.7, 1H, H3), 7.23-
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7.21 (m, 1H, H2), 7.20-7.18 (m, 1H, H5), 7.08 (t, J = 7.7, 1H, H4), 6.96 (br s, 1H, NH), 2.26 
(s, 3H, H7), 2.21 (s, 3H, H9); 
13C NMR (176 MHz; CDCl3) δ 168.4 (C8), 135.8 (C1), 130.6 
(C5), 129.3 (C6), 126.9 (C2), 125.5 (C4), 123.5 (C3), 24.5 (C9), 17.9 (C7); IR (neat) vmax/cm
-1 
3283m (N-H), 3220m (N-H), 1651s (C=O); MS (ES+): m/z = 150 [M + H]+; HRMS (ES+) 
calcd. for C9H11NO [M + H]
+: 150.0919, found: 150.0900.  
 
N-(3-Methylbut-2-enyl)-N-o-tolylacetamide (65) 
 
A mixture of N-o-tolylacetamide 64 (23.0 g, 154 mmol), K2CO3 (23.4 g, 170 mmol), 
NaOH (6.8 g, 170 mmol), [CH3(CH2)3]4NBr (1.5 g, 4.6 mmol, 3 mol%) and 3,3’-
dimethylallyl bromide (28.0 g, 185 mmol) in toluene (600 mL) was heated to 70 °C with 
vigorous stirring. After 18 h, the resulting yellow suspension was cooled to room 
temperature, water (1 L) was added, and the mixture extracted with toluene (3 x 600 
mL). The combined organic layers were washed with 6 M HCl (600 mL), followed by 
brine (2 x 600 mL), and dried over MgSO4. The mixture was filtered, the solvent 
removed in vacuo, and the residue purified by column chromatography on silica gel 
(hexane:EtOAc, 8:2, as eluent) to provide the title compound as a yellow oil (25.1 g, 
75%): 1H NMR (700 MHz; CDCl3) δ 7.28 (unsymmet. d, J = 7.0, 1H, H5), 7.26 (t, J = 7.7, 
1H, H4), 7.22 (t, J = 7.7, 1H, H3), 7.07 (unsymmet. d, J = 7.7, 1H, H2), 5.28 (t, J = 7.0, 1H, 
H11), 4.55 (dd, J = 14.7 and 7.0, 1H, H10), 3.92 (dd, J = 14.7 and 7.7, 1H, H10), 2.25 (s, 3H, 
H7), 1.77 (s, 3H, H13), 1.68 (s, 3H, H9), 1.42 (s, 3H, H13); 
13C NMR (176 MHz; CDCl3) δ 
170.1 (C8), 141.6 (C1), 136.2 (C12), 135.8 (C6), 131.2 (5), 129.1 (C2), 128.1 (C4), 127.0 
(C3), 119.1 (C11), 45.7 (C10), 25.7 (C9), 22.2 (C13), 17.5 (C7), 17.5 (C13); IR (neat) max/cm
-1 
2918br (C-Halkyl), 1656s (C=O); MS (ES
+): m/z = 218 [M + H]+; HRMS (ES+) calcd. for 
C14H20NO [M + H]
+: 218.1545, found: 218.1547. 
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N-Isopentyl-N-o-tolylacetamide (76) 
 
N-(3-Methylbut-2-enyl)-N-o-tolylacetamide 65 (2.0 g, 9.2 mmol) and AlCl3 (2.7 g, 20.2 
mmol) were heated in chlorobenzene (6 mL) to 120 °C for 5 h, after which a TLC 
analysis showed that the starting material had been consumed, and a single product 
spot was present. Water (10 mL) was added to the cooled reaction mixture, and the 
organic layer was extracted with toluene (2 x 50 mL). The combined organic layers 
were washed with 6 M HCl (50 mL), followed by brine (2 x 50 mL), then dried over 
MgSO4. Following in vacuo removal of the solvent, the residue was purified by column 
chromatography on silica gel (hexane:EtOAc, 3:1, as eluent) to give an orange oil (490 
mg, 25%): Rf. 0.61 (hexane:EtOAc, 4:1, as eluent); 
1H NMR (700 MHz; CDCl3) δ 7.30 (dd, 
J = 7.7 and 1.4, 1H, H5), 7.26 (td, J = 7.7 and 1.4, 1H, H4), 7.23 (td, J = 7.7 and 1.4, 1H, 
H3), 7.07 (dd, J = 7.7 and 1.4, 1H, H2), 4.07 (ddd, J = 13.2, 10.7 and 5.6, 1H, H10), 3.14 
(ddd, J = 13.2, 10.7 and 5.2, 1H, H10), 2.23 (s, 3H, H7), 1.73 (s, 3H, H9), 1.57 (nonet, J = 
7.0, 1H, H12), 1.50-1.44 (m, 1H, H11), 1.38-1.32 (m, 1H, H11), 0.89 (d, J = 7.0, 3H, H13), 
0.87 (d, J = 6.3, 3H, H13); 
13C NMR (176 MHz; CDCl3) δ 170.4 (C8), 141.9 (C1), 135.8 (C6), 
131.6 (C5), 129.2 (C2), 128.3 (C4), 127.2 (C3), 46.9 (C10), 36.5 (C11), 26.3 (C12), 22.8 (C13), 
22.6 (C13), 22.5 (C9), 17.7 (C7); IR (neat) max/cm
-1 2954s (C-Halkyl), 2869s (C-Halkyl), 1657s 
(C=O); MS (ES+): m/z = 220 [M + H]+, 461 [2M + Na]; HRMS (ES+) calcd. for C14H22NO [M 
+ H]+: 220.1701, found: 220.1704; calcd. for C28H42N2O2Na [2M + Na]: 461.3144, found: 
461.3164. 
 
N-(3-Hydroxy-3-methylbutyl)-N-o-tolylacetamide (79) 
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Polyphosphoric acid (15 g) was heated to 120 °C in a conical flask, and N-(3-methylbut-
2-enyl)-N-o-tolylacetamide 65 (2.77 g, 12.7 mmol) was added dropwise with stirring. 
After 15 min, ice water (20 mL) was added, followed by cautious addition of aqueous 
NaOH until the solution was basic. The mixture was extracted with ethyl acetate (50 
mL), washed with water (2 x 50 mL), and the organic layer dried over MgSO4. The 
mixture was filtered, and the solvent was removed in vacuo to provide the title 
compound as an orange oil (1.20 g, 40%): 1H NMR (400 MHz; CDCl3) δ 7.32-7.29 (m, 
1H, H5), 7.28-7.25 (m, 1H, H4), 7.23 (dd, J = 7.2 and 2, 1H, H3), 7.10 (dd, J = 7.6 and 1.6, 
1H, H2), 4.23 (ddd, J = 13.6, 9.2 and 6.4, 1H, H10), 3.22 (ddd, J = 13.6, 8.8 and 5.6, 1H, 
H10), 2.45 (br s, 1H, OH), 2.24 (s, 3H, H7), 1.82 (ddd, J = 14.4, 8.8 and 6.4, 1H, H11), 1.74 
(s, 3H, H9), 1.68 (ddd, J = 14.4, 8.8 and 5.6, 1H, H11), 1.25 (s, 3H, H13), 1.24 (s, 3H, H13); 
13C NMR (176 MHz; CDCl3) δ 171.2 (C8), 141.9 (C1), 135.6 (C6), 131.8 (C5), 129.0 (C2), 
128.5 (C4), 127.3 (C3), 69.7 (C12), 44.7 (C10), 40.8 (C11), 29.8 (C13), 29.6 (C13), 22.5 (C9), 
17.7 (C7); IR (neat) max/cm
-1 3400s br (O-H), 2972s (C-Halkyl), 1633s (C=O); MS (ES
+): 
m/z = 258 [M + Na], 493 [2M + Na]; HRMS (ES+) calcd. for C14H21NO2Na [M + Na]: 
258.1470, found: 258.1470; calcd. for C28H42N2O4Na [2M + Na]: 493.3042, found: 
493.3046. 
 
4,4,8-Trimethyl-1,2,3,4-tetrahydroquinoline (80) 
 
Polyphosphoric acid (15 g) was heated to 120 °C in a conical flask, and N-(3-methylbut-
2-enyl)-N-o-tolylacetamide 65 (3.72 g, 17.1 mmol) was added dropwise with stirring. 
After 2 h, ice water (20 mL) was added to the black mixture, followed by cautious 
addition of aqueous NaOH until the solution was basic. The mixture was extracted 
with ethyl acetate (50 mL), washed with water (2 x 50 mL), dried over MgSO4 and the 
solvent removed in vacuo to provide the title compound as a viscous black oil (1.50 g, 
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50%): 1H NMR (600 MHz; CDCl3) δ 7.11 (dd, J = 7.8 and 1.2, 1H, H3), 6.89 (dq, J = 7.8 
and 1.2, 1H, H5), 6.61 (t, J = 7.8, 1H, H4), 3.40-3.37 (m, 2H, H8), 2.10 (s, 3H, H7), 1.78-
1.75 (m, 2H, H9), 1.32 (s, 6H, H11+11’); 
13C NMR (176 MHz; CDCl3) δ 141.7 (C1), 139.8 (C6), 
127.9 (C5), 124.5 (C3), 121.1 (C2), 116.5 (C4), 38.7 (C8), 37.4 (C9), 32.0 (C10), 31.4 (C11+11’), 
17.7 (C7); IR (neat) max/cm
-1 3428s br (N-H), 2957s (C-Halkyl), 2924s (C-Halkyl), 2854s (C-
Halkyl), 1598s (C=Car.); MS (ES
+): m/z = 176 [M + H]+; HRMS (ES+) calcd. for C12H18N [M + 
H]+: 176.1439, found: 176.1437. 
 
6.7. Synthetic procedures for amide-containing retinoids 
4-Iodo-2-methylaniline (89) 
 
Commercially available from Sigma-Aldrich, otherwise, synthesis was follows: a 
solution of o-toluidine (10.0 g, 93 mmol) in pyridine and dioxane (500 mL, 1:1) was 
cooled to 0 °C in an ice bath. Iodine (71.0 g, 280 mmol) was added in one portion and 
the brown mixture stirred for 1 h at 0 °C followed by 1 h at room temperature. A 
saturated aqueous solution of sodium thiosulfate was then added until the brown 
colour disappeared. The mixture was extracted with dichloromethane (500 mL), 
washed with water (2 x 300 mL), and dried over MgSO4. After in vacuo removal of the 
solvent, the residue was recrystallised from methanol to provide the title compound 
as a light-brown crystalline solid (13.1 g, 61%): m.p. 107-110 °C; 1H NMR (600 MHz; 
CDCl3) δ 7.34 (d, J = 1.6, 1H, H5), 7.30 (dd, J = 8.4 and 2.0, 1H, Hl3), 6.44 (d, J = 8.0, 1H, 
H2), 3.61 (br s, 2H, NH), 2.11 (s, 3H, H7); 
13C NMR (100.6 MHz; CDCl3) δ 144.4 (C1), 
138.8 (C5), 135.7 (C3), 125.1 (C6), 117.0 (C2), 79.6 (C4), 17.2 (C7). All other spectroscopic 
data were identical to those reported in the literature.198 
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N-(4-Iodo-2-methylphenyl)-3-methylbut-2-enamide (92) 
 
3,3-Dimethylacryloyl chloride (6.20 mL, 56 mmol) in dichloromethane (40 mL) was 
added slowly dropwise to a stirred solution of 4-iodo-2-methylaniline 89 (25.9 g, 111 
mmol) in dichloromethane (850 mL). The mixture was heated to reflux (50 °C) for 5 h, 
then cooled to room temperature. The precipitate was removed by vacuum filtration, 
and the filtrate was washed with 2 M HCl (500 mL), sat. NaHCO3 (500 mL), brine (500 
mL), and the organic layer was dried over MgSO4. Following in vacuo removal of the 
solvent, the residue was recrystallised from methanol to provide the title compound 
as a white crystalline solid (14.0 g, 79%): m.p. 119-121 °C; 1H NMR (700 MHz; CDCl3) δ 
7.72 (s, 1H, H5), 7.51-7.49 (m, 1H, H2), 7.49-7.48 (m, 1H, H3), 6.83 (br s, 1H, OH), 5.72 
(s, 1H, H9), 2.21 (s, 3H, H11’), 2.19 (s, 3H, H7), 1.90 (s, 3H, H11); 
13C NMR (176 MHz; 
CDCl3) δ 165.1 (C8), 154.4 (C10), 139.3 (C2), 136.3 (C4), 136.0 (C3), 130.8 (C6), 124.5 (C5), 
118.7 (C9), 88.7 (C1), 27.8 (C11’), 20.4 (C11), 17.8 (C7); IR (neat) max/cm
-1 3289br (N-H), 
2357br (N-H), 1636s (C=O); MS (ES+): m/z = 338 [M + Na]+; HRMS (ES+) calcd. for 
C12H15INO [M + H]
+: 316.0198, found: 316.0203. Anal. calcd. for C12H14INO: C, 45.73; H, 
4.48; N, 4.44. Found: C, 45.89; H, 4.48; N, 4.35. 
 
6-Iodo-4,4,8-trimethyl-3,4-dihydroquinolin-2(1H)-one (93) 
 
A solution of AlCl3 (3.65 g, 27.4 mmol) in dry dichloromethane (100 mL) was stirred for 
20 min at room temperature, followed by the addition of N-(4-iodo-2-methylphenyl)-
3-methylbut-2-enamide 92 (5.76 g, 18.3 mmol) in dry dichloromethane (50 mL) via 
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cannula. After 3 h, ice water (150 mL) was added, and the mixture was extracted into 
dichloromethane (200 mL). The organic layer was separated, washed with 2 M HCl 
(300 mL), water (2 x 300 mL), 10% Na2S2O3 (300 mL), and brine (300 mL). After drying 
the organic layer over MgSO4, the solvent was removed in vacuo, and the product 
triturated from ethanol to provide the title compound as a white crystalline solid (4.66 
g, 81%): m.p. 186-188 °C; 1H NMR (600 MHz; CDCl3) δ 7.63 (br s, 1H, NH), 7.44 (d, J = 
1.8, 1H, H3), 7.38 (d, J = 1.8, 1H, H5), 2.45 (s, 2H, H9), 2.20 (s, 3H, H7), 1.30 (s, 6H, 
H11+11’); 
13C NMR (176 MHz; CDCl3) δ 170.2 (C8), 137.7 (C5), 134.9 (C1), 134.2 (C2), 131.5 
(C3), 125.5 (C4), 86.5 (C6), 45.1 (C9), 34.2 (C10), 27.6 (C11+11’), 16.8 (C7); IR (neat) max/cm
-
1 3193m (N-H), 3120m(N-H), 2949m (C-Halkyl), 1678s (C=O); MS (ES
+): m/z = 338 [M + 
Na]+; HRMS (ES+) calcd. for C12H15INO [M + H]
+: 316.0198, found: 316.0211. Anal. calcd. 
for C12H14INO: C, 45.73; H, 4.48; N, 4.44. Found: C, 45.54; H, 4.38; N, 4.35. 
 
3-Methyl-N-o-tolylbut-2-enamide (95) 
 
3,3-Dimethylacryloyl chloride (2.60 mL, 23.3 mmol) in chloroform (10 mL) was added 
slowly dropwise to a stirred solution of o-toluidine (5.00 g, 46.7 mmol) in chloroform 
(200 mL). The mixture was heated to reflux (70 °C) for 5 h, then cooled to room 
temperature. The precipitate was removed by vacuum filtration, and the filtrate was 
washed with 2 M HCl (200 mL), sat. NaHCO3 (200 mL), brine (200 mL), dried over 
MgSO4, and the solvent removed in vacuo to provide the title compound as a white 
crystalline solid following recrystallisation from methanol (3.92 g, 89%): m.p. 99-101 
°C; 1H NMR (700 MHz; CDCl3) δ 7.86 (s, 1H, H2), 7.19 (unsymmet. d, J = 7.0, 1H, H3), 
7.16 (unsymmet. d, J = 8.4, 1H, H4), 7.08-7.04 (m, 1H, H5), 6.98 (br s, 1H, NH), 5.76 (s, 
1H, H9), 2.24 (s, 3H, H7), 2.21 and 1.90 (2 x s, 3H, H11+11’); 
13C NMR (176 MHz; CDCl3) δ 
165.1 (C8), 153.1 (C10), 136.1 (C1), 130.5 (C4), 128.9 (C6), 126.7 (C3), 124.9 (C5), 123.1 
(C2), 118.8 (C9), 27.4 and 20.1 (C11+11’), 17.9 (C7); IR (neat) max/cm
-1 3294s (N-H), 1667s 
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(C=O), 1640s (C=Car.); MS (ES
+): m/z = 190 [M + H]+. Anal. calcd. for C12H15NO: C, 76.16; 
H, 7.99; N, 7.40. Found: C, 76.00; H, 7.89; N, 7.29. 
 
4,4,8-Trimethyl-3,4-dihydroquinolin-2(1H)-one (94) 
 
A solution of AlCl3 (4.90 g, 37.0 mmol) in dry dichloromethane (200 mL) was stirred for 
15 min at room temperature, followed by the addition of 3-methyl-N-o-tolylbut-2-
enamide 95 (3.50 g, 18.5 mmol) in dry dichloromethane (20 mL). After stirring for 1 h, 
ice water (100 mL) was added, and the mixture was extracted into dichloromethane 
(200 mL). The organic layer was separated, washed with 2 M HCl (200 mL), water (2 x 
200 mL) and dried over MgSO4. The solvent was removed in vacuo, and the residue 
recrystallised from acetonitrile to provide the title compound as a white crystalline 
solid (3.20 g, 91%): m.p. 133-135 °C; 1H NMR (600 MHz; CDCl3) δ 7.50 (br s, 1H, NH), 
7.17 (unsymmet. d, J = 7.8, 1H, H3), 7.06-7.03 (m, 1H, H5), 6.97 (t, J = 7.8, 1H, H4), 2.48 
(s, 2H, H9), 2.25 (s, 3H, H7), 1.33 (s, 6H, H11+11’); 
13C NMR (176 MHz; CDCl3) δ 170.5 (C8), 
134.2 (C2), 132.6 (C1), 129.2 (C5), 123.3 (C4), 122.9 (C6), 122.5 (C3), 45.3 (C9), 34.2 (C10), 
27.8 (C11+11’), 17.2 (C7); IR (neat) max/cm
-1 3220br (N-H), 2963m (C-Halkyl), 1669s (C=O); 
MS (ES+): m/z = 212 [M + Na]+. Anal. calcd. for C12H15NO: C, 76.16; H, 7.99; N, 7.40. 
Found: C, 76.00; H, 7.89; N, 7.29. 
 
6-Iodo-4,4,8-trimethyl-1,2,3,4-tetrahydroquinoline (68) 
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A solution of 6-iodo-4,4,8-trimethyl-3,4-dihydroquinolin-2(1H)-one 93 (740 mg, 2.35 
mmol) in dry toluene (10 mL) was cooled to 0 °C in an ice bath. Borane-dimethyl 
sulfide (1.23 mL of a 2.0 M solution in toluene, 2.47 mmol) was added dropwise and 
the mixture stirred at 0 °C for 15 min, then refluxed (110 °C) overnight. After cooling to 
room temperature, 10% Na2CO3 (15 mL) was added, and the solution stirred for a 
further 30 min. The organic layer was separated, washed with water (2 x 10 mL), dried 
over MgSO4, and concentrated in vacuo to provide the title compound as a dark 
orange oil (590 mg, 83%): 1H NMR (400 MHz; CDCl3) δ 7.35 (s, 1H, H3), 7.20 (s, 1H, H5), 
3.78 (br s, 1H, NH), 3.43-3.35 (m, 2H, H8), 2.05 (s, 3H, H7), 1.75-1.67 (m, 2H, H9), 1.29 
(s, 6H, H11+11’); MS (ES
+): m/z = 347 [M + 2Na]+; HRMS (ES+) calcd. for C12H17IN [M + H]
+: 
302.0406, found: 302.0414. 
 
Methyl 4-((4,4,8-trimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)ethynyl)benzoate 
(96) 
 
6-Iodo-4,4,8-trimethyl-3,4-dihydroquinolin-2(1H)-one 93 (1.00 g, 3.17 mmol) and 
methyl 4-ethynylbenzoate 16 (483 mg, 3.01 mmol) were mixed in triethylamine (50 
mL) under an inert nitrogen atmosphere in a Schlenk tube. Nitrogen gas was bubbled 
through the mixture for 10 min, then Pd(PPh3)2Cl2 (111 mg, 0.16 mmol, 5 mol%) and 
CuI (30 mg, 0.16 mmol, 5 mol%) were added, and the mixture was purged with 
nitrogen for a further 10 min. The flask was sealed, and the mixture heated to 80 °C 
overnight, after which the solvent was removed under high vacuum. Given that the 
product proved unstable to purification via chromatographic means, the residue was 
dissolved in ethanol (10 mL), and the insoluble title product was filtered out as a 
green-coloured powdery solid (690 mg, 66%): m.p. 222-224 °C; 1H NMR (700 MHz; 
CDCl3) δ 8.02 (unsymmet. d, J = 8.4, 2H, H16+16’), 7.67 (br s, 1H, NH), 7.57 (unsymmet. d, 
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J = 8.4, 2H, H15+15’), 7.36 (s, 1H, H3), 7.27 (s, 1H, H5), 3.93 (s, 3H, H19), 2.50 (s, 2H, H9), 
2.26 (s, 3H, H7), 1.35 (s, 6H, H11); 
13C NMR (176 MHz; CDCl3) δ 170.3 (C8), 166.7 (C18), 
134.9 (C1), 132.9 (C2), 132.6 (C5), 131.5 (C15+15’), 129.7 (C16+16’), 129.5 (C17), 128.2 (C14), 
126.3 (C3), 123.3 (C6), 117.2 (C4), 92.6 (C12), 88.1 (C13), 52.4 (C19), 45.1 (C9), 34.3 (C10), 
27.7 (C11+11’), 17.1 (C7); IR (neat) max/cm
-1 2962m (C-Halkyl), 2209m (C≡Cdisub.), 1713s 
(C=Oester), 1673s (C=Oamide), 1599s (C=Car.), 1475s (C=Car.); MS (ES
+): m/z = 348 [M + H]+; 
UV-vis (EtOH) max/nm (/M
-1 cm-1): 324 (33 800). Anal. calcd. for C22H21NO3: C, 76.06; 
H, 6.09; N, 4.03. Found: C, 75.17; H, 6.08; N, 4.05. 
 
4-((4-Amino-3-(1-carboxy-2-methylpropan-2-yl)-5-methylphenyl)ethynyl)benzoic 
acid (97)  
 
Methyl 4-((4,4,8-trimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)ethynyl)benzoate 96 
(300 mg, 0.86 mmol) was dissolved in THF/H2O (3:1, 24 mL), and NaOH (35 mg, 0.86 
mmol) was added. The mixture was heated to 70 °C overnight, after which diethyl 
ether (20 mL) and water (10 mL) were added to the cooled mixture. The aqueous layer 
was acidified to pH 1, which resulted in a white suspension that was insoluble in 
organic solvents. The solution was basified to pH 5-7 with aqueous KOH, then 
extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over 
MgSO4, and following in vacuo removal of the solvent, the title compound was 
obtained as a white solid (100 mg, 33%): 1H NMR (700 MHz; DMSO-d6) δ 9.66 (d, J = 
4.2, 1H, OH), 7.98 and 7.95 (2 x d, J = 8.4, 1H, H16+16’), 7.66 and 7.62 (2 x d, J = 8.4, 1H, 
H15+15’), 7.36 (d, J = 4.2, 1H, H3), 7.29 (s, 1H, H5), 3.87 (s, 1.5H, OMe), 2.38 (s, 2H, H10), 
2.24 (s, 3H, H7), 1.26 (s, 6H, H9+9’); 
13C NMR (176 MHz; DMSO-d6) δ 170.2 (C11), 166.9 
(C18), 166.0 (CCOOMe), 136.2 (C1), 133.6 (C2), 132.4 (C5), 131.6 (C15+15’), 129.7 (C16+16’), 
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129.1 (C17), 127.7 (C14), 125.8 (C3), 124.8 (C6), 115.5 (C4), 93.3 (C12), 87.7 (C13), 52.5 
(CCOOMe), 44.7 (C10), 33.8 (C8), 27.2 (C9+9’), 17.4 (C7); IR (neat) max/cm
-1 3200m br (N-H), 
2960w (C-Halkyl), 2180w (C≡Cdisub.), 1694s (C=Oacid), 1674s (C=Oamide), 1644s (N-H), 
1599s (C=Car.), 1476s (C=Car.); MS (ES
-): m/z = 332 [M - H+ - H2O]
-; UV-vis (EtOH) 
max/nm (/M
-1 cm-1): 316 (5 300). HRMS (ES+) calcd. for C21H18NO3 [M - H
+ - H2O]
-: 
332.1287, found: 332.1286. 
 
6-Iodo-1-isopropyl-4,4,8-trimethyl-3,4-dihydroquinolin-2(1H)-one (87) 
 
6-Iodo-4,4,8-trimethyl-3,4-dihydroquinolin-2(1H)-one 93 (1.50 g, 4.76 mmol) and NaH 
- 60% dispersion in mineral oil - (476 mg, 11.9 mmol) were added to a Schlenk flask. 
The flask was evacuated and purged with nitrogen three times, then dry DMF (25 mL) 
was added and the mixture heated to 85 °C for 1 h. 2-Iodopropane (950 µl, 9.52 mmol) 
was added to the cooled mixture, followed by heating to 85 °C. After overnight 
reaction, the reaction mixture was cooled, and water (20 mL) was added. The mixture 
was then extracted with dichloromethane (3 x 30 mL), and the combined organic 
layers were washed with water (50 mL), followed by brine (50 mL), and dried over 
MgSO4. The solvent was removed in vacuo, and the residue was purified by flash 
chromatography on silica gel (hexane:EtOAc, 9:1, as eluent) to provide the title 
compound as a pale yellow solid (1.18 g, 69%) following in vacuo removal of the 
solvent: m.p. 91-93 °C; 1H NMR (700 MHz; CDCl3) δ 7.40 (unsymmet. d, J = 1.4, 1H, H5), 
7.39 (unsymmet. d, J = 2.1, 1H, H3), 5.39 (septet, J = 6.3, 1H, H8), 2.30 (s, 3H, H7), 2.19 
(s, 2H, H11), 1.33 (d, J = 6.3, 6H, H9+9’), 1.21 (s, 6H, H13+13’); 
13C NMR (176 MHz; CDCl3) δ 
164.6 (C10), 141.6 (C1), 138.0 (C2), 137.4 (C5), 135.7 (C4), 130.1 (C3), 88.2 (C6), 68.4 (C8), 
40.0 (C11), 33.8 (C12), 27.6 (C13+13’), 21.9 (C9+9’). 17.6 (C7); IR (neat) max/cm
-1 2968s (C-
Halkyl), 1621s (C=O); MS (ES
+): m/z = 358 [M + H]+; HRMS (ES+) calcd. for C15H21INO [M + 
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H]+: 358.0668, found: 358,0657. Anal. calcd. for C15H20INO: C, 50.43; H, 5.64; N, 3.92. 
Found: C, 49.61; H, 5.54; N, 3.72. 
 
Methyl 4-((1-isopropyl-4,4,8-trimethyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-
yl)ethynyl)benzoate (98) 
 
6-Iodo-1-isopropyl-4,4,8-trimethyl-3,4-dihydroquinolin-2(1H)-one 87 (240 mg, 0.67 
mmol) and methyl 4-ethynylbenzoate 16 (108 mg, 0.67 mmol) were dissolved in 
triethylamine (10 mL) in a Schlenk tube, and nitrogen gas was bubbled through the 
mixture for 10 min. Pd(PPh3)2Cl2 (24 mg, 0.03 mmol, 5 mol%) and CuI (6 mg, 0.03 
mmol, 5 mol%) were added, and the mixture was purged with nitrogen for a further 10 
min. The sealed flask was heated to 80 °C overnight, after which the solvent was 
removed under high vacuum, and the residue purified by column chromatography on 
silica gel (hexane:EtOAc, 93:7, as eluent). Following in vacuo removal of the solvent, 
the title compound was obtained as a yellow solid (233 mg, 89%): m.p. 85-87 °C; 1H 
NMR (700 MHz; CDCl3) δ 8.00 (d, J = 8.4, 2H, H18+18’), 7.58 (d, J = 8.4, 2H, H17+17’), 7.31 
(d, J = 1.4, 1H, H3), 7.28 (d, J = 1.4, 1H, H5), 5.43 (septet, J = 6.3, 1H, H8), 3.93 (s, 3H, 
H21), 2.36 (s, 3H, H7), 2.24 (s, 2H, H11), 1.35 (d, J = 6.3, 6H, H9+9’), 1.25 (s, 6H, H13+13’); 
13C 
NMR (176 MHz; CDCl3) δ 166.8 (C20), 165.2 (C10), 142.7 (C1), 135.8 (C2), 133.3 (C6), 
132.2 (C5), 131.5 (C17+17’), 129.6 (C18+18’), 129.2 (C19), 128.7 (C16), 124.9 (C3), 117.6 (C4), 
93.8 (C14), 87.8 (C15), 68.5 (C8), 52.3 (C21), 40.1 (C11), 33.9 (C12), 27.7 (C13+13’), 21.9 
(C9+9’), 17.9 (C7); IR (neat) max/cm
-1 2962s (C-Halkyl), 2925s (C-Halkyl), 2203m (C≡Cdisub.), 
1726s (C=Oester), 1633s (C=Oamide), 1587s (C=Car.), 1463s (C=Car.), 1434s (C=Car.); MS 
(ES+): m/z = 390 [M + H]+; UV-vis (EtOH) max/nm (/M
-1 cm-1): 332 (22 900). Anal. 
calcd. for C25H27NO3: C, 77.09; H, 6.99; N, 3.60. Found: C, 76.98; H, 7.00; N, 3.41. 
6. Experimental 
 
186 
 
6.8. Synthetic procedures for oxazoline-containing compounds 
N-(2-Hydroxyethyl)-4-iodobenzamide (99) 
 
Methyl 4-iodobenzoate 45 (7.7 g, 29.4 mmol) was dissolved in dry tetrahydrofuran (50 
mL), after which ethanolamine (3.5 mL, 58.8 mmol) and sodium methoxide (222 mg, 
4.11 mmol) were added. The flask was sealed, and the mixture stirred at 30 °C for 18 
h, with reaction completion monitored by TLC analysis. Water (250 mL) was added, 
and the resulting precipitate was filtered, washed with water (50 mL), and dried in 
vacuo to provide the product as a white crystalline solid (7.5 g, 88%): m.p. 161-163 °C; 
1H NMR (700 MHz; CD3OD) δ 7.83 (unsymmet. d, J = 8.4, 2H, H2+2’), 7.59 (unsymmet. d, 
J = 8.4, 2H, H3+3’), 3.70 (t, J = 5.6, 2H, H7), 3.49 (t, J = 5.6, 2H, H6); 
13C NMR (176 MHz; 
CD3OD) δ 169.6 (C5), 138.9 (C2+2’), 135.2 (C4), 130.0 (C3+3’), 99.1 (C1), 61.5 (C6), 43.6 (C7); 
IR (neat) max/cm
-1 3294s br (O-H), 2872m (C-Halkyl), 1625s (C=Oamide), 1589s (C=Car.), 
1552s (C=Car.); MS (ES
+): m/z = 292 [M + 1]+, 314 [M + Na]+. Anal. calcd. for C9H10INO2: 
C, 37.14; H, 3.46; N, 4.81. Found: C, 37.21; H, 3.46; N, 4.76. 
 
2-(4-Iodophenyl)-4,5-dihydrooxazole (100) 
 
N-(2-Hydroxyethyl)-4-iodobenzamide 99 (7.50 g, 25.8 mmol), 4-dimethylaminopyridine 
(630 mg, 5.2 mmol) and triethylamine (10.2 mL, 73.2 mmol) were stirred in dry 
dichloromethane (200 mL). 4-Toluenesulfonyl chloride (8.35 g, 43.8 mmol) was added, 
the flask sealed, and the mixture stirred at 30 °C for 18 h, with reaction completion 
monitored by TLC analysis. The mixture was poured onto water (200 mL) and the 
organic layer was separated. The aqueous layer was extracted with chloroform (3 x 
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150 mL). The combined organic layers were dried over MgSO4, and the solvent 
removed in vacuo. The residue was then dissolved in methanol (200 mL), and NaOH 
(3.1 g, 77.5 mmol) was added. After stirring the mixture at room temperature for 2 h, 
chloroform (200 mL) and water (200 mL) were added. The organic layer was 
separated, and the aqueous layer was extracted with chloroform (3 x 150 mL). The 
combined organic layers were dried over MgSO4 and the solvent removed in vacuo. 
The residue was then filtered through a pad of silica (CH2Cl2:MeOH, 95:5, as eluent) to 
obtain the product as a pale yellow crystalline solid (5.11 g, 72%) following in vacuo 
removal of the solvent: m.p. 108-110 °C; 1H NMR (700 MHz; CDCl3) δ 7.76 (unsymmet. 
d, J = 8.4, 2H, H2+2’), 7.65 (unsymmet. d, J = 8.4, 2H, H3+3’), 4.42 (t, J = 9.8, 2H, H7), 4.04 
(t, J = 9.8, 2H, H6); 
13C NMR (176 MHz; CDCl3) δ 164.2 (C5), 137.7 (C2+2’), 129.8 (C3+3’), 
127.4 (C4), 98.3 (C1), 67.9 (C6), 55.1 (C7); IR (neat) max/cm
-1 2926m (C-Halkyl), 2871m (C-
Halkyl), 1640s (C=N), 1587s (C=Car.); MS (ES
+): m/z = 274 [M + H]+. Anal. calcd. for 
C9H8INO: C, 39.59; H, 2.95; N, 5.13. Found: C, 39.48; H, 3.03; N, 5.04. 
 
2-(4-((Trimethylsilyl)ethynyl)phenyl)-4,5-dihydrooxazole (101) 
 
A Schlenk tube was charged with 2-(4-iodophenyl)-4,5-dihydrooxazole 100 (2.0 g, 7.3 
mmol), CuI (70 mg, 0.37 mmol) and Pd(PPh3)2Cl2 (257 mg, 0.37 mmol). After 
evacuating and filling the flask with argon three times, dry DMF (20 mL) was added, 
and argon was bubbled through the stirred mixture for 10 minutes. Triethylamine 
(2.04 mL, 14.6 mmol) and trimethylsilylacetylene (2.07 mL, 14.6 mmol) were added, 
the flask was sealed, and the mixture stirred at room temperature for 18 hours. Ethyl 
acetate (50 mL) was added, and the mixture was washed with water (3 x 50 mL). The 
organic layer was dried over MgSO4 and the solvent removed in vacuo to provide a 
brown solid (purified yield not yet available): 1H NMR (700 MHz; CDCl3) δ 7.87 
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(unsymmet. d, J = 8.4, 2H, H3+3’), 7.49 (unsymmet. d, J = 8.4, 2H, H2+2’), 4.42 (t, J = 9.8, 
2H, H7), 4.05 (t, J = 9.8, 2H, H6), 0.25 (s, 9H, H10+10’+10’’); 
13C NMR (176 MHz; CDCl3) δ 
164.2 (C5), 132.0 (C2+2’), 128.1 (C3+3’), 127.6 (C4), 126.1 (C1), 104.5 (C8), 96.9 (C9), 67.8 
(C7), 55.1 (C6), 0.00 (C10+10’+10’’); MS (GC): m/z = 243 [M]
+. 
 
2-(4-Ethynylphenyl)-4,5-dihydrooxazole (102) 
 
2-(4-((Trimethylsilyl)ethynyl)phenyl)-4,5-dihydrooxazole 101 (380 mg, 1.6 mmol) and 
Na2CO3 (662 mg, 6.3 mmol) were mixed in methanol and water (11 mL, 10:1) and 
stirred overnight at room temperature. Diethyl ether (10 mL) was then added, and the 
mixture was washed with water (3 x 10 mL), the aqueous layers were combined and 
extracted with diethyl ether (2 x 20 mL). The combined organic extracts were dried 
over MgSO4 and the solvent removed in vacuo to give a yellow crystalline solid (220 
mg, 82%): 1H NMR (700 MHz; CDCl3) δ 7.90 (unsymmet. d, J = 8.4, 2H, H3+3’), 7.52 
(unsymmet. d, J = 8.4, 2H, H2+2’), 4.43 (t, J = 9.8, 2H, H7), 4.07 (t, J = 9.8, 2H, H6), 3.18 (s, 
1H, H9); 
13C NMR (176 MHz; CDCl3) δ 164.2 (C5), 132.2 (C2+2’), 128.2 (C3+3’), 128.1 (C4), 
125.1 (C1), 83.2 (C8), 79.4 (C9), 67.9 (C7), 55.2 (C6); MS (ES
+): m/z = 172 [M + H]+. 
 
6-((4-(4,5-dihydrooxazol-2-yl)phenyl)ethynyl)-4,4,8-trimethyl-3,4-dihydroquinolin-
2(1H)-one (103) 
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In order to reduce compound degradation/decomposition, and to improve the yield, 
this procedure should be repeated using DMF as the solvent (see procedure for 
synthesis of compound 101), and purification via chromatographic means should be 
avoided.  
A Schlenk tube was charged with 6-iodo-4,4,8-trimethyl-3,4-dihydroquinolin-2(1H)-one 
93 (386 mg, 1.22 mmol), 2-(4-ethynylphenyl)-4,5-dihydrooxazole 102 (220 mg, 1.29 
mmol), Pd(PPh3)2Cl2 (43 mg, 0.06 mmol, 5 mol%) and CuI (12 mg, 0.06 mmol, 5 mol%). 
The flask was evacuated and filled with argon three times, after which dry 
triethylamine (10 mL) was added, and argon was bubbled through the stirred mixture. 
After 10 min, the flask was sealed and heated to 80 °C overnight. The cooled mixture 
was filtered, and triethylamine was removed in vacuo. The product was triturated 
from acetonitrile to provide compound 103 as an orange solid (160 mg, 37%): m.p. 
224-226 °C; 1H NMR (700 MHz; CDCl3) δ 7.92 (d, J = 8.4, 2H, H16+16’), 7.55 (d, J = 8.4, 2H, 
H15+15’), 7.45 (br s, 1H, NH), 7.36 (s, 1H, H3), 7.26 (s, 1H, H5), 4.45 (t, J = 9.1, 2H, H20), 
4.08 (t, J = 9.1, 2H, H19), 2.50 (s, 2H, H9), 2.25 (s, 3H, H7), 1.35 (s, 6H, H11+11’); 
13C NMR 
(176 MHz; CDCl3) δ 170.2 (C8), 164.3 (C18), 134.7 (C1), 132.8 (C2), 132.5 (C5), 131.5 
(C15+15’), 128.3 (C16+!6’), 127.3 (C17), 126.5 (C14), 126.3 (C3), 123.1 (C6), 117.5 (C4), 91.8 
(C12), 88.4 (C13), 67.9 (C20), 55.2 (C19), 45.1 (C9), 34.3 (C10), 27.8 (C11+11’), 17.0 (C7); IR 
(neat) max/cm
-1 3236m br (N-H), 2960m (C-Halkyl), 1674s (C=N), 1650s (C=O), 1600m 
(C=Car.), 1511m (C=Car.), 1475s (C=Car.); MS (ES
+): m/z = 359 [M + H]+; UV-vis (EtOH) 
max/nm (/M
-1 cm-1): 324 (34 700). Anal. calcd. for C23H22N2O2: C, 77.07; H, 6.19; N, 
7.82. Found: C, 76.24; H, 6.10; N, 7.63. 
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